CN1942206A - 治疗免疫性疾病的药物组合物 - Google Patents
治疗免疫性疾病的药物组合物 Download PDFInfo
- Publication number
- CN1942206A CN1942206A CNA2005800082091A CN200580008209A CN1942206A CN 1942206 A CN1942206 A CN 1942206A CN A2005800082091 A CNA2005800082091 A CN A2005800082091A CN 200580008209 A CN200580008209 A CN 200580008209A CN 1942206 A CN1942206 A CN 1942206A
- Authority
- CN
- China
- Prior art keywords
- ser
- pro
- leu
- val
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 30
- 208000026278 immune system disease Diseases 0.000 title claims abstract description 22
- 102000004127 Cytokines Human genes 0.000 claims abstract description 21
- 108090000695 Cytokines Proteins 0.000 claims abstract description 21
- 230000004913 activation Effects 0.000 claims abstract description 19
- 239000000539 dimer Substances 0.000 claims description 135
- 102000005962 receptors Human genes 0.000 claims description 120
- 108020003175 receptors Proteins 0.000 claims description 120
- 108090000623 proteins and genes Proteins 0.000 claims description 95
- 102000004169 proteins and genes Human genes 0.000 claims description 88
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 74
- 230000004927 fusion Effects 0.000 claims description 74
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 71
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 64
- 102000017578 LAG3 Human genes 0.000 claims description 64
- 239000000463 material Substances 0.000 claims description 52
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 41
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 41
- 230000000527 lymphocytic effect Effects 0.000 claims description 34
- 108060003951 Immunoglobulin Proteins 0.000 claims description 25
- 102000018358 immunoglobulin Human genes 0.000 claims description 25
- 230000000638 stimulation Effects 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 230000013595 glycosylation Effects 0.000 claims description 16
- 238000006206 glycosylation reaction Methods 0.000 claims description 16
- 208000023275 Autoimmune disease Diseases 0.000 claims description 13
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 12
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 12
- 206010052779 Transplant rejections Diseases 0.000 claims description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 claims description 6
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 6
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 108010084313 CD58 Antigens Proteins 0.000 claims description 5
- -1 LIGHT Proteins 0.000 claims description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000003807 Graves Disease Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 230000005784 autoimmunity Effects 0.000 claims description 3
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims description 2
- 101150089023 FASLG gene Proteins 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims description 2
- 102100034980 ICOS ligand Human genes 0.000 claims description 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 102000000589 Interleukin-1 Human genes 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 102100039897 Interleukin-5 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102100021592 Interleukin-7 Human genes 0.000 claims description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 101710113649 Thyroid peroxidase Proteins 0.000 claims description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 2
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims description 2
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims description 2
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 claims description 2
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims description 2
- 108040006859 interleukin-5 receptor activity proteins Proteins 0.000 claims description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 2
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 claims description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 1
- 102100027188 Thyroid peroxidase Human genes 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 25
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract description 22
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract description 22
- 230000000903 blocking effect Effects 0.000 abstract description 7
- 230000027455 binding Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 92
- 241000699670 Mus sp. Species 0.000 description 68
- 235000018102 proteins Nutrition 0.000 description 68
- 208000009329 Graft vs Host Disease Diseases 0.000 description 56
- 208000024908 graft versus host disease Diseases 0.000 description 56
- 108020004414 DNA Proteins 0.000 description 50
- 241000282326 Felis catus Species 0.000 description 46
- 241000880493 Leptailurus serval Species 0.000 description 36
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 36
- 230000000694 effects Effects 0.000 description 34
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 32
- 108010060199 cysteinylproline Proteins 0.000 description 32
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 28
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 28
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 28
- 230000004083 survival effect Effects 0.000 description 25
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 24
- 239000002953 phosphate buffered saline Substances 0.000 description 24
- 108010031719 prolyl-serine Proteins 0.000 description 24
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 22
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 22
- 238000011740 C57BL/6 mouse Methods 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 21
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 20
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 108010017391 lysylvaline Proteins 0.000 description 20
- 108010077112 prolyl-proline Proteins 0.000 description 20
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 18
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 18
- 108010010147 glycylglutamine Proteins 0.000 description 18
- 108010015792 glycyllysine Proteins 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 18
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 18
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 18
- 208000009386 Experimental Arthritis Diseases 0.000 description 17
- 206010003246 arthritis Diseases 0.000 description 17
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 16
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 16
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 16
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 16
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 16
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 16
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 16
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 16
- NRUPKQSXTJNQGD-XGEHTFHBSA-N Thr-Cys-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NRUPKQSXTJNQGD-XGEHTFHBSA-N 0.000 description 16
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 16
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 16
- 108010047857 aspartylglycine Proteins 0.000 description 16
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 16
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 14
- ZUVMUOOHJYNJPP-XIRDDKMYSA-N Arg-Trp-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZUVMUOOHJYNJPP-XIRDDKMYSA-N 0.000 description 14
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 14
- HZWWOGWOBQBETJ-CUJWVEQBSA-N His-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O HZWWOGWOBQBETJ-CUJWVEQBSA-N 0.000 description 14
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 14
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 14
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 14
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 14
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 14
- MWVUEPNEPWMFBD-SRVKXCTJSA-N Lys-Cys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCCN MWVUEPNEPWMFBD-SRVKXCTJSA-N 0.000 description 14
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 14
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- JOXIIFVCSATTDH-IHPCNDPISA-N Phe-Asn-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JOXIIFVCSATTDH-IHPCNDPISA-N 0.000 description 14
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 14
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 14
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 14
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 14
- UDCHKDYNMRJYMI-QEJZJMRPSA-N Trp-Glu-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UDCHKDYNMRJYMI-QEJZJMRPSA-N 0.000 description 14
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 14
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 14
- 108010089804 glycyl-threonine Proteins 0.000 description 14
- 108010009298 lysylglutamic acid Proteins 0.000 description 14
- 108010051242 phenylalanylserine Proteins 0.000 description 14
- 108010029020 prolylglycine Proteins 0.000 description 14
- 108010071207 serylmethionine Proteins 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 12
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 12
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 12
- XKBASPWPBXNVLQ-WDSKDSINSA-N Gln-Gly-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XKBASPWPBXNVLQ-WDSKDSINSA-N 0.000 description 12
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 12
- CSTDQOOBZBAJKE-BWAGICSOSA-N His-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N)O CSTDQOOBZBAJKE-BWAGICSOSA-N 0.000 description 12
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 12
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 12
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 12
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 12
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 12
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 12
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 12
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 12
- 239000012980 RPMI-1640 medium Substances 0.000 description 12
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 12
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 12
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 12
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 12
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 12
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 12
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 12
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 12
- 108010049041 glutamylalanine Proteins 0.000 description 12
- 108010057821 leucylproline Proteins 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 108010044292 tryptophyltyrosine Proteins 0.000 description 12
- 108010051110 tyrosyl-lysine Proteins 0.000 description 12
- 238000005520 cutting process Methods 0.000 description 11
- 238000006062 fragmentation reaction Methods 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 10
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 10
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 10
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 10
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 10
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 10
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 10
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 10
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 10
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 10
- MAABHGXCIBEYQR-XVYDVKMFSA-N His-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MAABHGXCIBEYQR-XVYDVKMFSA-N 0.000 description 10
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 10
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 10
- HASRFYOMVPJRPU-SRVKXCTJSA-N Leu-Arg-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HASRFYOMVPJRPU-SRVKXCTJSA-N 0.000 description 10
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 10
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 10
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 10
- JLPMFVAIQHCBDC-CIUDSAMLSA-N Ser-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N JLPMFVAIQHCBDC-CIUDSAMLSA-N 0.000 description 10
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 10
- KISFXYYRKKNLOP-IHRRRGAJSA-N Val-Phe-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N KISFXYYRKKNLOP-IHRRRGAJSA-N 0.000 description 10
- 108010087924 alanylproline Proteins 0.000 description 10
- 108010013835 arginine glutamate Proteins 0.000 description 10
- 108010060035 arginylproline Proteins 0.000 description 10
- 108010093581 aspartyl-proline Proteins 0.000 description 10
- 238000013467 fragmentation Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 108010027338 isoleucylcysteine Proteins 0.000 description 10
- 108010003700 lysyl aspartic acid Proteins 0.000 description 10
- 108010005652 splenotritin Proteins 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 108010080629 tryptophan-leucine Proteins 0.000 description 10
- 108010038745 tryptophylglycine Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000003526 lymphopoietic effect Effects 0.000 description 9
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 8
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 8
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 8
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 8
- WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 8
- HCIUUZGFTDTEGM-NAKRPEOUSA-N Arg-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N HCIUUZGFTDTEGM-NAKRPEOUSA-N 0.000 description 8
- NIUDXSFNLBIWOB-DCAQKATOSA-N Arg-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NIUDXSFNLBIWOB-DCAQKATOSA-N 0.000 description 8
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 8
- STHNZYKCJHWULY-AVGNSLFASA-N Arg-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O STHNZYKCJHWULY-AVGNSLFASA-N 0.000 description 8
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 8
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 8
- TVVYVAUGRHNTGT-UGYAYLCHSA-N Asp-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O TVVYVAUGRHNTGT-UGYAYLCHSA-N 0.000 description 8
- ZSJFGGSPCCHMNE-LAEOZQHASA-N Asp-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N ZSJFGGSPCCHMNE-LAEOZQHASA-N 0.000 description 8
- LBFYTUPYYZENIR-GHCJXIJMSA-N Asp-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N LBFYTUPYYZENIR-GHCJXIJMSA-N 0.000 description 8
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 8
- PKNIZMPLMSKROD-BIIVOSGPSA-N Cys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N PKNIZMPLMSKROD-BIIVOSGPSA-N 0.000 description 8
- YMBAVNPKBWHDAW-CIUDSAMLSA-N Cys-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N YMBAVNPKBWHDAW-CIUDSAMLSA-N 0.000 description 8
- SRIRHERUAMYIOQ-CIUDSAMLSA-N Cys-Leu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SRIRHERUAMYIOQ-CIUDSAMLSA-N 0.000 description 8
- XMVZMBGFIOQONW-GARJFASQSA-N Cys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)C(=O)O XMVZMBGFIOQONW-GARJFASQSA-N 0.000 description 8
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 8
- YNJBLTDKTMKEET-ZLUOBGJFSA-N Cys-Ser-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O YNJBLTDKTMKEET-ZLUOBGJFSA-N 0.000 description 8
- NDNZRWUDUMTITL-FXQIFTODSA-N Cys-Ser-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NDNZRWUDUMTITL-FXQIFTODSA-N 0.000 description 8
- GXMBDEGTXHQBAO-NKIYYHGXSA-N Gln-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)N)N)O GXMBDEGTXHQBAO-NKIYYHGXSA-N 0.000 description 8
- DAAUVRPSZRDMBV-KBIXCLLPSA-N Gln-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N DAAUVRPSZRDMBV-KBIXCLLPSA-N 0.000 description 8
- UWMDGPFFTKDUIY-HJGDQZAQSA-N Gln-Pro-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWMDGPFFTKDUIY-HJGDQZAQSA-N 0.000 description 8
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 8
- ALCAUWPAMLVUDB-FXQIFTODSA-N Glu-Gln-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ALCAUWPAMLVUDB-FXQIFTODSA-N 0.000 description 8
- LYCDZGLXQBPNQU-WDSKDSINSA-N Glu-Gly-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O LYCDZGLXQBPNQU-WDSKDSINSA-N 0.000 description 8
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 8
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 8
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 8
- YOBGUCWZPXJHTN-BQBZGAKWSA-N Gly-Ser-Arg Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YOBGUCWZPXJHTN-BQBZGAKWSA-N 0.000 description 8
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 8
- GWCJMBNBFYBQCV-XPUUQOCRSA-N Gly-Val-Ala Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O GWCJMBNBFYBQCV-XPUUQOCRSA-N 0.000 description 8
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 8
- SKOKHBGDXGTDDP-MELADBBJSA-N His-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N SKOKHBGDXGTDDP-MELADBBJSA-N 0.000 description 8
- DFJJAVZIHDFOGQ-MNXVOIDGSA-N Ile-Glu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DFJJAVZIHDFOGQ-MNXVOIDGSA-N 0.000 description 8
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 8
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 8
- CQGSYZCULZMEDE-SRVKXCTJSA-N Leu-Gln-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CQGSYZCULZMEDE-SRVKXCTJSA-N 0.000 description 8
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 8
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 8
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 8
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 8
- CTJUSALVKAWFFU-CIUDSAMLSA-N Lys-Ser-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N CTJUSALVKAWFFU-CIUDSAMLSA-N 0.000 description 8
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 8
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 8
- ULNXMMYXQKGNPG-LPEHRKFASA-N Met-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N ULNXMMYXQKGNPG-LPEHRKFASA-N 0.000 description 8
- TWTNGJMBFRTKEX-FXQIFTODSA-N Met-Cys-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O TWTNGJMBFRTKEX-FXQIFTODSA-N 0.000 description 8
- RKIIYGUHIQJCBW-SRVKXCTJSA-N Met-His-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RKIIYGUHIQJCBW-SRVKXCTJSA-N 0.000 description 8
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 8
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 8
- AXIOGMQCDYVTNY-ACRUOGEOSA-N Phe-Phe-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 AXIOGMQCDYVTNY-ACRUOGEOSA-N 0.000 description 8
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 8
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 8
- XQSREVQDGCPFRJ-STQMWFEESA-N Pro-Gly-Phe Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XQSREVQDGCPFRJ-STQMWFEESA-N 0.000 description 8
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 8
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 8
- MHHQQZIFLWFZGR-DCAQKATOSA-N Pro-Lys-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O MHHQQZIFLWFZGR-DCAQKATOSA-N 0.000 description 8
- WIPAMEKBSHNFQE-IUCAKERBSA-N Pro-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1 WIPAMEKBSHNFQE-IUCAKERBSA-N 0.000 description 8
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 8
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 8
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 8
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 8
- BYCVMHKULKRVPV-GUBZILKMSA-N Ser-Lys-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYCVMHKULKRVPV-GUBZILKMSA-N 0.000 description 8
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 8
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 8
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 8
- DDPVJPIGACCMEH-XQXXSGGOSA-N Thr-Ala-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DDPVJPIGACCMEH-XQXXSGGOSA-N 0.000 description 8
- RKDFEMGVMMYYNG-WDCWCFNPSA-N Thr-Gln-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O RKDFEMGVMMYYNG-WDCWCFNPSA-N 0.000 description 8
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 8
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 8
- JWQNAFHCXKVZKZ-UVOCVTCTSA-N Thr-Lys-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWQNAFHCXKVZKZ-UVOCVTCTSA-N 0.000 description 8
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 8
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 8
- HYLNRGXEQACDKG-NYVOZVTQSA-N Trp-Asn-Trp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HYLNRGXEQACDKG-NYVOZVTQSA-N 0.000 description 8
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 8
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 8
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 8
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 8
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 8
- OACSGBOREVRSME-NHCYSSNCSA-N Val-His-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(O)=O OACSGBOREVRSME-NHCYSSNCSA-N 0.000 description 8
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 8
- YQMILNREHKTFBS-IHRRRGAJSA-N Val-Phe-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N YQMILNREHKTFBS-IHRRRGAJSA-N 0.000 description 8
- 108010044940 alanylglutamine Proteins 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108010025306 histidylleucine Proteins 0.000 description 8
- 239000003018 immunosuppressive agent Substances 0.000 description 8
- 108010053037 kyotorphin Proteins 0.000 description 8
- 108010034529 leucyl-lysine Proteins 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108010026333 seryl-proline Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 108010027345 wheylin-1 peptide Proteins 0.000 description 8
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 7
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000003259 recombinant expression Methods 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 6
- UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 description 6
- JDIQCVUDDFENPU-ZKWXMUAHSA-N Ala-His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CNC=N1 JDIQCVUDDFENPU-ZKWXMUAHSA-N 0.000 description 6
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 6
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 6
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 6
- VYSRNGOMGHOJCK-GUBZILKMSA-N Arg-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N VYSRNGOMGHOJCK-GUBZILKMSA-N 0.000 description 6
- YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 6
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 6
- GIMTZGADWZTZGV-DCAQKATOSA-N Arg-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N GIMTZGADWZTZGV-DCAQKATOSA-N 0.000 description 6
- OVQJAKFLFTZDNC-GUBZILKMSA-N Arg-Pro-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O OVQJAKFLFTZDNC-GUBZILKMSA-N 0.000 description 6
- DNLQVHBBMPZUGJ-BQBZGAKWSA-N Arg-Ser-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O DNLQVHBBMPZUGJ-BQBZGAKWSA-N 0.000 description 6
- IZSMEUDYADKZTJ-KJEVXHAQSA-N Arg-Tyr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IZSMEUDYADKZTJ-KJEVXHAQSA-N 0.000 description 6
- XYOVHPDDWCEUDY-CIUDSAMLSA-N Asn-Ala-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O XYOVHPDDWCEUDY-CIUDSAMLSA-N 0.000 description 6
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 6
- JREOBWLIZLXRIS-GUBZILKMSA-N Asn-Glu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JREOBWLIZLXRIS-GUBZILKMSA-N 0.000 description 6
- TZFQICWZWFNIKU-KKUMJFAQSA-N Asn-Leu-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 TZFQICWZWFNIKU-KKUMJFAQSA-N 0.000 description 6
- WQAOZCVOOYUWKG-LSJOCFKGSA-N Asn-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC(=O)N)N WQAOZCVOOYUWKG-LSJOCFKGSA-N 0.000 description 6
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 6
- DRCOAZZDQRCGGP-GHCJXIJMSA-N Asp-Ser-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DRCOAZZDQRCGGP-GHCJXIJMSA-N 0.000 description 6
- JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 6
- AOZBJZBKFHOYHL-AVGNSLFASA-N Cys-Glu-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O AOZBJZBKFHOYHL-AVGNSLFASA-N 0.000 description 6
- OXFOKRAFNYSREH-BJDJZHNGSA-N Cys-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CS)N OXFOKRAFNYSREH-BJDJZHNGSA-N 0.000 description 6
- KJJASVYBTKRYSN-FXQIFTODSA-N Cys-Pro-Asp Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CC(=O)O)C(=O)O KJJASVYBTKRYSN-FXQIFTODSA-N 0.000 description 6
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- SHERTACNJPYHAR-ACZMJKKPSA-N Gln-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O SHERTACNJPYHAR-ACZMJKKPSA-N 0.000 description 6
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 6
- BVELAHPZLYLZDJ-HGNGGELXSA-N Gln-His-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O BVELAHPZLYLZDJ-HGNGGELXSA-N 0.000 description 6
- JKGHMESJHRTHIC-SIUGBPQLSA-N Gln-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JKGHMESJHRTHIC-SIUGBPQLSA-N 0.000 description 6
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 description 6
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 6
- ZZLDMBMFKZFQMU-NRPADANISA-N Gln-Val-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O ZZLDMBMFKZFQMU-NRPADANISA-N 0.000 description 6
- DWBBKNPKDHXIAC-SRVKXCTJSA-N Glu-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O DWBBKNPKDHXIAC-SRVKXCTJSA-N 0.000 description 6
- MWTGQXBHVRTCOR-GLLZPBPUSA-N Glu-Thr-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MWTGQXBHVRTCOR-GLLZPBPUSA-N 0.000 description 6
- MLILEEIVMRUYBX-NHCYSSNCSA-N Glu-Val-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MLILEEIVMRUYBX-NHCYSSNCSA-N 0.000 description 6
- WKJKBELXHCTHIJ-WPRPVWTQSA-N Gly-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N WKJKBELXHCTHIJ-WPRPVWTQSA-N 0.000 description 6
- WJZLEENECIOOSA-WDSKDSINSA-N Gly-Asn-Gln Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O WJZLEENECIOOSA-WDSKDSINSA-N 0.000 description 6
- OCDLPQDYTJPWNG-YUMQZZPRSA-N Gly-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN OCDLPQDYTJPWNG-YUMQZZPRSA-N 0.000 description 6
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 6
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 6
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 6
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 6
- FYVHHKMHFPMBBG-GUBZILKMSA-N His-Gln-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FYVHHKMHFPMBBG-GUBZILKMSA-N 0.000 description 6
- NELVFWFDOKRTOR-SDDRHHMPSA-N His-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O NELVFWFDOKRTOR-SDDRHHMPSA-N 0.000 description 6
- RNMNYMDTESKEAJ-KKUMJFAQSA-N His-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 RNMNYMDTESKEAJ-KKUMJFAQSA-N 0.000 description 6
- CYHJCEKUMCNDFG-LAEOZQHASA-N Ile-Gln-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N CYHJCEKUMCNDFG-LAEOZQHASA-N 0.000 description 6
- CAHCWMVNBZJVAW-NAKRPEOUSA-N Ile-Pro-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)N CAHCWMVNBZJVAW-NAKRPEOUSA-N 0.000 description 6
- OMDWJWGZGMCQND-CFMVVWHZSA-N Ile-Tyr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMDWJWGZGMCQND-CFMVVWHZSA-N 0.000 description 6
- GRZSCTXVCDUIPO-SRVKXCTJSA-N Leu-Arg-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRZSCTXVCDUIPO-SRVKXCTJSA-N 0.000 description 6
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 6
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 6
- XWEVVRRSIOBJOO-SRVKXCTJSA-N Leu-Pro-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O XWEVVRRSIOBJOO-SRVKXCTJSA-N 0.000 description 6
- ARNIBBOXIAWUOP-MGHWNKPDSA-N Leu-Tyr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ARNIBBOXIAWUOP-MGHWNKPDSA-N 0.000 description 6
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 6
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 6
- OJDFAABAHBPVTH-MNXVOIDGSA-N Lys-Ile-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OJDFAABAHBPVTH-MNXVOIDGSA-N 0.000 description 6
- QOJDBRUCOXQSSK-AJNGGQMLSA-N Lys-Ile-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O QOJDBRUCOXQSSK-AJNGGQMLSA-N 0.000 description 6
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 6
- RMOKGALPSPOYKE-KATARQTJSA-N Lys-Thr-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMOKGALPSPOYKE-KATARQTJSA-N 0.000 description 6
- UZVWDRPUTHXQAM-FXQIFTODSA-N Met-Asp-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O UZVWDRPUTHXQAM-FXQIFTODSA-N 0.000 description 6
- JOYFULUKJRJCSX-IUCAKERBSA-N Met-Met-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O JOYFULUKJRJCSX-IUCAKERBSA-N 0.000 description 6
- GMMLGMFBYCFCCX-KZVJFYERSA-N Met-Thr-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMMLGMFBYCFCCX-KZVJFYERSA-N 0.000 description 6
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 6
- MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 6
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 6
- IWNOFCGBMSFTBC-CIUDSAMLSA-N Pro-Ala-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IWNOFCGBMSFTBC-CIUDSAMLSA-N 0.000 description 6
- NXEYSLRNNPWCRN-SRVKXCTJSA-N Pro-Glu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXEYSLRNNPWCRN-SRVKXCTJSA-N 0.000 description 6
- FFSLAIOXRMOFIZ-GJZGRUSLSA-N Pro-Gly-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)CNC(=O)[C@@H]1CCCN1 FFSLAIOXRMOFIZ-GJZGRUSLSA-N 0.000 description 6
- GURGCNUWVSDYTP-SRVKXCTJSA-N Pro-Leu-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GURGCNUWVSDYTP-SRVKXCTJSA-N 0.000 description 6
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 6
- PKHDJFHFMGQMPS-RCWTZXSCSA-N Pro-Thr-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PKHDJFHFMGQMPS-RCWTZXSCSA-N 0.000 description 6
- QDDJNKWPTJHROJ-UFYCRDLUSA-N Pro-Tyr-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 QDDJNKWPTJHROJ-UFYCRDLUSA-N 0.000 description 6
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 6
- SWSRFJZZMNLMLY-ZKWXMUAHSA-N Ser-Asp-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O SWSRFJZZMNLMLY-ZKWXMUAHSA-N 0.000 description 6
- WTPKKLMBNBCCNL-ACZMJKKPSA-N Ser-Cys-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N WTPKKLMBNBCCNL-ACZMJKKPSA-N 0.000 description 6
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 6
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 description 6
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 6
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- XOTBWOCSLMBGMF-SUSMZKCASA-N Thr-Glu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOTBWOCSLMBGMF-SUSMZKCASA-N 0.000 description 6
- VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 description 6
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 6
- BRBCKMMXKONBAA-KWBADKCTSA-N Trp-Ala-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 BRBCKMMXKONBAA-KWBADKCTSA-N 0.000 description 6
- WFZYXGSAPWKTHR-XEGUGMAKSA-N Trp-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WFZYXGSAPWKTHR-XEGUGMAKSA-N 0.000 description 6
- XGFGVFMXDXALEV-XIRDDKMYSA-N Trp-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N XGFGVFMXDXALEV-XIRDDKMYSA-N 0.000 description 6
- SMLCYZYQFRTLCO-UWJYBYFXSA-N Tyr-Cys-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O SMLCYZYQFRTLCO-UWJYBYFXSA-N 0.000 description 6
- VXFXIBCCVLJCJT-JYJNAYRXSA-N Tyr-Pro-Pro Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(O)=O VXFXIBCCVLJCJT-JYJNAYRXSA-N 0.000 description 6
- OJCISMMNNUNNJA-BZSNNMDCSA-N Tyr-Tyr-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 OJCISMMNNUNNJA-BZSNNMDCSA-N 0.000 description 6
- CWSIBTLMMQLPPZ-FXQIFTODSA-N Val-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N CWSIBTLMMQLPPZ-FXQIFTODSA-N 0.000 description 6
- BWVHQINTNLVWGZ-ZKWXMUAHSA-N Val-Cys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N BWVHQINTNLVWGZ-ZKWXMUAHSA-N 0.000 description 6
- IRLYZKKNBFPQBW-XGEHTFHBSA-N Val-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N)O IRLYZKKNBFPQBW-XGEHTFHBSA-N 0.000 description 6
- YTPLVNUZZOBFFC-SCZZXKLOSA-N Val-Gly-Pro Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N1CCC[C@@H]1C(O)=O YTPLVNUZZOBFFC-SCZZXKLOSA-N 0.000 description 6
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 6
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 6
- RYQUMYBMOJYYDK-NHCYSSNCSA-N Val-Pro-Glu Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RYQUMYBMOJYYDK-NHCYSSNCSA-N 0.000 description 6
- JQTYTBPCSOAZHI-FXQIFTODSA-N Val-Ser-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N JQTYTBPCSOAZHI-FXQIFTODSA-N 0.000 description 6
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 6
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 6
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 6
- 108010043293 glycyl-prolyl-glycyl-glycine Proteins 0.000 description 6
- 108010077515 glycylproline Proteins 0.000 description 6
- 229960003444 immunosuppressant agent Drugs 0.000 description 6
- 230000001861 immunosuppressant effect Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 108010091871 leucylmethionine Proteins 0.000 description 6
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108010073101 phenylalanylleucine Proteins 0.000 description 6
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 6
- 108010079317 prolyl-tyrosine Proteins 0.000 description 6
- 108010070643 prolylglutamic acid Proteins 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 5
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 5
- 101710114827 Protein lag-3 Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WXPZDDCNKXMOMC-AVGNSLFASA-N (2s)-1-[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@H](C(O)=O)CCC1 WXPZDDCNKXMOMC-AVGNSLFASA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- JPGBXANAQYHTLA-DRZSPHRISA-N Ala-Gln-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JPGBXANAQYHTLA-DRZSPHRISA-N 0.000 description 4
- QHASENCZLDHBGX-ONGXEEELSA-N Ala-Gly-Phe Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QHASENCZLDHBGX-ONGXEEELSA-N 0.000 description 4
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 4
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 4
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 4
- KWKQGHSSNHPGOW-BQBZGAKWSA-N Arg-Ala-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(O)=O KWKQGHSSNHPGOW-BQBZGAKWSA-N 0.000 description 4
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 4
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 4
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 4
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 4
- CVXXSWQORBZAAA-SRVKXCTJSA-N Arg-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N CVXXSWQORBZAAA-SRVKXCTJSA-N 0.000 description 4
- BSYKSCBTTQKOJG-GUBZILKMSA-N Arg-Pro-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BSYKSCBTTQKOJG-GUBZILKMSA-N 0.000 description 4
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 4
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 4
- CPTXATAOUQJQRO-GUBZILKMSA-N Arg-Val-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O CPTXATAOUQJQRO-GUBZILKMSA-N 0.000 description 4
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 4
- MECFLTFREHAZLH-ACZMJKKPSA-N Asn-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N MECFLTFREHAZLH-ACZMJKKPSA-N 0.000 description 4
- WQLJRNRLHWJIRW-KKUMJFAQSA-N Asn-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)N)N)O WQLJRNRLHWJIRW-KKUMJFAQSA-N 0.000 description 4
- BXUHCIXDSWRSBS-CIUDSAMLSA-N Asn-Leu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BXUHCIXDSWRSBS-CIUDSAMLSA-N 0.000 description 4
- FHETWELNCBMRMG-HJGDQZAQSA-N Asn-Leu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FHETWELNCBMRMG-HJGDQZAQSA-N 0.000 description 4
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 4
- CBHVAFXKOYAHOY-NHCYSSNCSA-N Asn-Val-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O CBHVAFXKOYAHOY-NHCYSSNCSA-N 0.000 description 4
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 4
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 4
- FRSGNOZCTWDVFZ-ACZMJKKPSA-N Asp-Asp-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O FRSGNOZCTWDVFZ-ACZMJKKPSA-N 0.000 description 4
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 4
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 4
- KHGPWGKPYHPOIK-QWRGUYRKSA-N Asp-Gly-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KHGPWGKPYHPOIK-QWRGUYRKSA-N 0.000 description 4
- RTXQQDVBACBSCW-CFMVVWHZSA-N Asp-Ile-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RTXQQDVBACBSCW-CFMVVWHZSA-N 0.000 description 4
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 4
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 4
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 4
- ITGFVUYOLWBPQW-KKHAAJSZSA-N Asp-Thr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O ITGFVUYOLWBPQW-KKHAAJSZSA-N 0.000 description 4
- KNOGLZBISUBTFW-QRTARXTBSA-N Asp-Trp-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O KNOGLZBISUBTFW-QRTARXTBSA-N 0.000 description 4
- KOHBWQDSVCARMI-BWBBJGPYSA-N Cys-Cys-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KOHBWQDSVCARMI-BWBBJGPYSA-N 0.000 description 4
- URDUGPGPLNXXES-WHFBIAKZSA-N Cys-Gly-Cys Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O URDUGPGPLNXXES-WHFBIAKZSA-N 0.000 description 4
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 4
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 description 4
- HJXSYJVCMUOUNY-SRVKXCTJSA-N Cys-Ser-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N HJXSYJVCMUOUNY-SRVKXCTJSA-N 0.000 description 4
- NRVQLLDIJJEIIZ-VZFHVOOUSA-N Cys-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CS)N)O NRVQLLDIJJEIIZ-VZFHVOOUSA-N 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- UICOTGULOUGGLC-NUMRIWBASA-N Gln-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O UICOTGULOUGGLC-NUMRIWBASA-N 0.000 description 4
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 4
- LHMWTCWZARHLPV-CIUDSAMLSA-N Gln-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LHMWTCWZARHLPV-CIUDSAMLSA-N 0.000 description 4
- XUMFMAVDHQDATI-DCAQKATOSA-N Gln-Pro-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUMFMAVDHQDATI-DCAQKATOSA-N 0.000 description 4
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 4
- XQDGOJPVMSWZSO-SRVKXCTJSA-N Gln-Pro-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N XQDGOJPVMSWZSO-SRVKXCTJSA-N 0.000 description 4
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 4
- SVZIKUHLRKVZIF-GUBZILKMSA-N Glu-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N SVZIKUHLRKVZIF-GUBZILKMSA-N 0.000 description 4
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 4
- AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 4
- ZSWGJYOZWBHROQ-RWRJDSDZSA-N Glu-Ile-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSWGJYOZWBHROQ-RWRJDSDZSA-N 0.000 description 4
- BCYGDJXHAGZNPQ-DCAQKATOSA-N Glu-Lys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O BCYGDJXHAGZNPQ-DCAQKATOSA-N 0.000 description 4
- YKBUCXNNBYZYAY-MNXVOIDGSA-N Glu-Lys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YKBUCXNNBYZYAY-MNXVOIDGSA-N 0.000 description 4
- AAJHGGDRKHYSDH-GUBZILKMSA-N Glu-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O AAJHGGDRKHYSDH-GUBZILKMSA-N 0.000 description 4
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 4
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 4
- BPCLDCNZBUYGOD-BPUTZDHNSA-N Glu-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 BPCLDCNZBUYGOD-BPUTZDHNSA-N 0.000 description 4
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 4
- MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 4
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 4
- YFGONBOFGGWKKY-VHSXEESVSA-N Gly-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)CN)C(=O)O YFGONBOFGGWKKY-VHSXEESVSA-N 0.000 description 4
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 4
- ISSDODCYBOWWIP-GJZGRUSLSA-N Gly-Pro-Trp Chemical compound [H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O ISSDODCYBOWWIP-GJZGRUSLSA-N 0.000 description 4
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 4
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 4
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 4
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 4
- STOOMQFEJUVAKR-KKUMJFAQSA-N His-His-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 STOOMQFEJUVAKR-KKUMJFAQSA-N 0.000 description 4
- MVZASEMJYJPJSI-IHPCNDPISA-N His-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CN=CN3)N MVZASEMJYJPJSI-IHPCNDPISA-N 0.000 description 4
- YKRYHWJRQUSTKG-KBIXCLLPSA-N Ile-Ala-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKRYHWJRQUSTKG-KBIXCLLPSA-N 0.000 description 4
- TWYOYAKMLHWMOJ-ZPFDUUQYSA-N Ile-Leu-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O TWYOYAKMLHWMOJ-ZPFDUUQYSA-N 0.000 description 4
- UOPBQSJRBONRON-STECZYCISA-N Ile-Met-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UOPBQSJRBONRON-STECZYCISA-N 0.000 description 4
- JDCQDJVYUXNCGF-SPOWBLRKSA-N Ile-Ser-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N JDCQDJVYUXNCGF-SPOWBLRKSA-N 0.000 description 4
- 108010065920 Insulin Lispro Proteins 0.000 description 4
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 4
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 4
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 4
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 4
- WMTOVWLLDGQGCV-GUBZILKMSA-N Leu-Glu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WMTOVWLLDGQGCV-GUBZILKMSA-N 0.000 description 4
- QLDHBYRUNQZIJQ-DKIMLUQUSA-N Leu-Ile-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QLDHBYRUNQZIJQ-DKIMLUQUSA-N 0.000 description 4
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 4
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 4
- SYRTUBLKWNDSDK-DKIMLUQUSA-N Leu-Phe-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SYRTUBLKWNDSDK-DKIMLUQUSA-N 0.000 description 4
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 4
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 4
- HGUUMQWGYCVPKG-DCAQKATOSA-N Leu-Pro-Cys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N HGUUMQWGYCVPKG-DCAQKATOSA-N 0.000 description 4
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 4
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 4
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 4
- AKVBOOKXVAMKSS-GUBZILKMSA-N Leu-Ser-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O AKVBOOKXVAMKSS-GUBZILKMSA-N 0.000 description 4
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 4
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 4
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 4
- QQYRCUXKLDGCQN-SRVKXCTJSA-N Lys-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N QQYRCUXKLDGCQN-SRVKXCTJSA-N 0.000 description 4
- ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 description 4
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 4
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 4
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 4
- YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 4
- AZOFEHCPMBRNFD-BZSNNMDCSA-N Lys-Phe-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 AZOFEHCPMBRNFD-BZSNNMDCSA-N 0.000 description 4
- XGZDDOKIHSYHTO-SZMVWBNQSA-N Lys-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 XGZDDOKIHSYHTO-SZMVWBNQSA-N 0.000 description 4
- NKDSBBBPGIVWEI-RCWTZXSCSA-N Met-Arg-Thr Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NKDSBBBPGIVWEI-RCWTZXSCSA-N 0.000 description 4
- TZLYIHDABYBOCJ-FXQIFTODSA-N Met-Asp-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O TZLYIHDABYBOCJ-FXQIFTODSA-N 0.000 description 4
- GVIVXNFKJQFTCE-YUMQZZPRSA-N Met-Gly-Gln Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O GVIVXNFKJQFTCE-YUMQZZPRSA-N 0.000 description 4
- FIZZULTXMVEIAA-IHRRRGAJSA-N Met-Ser-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FIZZULTXMVEIAA-IHRRRGAJSA-N 0.000 description 4
- JZXKNNOWPBVZEV-XIRDDKMYSA-N Met-Trp-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N JZXKNNOWPBVZEV-XIRDDKMYSA-N 0.000 description 4
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 4
- YYRCPTVAPLQRNC-ULQDDVLXSA-N Phe-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC1=CC=CC=C1 YYRCPTVAPLQRNC-ULQDDVLXSA-N 0.000 description 4
- RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 description 4
- ZFVWWUILVLLVFA-AVGNSLFASA-N Phe-Gln-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N ZFVWWUILVLLVFA-AVGNSLFASA-N 0.000 description 4
- YKUGPVXSDOOANW-KKUMJFAQSA-N Phe-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKUGPVXSDOOANW-KKUMJFAQSA-N 0.000 description 4
- RMKGXGPQIPLTFC-KKUMJFAQSA-N Phe-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RMKGXGPQIPLTFC-KKUMJFAQSA-N 0.000 description 4
- CDHURCQGUDNBMA-UBHSHLNASA-N Phe-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 CDHURCQGUDNBMA-UBHSHLNASA-N 0.000 description 4
- AJLVKXCNXIJHDV-CIUDSAMLSA-N Pro-Ala-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O AJLVKXCNXIJHDV-CIUDSAMLSA-N 0.000 description 4
- OLTFZQIYCNOBLI-DCAQKATOSA-N Pro-Cys-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O OLTFZQIYCNOBLI-DCAQKATOSA-N 0.000 description 4
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 4
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 4
- YTWNSIDWAFSEEI-RWMBFGLXSA-N Pro-His-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@@H]3C(=O)O YTWNSIDWAFSEEI-RWMBFGLXSA-N 0.000 description 4
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 4
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 4
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 4
- WWXNZNWZNZPDIF-SRVKXCTJSA-N Pro-Val-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 WWXNZNWZNZPDIF-SRVKXCTJSA-N 0.000 description 4
- SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 4
- HZWAHWQZPSXNCB-BPUTZDHNSA-N Ser-Arg-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HZWAHWQZPSXNCB-BPUTZDHNSA-N 0.000 description 4
- UCXDHBORXLVBNC-ZLUOBGJFSA-N Ser-Asn-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O UCXDHBORXLVBNC-ZLUOBGJFSA-N 0.000 description 4
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 4
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 4
- BNFVPSRLHHPQKS-WHFBIAKZSA-N Ser-Asp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O BNFVPSRLHHPQKS-WHFBIAKZSA-N 0.000 description 4
- TUYBIWUZWJUZDD-ACZMJKKPSA-N Ser-Cys-Gln Chemical compound OC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCC(N)=O TUYBIWUZWJUZDD-ACZMJKKPSA-N 0.000 description 4
- RFBKULCUBJAQFT-BIIVOSGPSA-N Ser-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CO)N)C(=O)O RFBKULCUBJAQFT-BIIVOSGPSA-N 0.000 description 4
- GVMUJUPXFQFBBZ-GUBZILKMSA-N Ser-Lys-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GVMUJUPXFQFBBZ-GUBZILKMSA-N 0.000 description 4
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 4
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 4
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 4
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 4
- SYCFMSYTIFXWAJ-DCAQKATOSA-N Ser-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N SYCFMSYTIFXWAJ-DCAQKATOSA-N 0.000 description 4
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 4
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 4
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 4
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 4
- DHPPWTOLRWYIDS-XKBZYTNZSA-N Thr-Cys-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O DHPPWTOLRWYIDS-XKBZYTNZSA-N 0.000 description 4
- ZLNWJMRLHLGKFX-SVSWQMSJSA-N Thr-Cys-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZLNWJMRLHLGKFX-SVSWQMSJSA-N 0.000 description 4
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 4
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 4
- SXAGUVRFGJSFKC-ZEILLAHLSA-N Thr-His-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SXAGUVRFGJSFKC-ZEILLAHLSA-N 0.000 description 4
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 4
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 4
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 4
- XEVHXNLPUBVQEX-DVJZZOLTSA-N Thr-Trp-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N)O XEVHXNLPUBVQEX-DVJZZOLTSA-N 0.000 description 4
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 4
- BKVICMPZWRNWOC-RHYQMDGZSA-N Thr-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O BKVICMPZWRNWOC-RHYQMDGZSA-N 0.000 description 4
- SLOYNOMYOAOUCX-BVSLBCMMSA-N Trp-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SLOYNOMYOAOUCX-BVSLBCMMSA-N 0.000 description 4
- KXIQQAWIPDDVOE-BPUTZDHNSA-N Trp-Pro-Cys Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O KXIQQAWIPDDVOE-BPUTZDHNSA-N 0.000 description 4
- GZUIDWDVMWZSMI-KKUMJFAQSA-N Tyr-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GZUIDWDVMWZSMI-KKUMJFAQSA-N 0.000 description 4
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 4
- RIVVDNTUSRVTQT-IRIUXVKKSA-N Tyr-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O RIVVDNTUSRVTQT-IRIUXVKKSA-N 0.000 description 4
- ZLFHAAGHGQBQQN-AEJSXWLSSA-N Val-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZLFHAAGHGQBQQN-AEJSXWLSSA-N 0.000 description 4
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 4
- YLHLNFUXDBOAGX-DCAQKATOSA-N Val-Cys-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N YLHLNFUXDBOAGX-DCAQKATOSA-N 0.000 description 4
- KVRLNEILGGVBJX-IHRRRGAJSA-N Val-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CN=CN1 KVRLNEILGGVBJX-IHRRRGAJSA-N 0.000 description 4
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 4
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 4
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 4
- SVFRYKBZHUGKLP-QXEWZRGKSA-N Val-Met-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SVFRYKBZHUGKLP-QXEWZRGKSA-N 0.000 description 4
- QSPOLEBZTMESFY-SRVKXCTJSA-N Val-Pro-Val Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O QSPOLEBZTMESFY-SRVKXCTJSA-N 0.000 description 4
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 4
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 4
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 4
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 4
- UEXPMFIAZZHEAD-HSHDSVGOSA-N Val-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](C(C)C)N)O UEXPMFIAZZHEAD-HSHDSVGOSA-N 0.000 description 4
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 108010047495 alanylglycine Proteins 0.000 description 4
- 210000003423 ankle Anatomy 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 108010008355 arginyl-glutamine Proteins 0.000 description 4
- 230000002917 arthritic effect Effects 0.000 description 4
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 4
- 108010092854 aspartyllysine Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 108010074027 glycyl-seryl-phenylalanine Proteins 0.000 description 4
- 108010050848 glycylleucine Proteins 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 4
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 4
- 108010064235 lysylglycine Proteins 0.000 description 4
- 108010038320 lysylphenylalanine Proteins 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010004914 prolylarginine Proteins 0.000 description 4
- 108010090894 prolylleucine Proteins 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 235000011008 sodium phosphates Nutrition 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IESDGNYHXIOKRW-YXMSTPNBSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-YXMSTPNBSA-N 0.000 description 2
- DIBLBAURNYJYBF-XLXZRNDBSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-methylbutanoyl]amino]hexanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 DIBLBAURNYJYBF-XLXZRNDBSA-N 0.000 description 2
- ARNGIGOPGOEJCH-KKUMJFAQSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ARNGIGOPGOEJCH-KKUMJFAQSA-N 0.000 description 2
- HPYLHFWTUAGUNX-BGZSDMPXSA-N (3s)-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxo-3-[[(2s,6s)-2,6,10-triamino-4-[(diaminomethylideneamino)methyl]-5-oxodecanoyl]amino]butanoic acid Chemical compound NCCCC[C@H](N)C(=O)C(CN=C(N)N)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O HPYLHFWTUAGUNX-BGZSDMPXSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- BLGHHPHXVJWCNK-GUBZILKMSA-N Ala-Gln-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BLGHHPHXVJWCNK-GUBZILKMSA-N 0.000 description 2
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 2
- OMMDTNGURYRDAC-NRPADANISA-N Ala-Glu-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OMMDTNGURYRDAC-NRPADANISA-N 0.000 description 2
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 2
- BLTRAARCJYVJKV-QEJZJMRPSA-N Ala-Lys-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(O)=O BLTRAARCJYVJKV-QEJZJMRPSA-N 0.000 description 2
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 2
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 2
- RMAWDDRDTRSZIR-ZLUOBGJFSA-N Ala-Ser-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RMAWDDRDTRSZIR-ZLUOBGJFSA-N 0.000 description 2
- BOKLLPVAQDSLHC-FXQIFTODSA-N Ala-Val-Cys Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N BOKLLPVAQDSLHC-FXQIFTODSA-N 0.000 description 2
- JAYIQMNQDMOBFY-KKUMJFAQSA-N Arg-Glu-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JAYIQMNQDMOBFY-KKUMJFAQSA-N 0.000 description 2
- YNSGXDWWPCGGQS-YUMQZZPRSA-N Arg-Gly-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O YNSGXDWWPCGGQS-YUMQZZPRSA-N 0.000 description 2
- PZVMBNFTBWQWQL-DCAQKATOSA-N Arg-His-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N PZVMBNFTBWQWQL-DCAQKATOSA-N 0.000 description 2
- SSZGOKWBHLOCHK-DCAQKATOSA-N Arg-Lys-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N SSZGOKWBHLOCHK-DCAQKATOSA-N 0.000 description 2
- WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 description 2
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 2
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 2
- KXFCBAHYSLJCCY-ZLUOBGJFSA-N Asn-Asn-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O KXFCBAHYSLJCCY-ZLUOBGJFSA-N 0.000 description 2
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 2
- GMCOADLDNLGOFE-ZLUOBGJFSA-N Asn-Asp-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)N GMCOADLDNLGOFE-ZLUOBGJFSA-N 0.000 description 2
- SPIPSJXLZVTXJL-ZLUOBGJFSA-N Asn-Cys-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O SPIPSJXLZVTXJL-ZLUOBGJFSA-N 0.000 description 2
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 2
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 2
- NPZJLGMWMDNQDD-GHCJXIJMSA-N Asn-Ser-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NPZJLGMWMDNQDD-GHCJXIJMSA-N 0.000 description 2
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 2
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 2
- WSOKZUVWBXVJHX-CIUDSAMLSA-N Asp-Arg-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O WSOKZUVWBXVJHX-CIUDSAMLSA-N 0.000 description 2
- FMWHSNJMHUNLAG-FXQIFTODSA-N Asp-Cys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FMWHSNJMHUNLAG-FXQIFTODSA-N 0.000 description 2
- KVPHTGVUMJGMCX-BIIVOSGPSA-N Asp-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N)C(=O)O KVPHTGVUMJGMCX-BIIVOSGPSA-N 0.000 description 2
- IJHUZMGJRGNXIW-CIUDSAMLSA-N Asp-Glu-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IJHUZMGJRGNXIW-CIUDSAMLSA-N 0.000 description 2
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 2
- NVFSJIXJZCDICF-SRVKXCTJSA-N Asp-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N NVFSJIXJZCDICF-SRVKXCTJSA-N 0.000 description 2
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 2
- ZUNMTUPRQMWMHX-LSJOCFKGSA-N Asp-Val-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O ZUNMTUPRQMWMHX-LSJOCFKGSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000002734 Collagen Type VI Human genes 0.000 description 2
- 108010043741 Collagen Type VI Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- NOCCABSVTRONIN-CIUDSAMLSA-N Cys-Ala-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CS)N NOCCABSVTRONIN-CIUDSAMLSA-N 0.000 description 2
- CLDCTNHPILWQCW-CIUDSAMLSA-N Cys-Arg-Glu Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N CLDCTNHPILWQCW-CIUDSAMLSA-N 0.000 description 2
- YZFCGHIBLBDZDA-ZLUOBGJFSA-N Cys-Asp-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YZFCGHIBLBDZDA-ZLUOBGJFSA-N 0.000 description 2
- VBPGTULCFGKGTF-ACZMJKKPSA-N Cys-Glu-Asp Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VBPGTULCFGKGTF-ACZMJKKPSA-N 0.000 description 2
- ZEXHDOQQYZKOIB-ACZMJKKPSA-N Cys-Glu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZEXHDOQQYZKOIB-ACZMJKKPSA-N 0.000 description 2
- HBHMVBGGHDMPBF-GARJFASQSA-N Cys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N HBHMVBGGHDMPBF-GARJFASQSA-N 0.000 description 2
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 2
- WZJLBUPPZRZNTO-CIUDSAMLSA-N Cys-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N WZJLBUPPZRZNTO-CIUDSAMLSA-N 0.000 description 2
- YWEHYKGJWHPGPY-XGEHTFHBSA-N Cys-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N)O YWEHYKGJWHPGPY-XGEHTFHBSA-N 0.000 description 2
- FTTZLFIEUQHLHH-BWBBJGPYSA-N Cys-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O FTTZLFIEUQHLHH-BWBBJGPYSA-N 0.000 description 2
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LJEPDHWNQXPXMM-NHCYSSNCSA-N Gln-Arg-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O LJEPDHWNQXPXMM-NHCYSSNCSA-N 0.000 description 2
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 2
- XSBGUANSZDGULP-IUCAKERBSA-N Gln-Gly-Lys Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O XSBGUANSZDGULP-IUCAKERBSA-N 0.000 description 2
- HXOLDXKNWKLDMM-YVNDNENWSA-N Gln-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HXOLDXKNWKLDMM-YVNDNENWSA-N 0.000 description 2
- SFAFZYYMAWOCIC-KKUMJFAQSA-N Gln-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N SFAFZYYMAWOCIC-KKUMJFAQSA-N 0.000 description 2
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 2
- GTBXHETZPUURJE-KKUMJFAQSA-N Gln-Tyr-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GTBXHETZPUURJE-KKUMJFAQSA-N 0.000 description 2
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 2
- CSMHMEATMDCQNY-DZKIICNBSA-N Gln-Val-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CSMHMEATMDCQNY-DZKIICNBSA-N 0.000 description 2
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 2
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 description 2
- PKYAVRMYTBBRLS-FXQIFTODSA-N Glu-Cys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O PKYAVRMYTBBRLS-FXQIFTODSA-N 0.000 description 2
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 2
- ZHNHJYYFCGUZNQ-KBIXCLLPSA-N Glu-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O ZHNHJYYFCGUZNQ-KBIXCLLPSA-N 0.000 description 2
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 2
- CUPSDFQZTVVTSK-GUBZILKMSA-N Glu-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O CUPSDFQZTVVTSK-GUBZILKMSA-N 0.000 description 2
- UJMNFCAHLYKWOZ-DCAQKATOSA-N Glu-Lys-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O UJMNFCAHLYKWOZ-DCAQKATOSA-N 0.000 description 2
- YHOJJFFTSMWVGR-HJGDQZAQSA-N Glu-Met-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YHOJJFFTSMWVGR-HJGDQZAQSA-N 0.000 description 2
- BFEZQZKEPRKKHV-SRVKXCTJSA-N Glu-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O BFEZQZKEPRKKHV-SRVKXCTJSA-N 0.000 description 2
- DCBSZJJHOTXMHY-DCAQKATOSA-N Glu-Pro-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DCBSZJJHOTXMHY-DCAQKATOSA-N 0.000 description 2
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 description 2
- VNCNWQPIQYAMAK-ACZMJKKPSA-N Glu-Ser-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O VNCNWQPIQYAMAK-ACZMJKKPSA-N 0.000 description 2
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 2
- QVXWAFZDWRLXTI-NWLDYVSISA-N Glu-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O QVXWAFZDWRLXTI-NWLDYVSISA-N 0.000 description 2
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 2
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 2
- NTNUEBVGKMVANB-NHCYSSNCSA-N Glu-Val-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O NTNUEBVGKMVANB-NHCYSSNCSA-N 0.000 description 2
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 2
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 2
- RQZGFWKQLPJOEQ-YUMQZZPRSA-N Gly-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN)CN=C(N)N RQZGFWKQLPJOEQ-YUMQZZPRSA-N 0.000 description 2
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 2
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 2
- BGVYNAQWHSTTSP-BYULHYEWSA-N Gly-Asn-Ile Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BGVYNAQWHSTTSP-BYULHYEWSA-N 0.000 description 2
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 2
- JMQFHZWESBGPFC-WDSKDSINSA-N Gly-Gln-Asp Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JMQFHZWESBGPFC-WDSKDSINSA-N 0.000 description 2
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 2
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 2
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 2
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 2
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 2
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 2
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 2
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 2
- FOKISINOENBSDM-WLTAIBSBSA-N Gly-Thr-Tyr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FOKISINOENBSDM-WLTAIBSBSA-N 0.000 description 2
- IROABALAWGJQGM-OALUTQOASA-N Gly-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)CN IROABALAWGJQGM-OALUTQOASA-N 0.000 description 2
- ZVXMEWXHFBYJPI-LSJOCFKGSA-N Gly-Val-Ile Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZVXMEWXHFBYJPI-LSJOCFKGSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 2
- VCDNHBNNPCDBKV-DLOVCJGASA-N His-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VCDNHBNNPCDBKV-DLOVCJGASA-N 0.000 description 2
- WMKXFMUJRCEGRP-SRVKXCTJSA-N His-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N WMKXFMUJRCEGRP-SRVKXCTJSA-N 0.000 description 2
- SDTPKSOWFXBACN-GUBZILKMSA-N His-Glu-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O SDTPKSOWFXBACN-GUBZILKMSA-N 0.000 description 2
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 description 2
- ZVKDCQVQTGYBQT-LSJOCFKGSA-N His-Pro-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O ZVKDCQVQTGYBQT-LSJOCFKGSA-N 0.000 description 2
- XJFITURPHAKKAI-SRVKXCTJSA-N His-Pro-Gln Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CN=CN1 XJFITURPHAKKAI-SRVKXCTJSA-N 0.000 description 2
- VCBWXASUBZIFLQ-IHRRRGAJSA-N His-Pro-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O VCBWXASUBZIFLQ-IHRRRGAJSA-N 0.000 description 2
- MUENHEQLLUDKSC-PMVMPFDFSA-N His-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CNC=N1 MUENHEQLLUDKSC-PMVMPFDFSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- MKWSZEHGHSLNPF-NAKRPEOUSA-N Ile-Ala-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N MKWSZEHGHSLNPF-NAKRPEOUSA-N 0.000 description 2
- XENGULNPUDGALZ-ZPFDUUQYSA-N Ile-Asn-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N XENGULNPUDGALZ-ZPFDUUQYSA-N 0.000 description 2
- HVWXAQVMRBKKFE-UGYAYLCHSA-N Ile-Asp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HVWXAQVMRBKKFE-UGYAYLCHSA-N 0.000 description 2
- BEWFWZRGBDVXRP-PEFMBERDSA-N Ile-Glu-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BEWFWZRGBDVXRP-PEFMBERDSA-N 0.000 description 2
- CEPIAEUVRKGPGP-DSYPUSFNSA-N Ile-Lys-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 CEPIAEUVRKGPGP-DSYPUSFNSA-N 0.000 description 2
- IIWQTXMUALXGOV-PCBIJLKTSA-N Ile-Phe-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N IIWQTXMUALXGOV-PCBIJLKTSA-N 0.000 description 2
- 108010079091 KRDS peptide Proteins 0.000 description 2
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 2
- NTRAGDHVSGKUSF-AVGNSLFASA-N Leu-Arg-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NTRAGDHVSGKUSF-AVGNSLFASA-N 0.000 description 2
- FJUKMPUELVROGK-IHRRRGAJSA-N Leu-Arg-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N FJUKMPUELVROGK-IHRRRGAJSA-N 0.000 description 2
- BAJIJEGGUYXZGC-CIUDSAMLSA-N Leu-Asn-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N BAJIJEGGUYXZGC-CIUDSAMLSA-N 0.000 description 2
- PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 description 2
- HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 description 2
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 2
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 2
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 2
- PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 2
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 2
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 2
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 2
- LZWNAOIMTLNMDW-NHCYSSNCSA-N Lys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N LZWNAOIMTLNMDW-NHCYSSNCSA-N 0.000 description 2
- SVJRVFPSHPGWFF-DCAQKATOSA-N Lys-Cys-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SVJRVFPSHPGWFF-DCAQKATOSA-N 0.000 description 2
- XFBBBRDEQIPGNR-KATARQTJSA-N Lys-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N)O XFBBBRDEQIPGNR-KATARQTJSA-N 0.000 description 2
- YFGWNAROEYWGNL-GUBZILKMSA-N Lys-Gln-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YFGWNAROEYWGNL-GUBZILKMSA-N 0.000 description 2
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 2
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 2
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 2
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 2
- SLQJJFAVWSZLBL-BJDJZHNGSA-N Lys-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN SLQJJFAVWSZLBL-BJDJZHNGSA-N 0.000 description 2
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 2
- PINHPJWGVBKQII-SRVKXCTJSA-N Lys-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N PINHPJWGVBKQII-SRVKXCTJSA-N 0.000 description 2
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 2
- ODTZHNZPINULEU-KKUMJFAQSA-N Lys-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N ODTZHNZPINULEU-KKUMJFAQSA-N 0.000 description 2
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 2
- IEVXCWPVBYCJRZ-IXOXFDKPSA-N Lys-Thr-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IEVXCWPVBYCJRZ-IXOXFDKPSA-N 0.000 description 2
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 2
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 2
- IMDJSVBFQKDDEQ-MGHWNKPDSA-N Lys-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)N IMDJSVBFQKDDEQ-MGHWNKPDSA-N 0.000 description 2
- IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 2
- RMLWDZINJUDMEB-IHRRRGAJSA-N Met-Tyr-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N RMLWDZINJUDMEB-IHRRRGAJSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 2
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 2
- 108010066427 N-valyltryptophan Proteins 0.000 description 2
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 2
- AYPMIIKUMNADSU-IHRRRGAJSA-N Phe-Arg-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O AYPMIIKUMNADSU-IHRRRGAJSA-N 0.000 description 2
- UUWCIPUVJJIEEP-SRVKXCTJSA-N Phe-Asn-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N UUWCIPUVJJIEEP-SRVKXCTJSA-N 0.000 description 2
- YEEFZOKPYOUXMX-KKUMJFAQSA-N Phe-Gln-Met Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O YEEFZOKPYOUXMX-KKUMJFAQSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 2
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 2
- HQVPQXMCQKXARZ-FXQIFTODSA-N Pro-Cys-Ser Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O HQVPQXMCQKXARZ-FXQIFTODSA-N 0.000 description 2
- ODPIUQVTULPQEP-CIUDSAMLSA-N Pro-Gln-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ODPIUQVTULPQEP-CIUDSAMLSA-N 0.000 description 2
- ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 2
- QCARZLHECSFOGG-CIUDSAMLSA-N Pro-Glu-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O QCARZLHECSFOGG-CIUDSAMLSA-N 0.000 description 2
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 2
- STASJMBVVHNWCG-IHRRRGAJSA-N Pro-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 STASJMBVVHNWCG-IHRRRGAJSA-N 0.000 description 2
- KWMUAKQOVYCQJQ-ZPFDUUQYSA-N Pro-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 KWMUAKQOVYCQJQ-ZPFDUUQYSA-N 0.000 description 2
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 2
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 2
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 2
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 2
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 2
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 2
- CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 2
- DMNANGOFEUVBRV-GJZGRUSLSA-N Pro-Trp-Gly Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)O)C(=O)[C@@H]1CCCN1 DMNANGOFEUVBRV-GJZGRUSLSA-N 0.000 description 2
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 2
- FHJQROWZEJFZPO-SRVKXCTJSA-N Pro-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FHJQROWZEJFZPO-SRVKXCTJSA-N 0.000 description 2
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 2
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 2
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 2
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 2
- MESDJCNHLZBMEP-ZLUOBGJFSA-N Ser-Asp-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MESDJCNHLZBMEP-ZLUOBGJFSA-N 0.000 description 2
- KNCJWSPMTFFJII-ZLUOBGJFSA-N Ser-Cys-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O KNCJWSPMTFFJII-ZLUOBGJFSA-N 0.000 description 2
- MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 2
- MPPHJZYXDVDGOF-BWBBJGPYSA-N Ser-Cys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CO MPPHJZYXDVDGOF-BWBBJGPYSA-N 0.000 description 2
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 2
- HMRAQFJFTOLDKW-GUBZILKMSA-N Ser-His-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMRAQFJFTOLDKW-GUBZILKMSA-N 0.000 description 2
- IAORETPTUDBBGV-CIUDSAMLSA-N Ser-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N IAORETPTUDBBGV-CIUDSAMLSA-N 0.000 description 2
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 2
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 2
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 2
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 2
- KJKQUQXDEKMPDK-FXQIFTODSA-N Ser-Met-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O KJKQUQXDEKMPDK-FXQIFTODSA-N 0.000 description 2
- RRVFEDGUXSYWOW-BZSNNMDCSA-N Ser-Phe-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RRVFEDGUXSYWOW-BZSNNMDCSA-N 0.000 description 2
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 2
- OVQZAFXWIWNYKA-GUBZILKMSA-N Ser-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)N OVQZAFXWIWNYKA-GUBZILKMSA-N 0.000 description 2
- VFWQQZMRKFOGLE-ZLUOBGJFSA-N Ser-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O VFWQQZMRKFOGLE-ZLUOBGJFSA-N 0.000 description 2
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 2
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 2
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 2
- BCAVNDNYOGTQMQ-AAEUAGOBSA-N Ser-Trp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(O)=O BCAVNDNYOGTQMQ-AAEUAGOBSA-N 0.000 description 2
- SGZVZUCRAVSPKQ-FXQIFTODSA-N Ser-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N SGZVZUCRAVSPKQ-FXQIFTODSA-N 0.000 description 2
- FQPQPTHMHZKGFM-XQXXSGGOSA-N Thr-Ala-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O FQPQPTHMHZKGFM-XQXXSGGOSA-N 0.000 description 2
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 2
- YOSLMIPKOUAHKI-OLHMAJIHSA-N Thr-Asp-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O YOSLMIPKOUAHKI-OLHMAJIHSA-N 0.000 description 2
- UCCNDUPVIFOOQX-CUJWVEQBSA-N Thr-Cys-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 UCCNDUPVIFOOQX-CUJWVEQBSA-N 0.000 description 2
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 description 2
- KWQBJOUOSNJDRR-XAVMHZPKSA-N Thr-Cys-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N)O KWQBJOUOSNJDRR-XAVMHZPKSA-N 0.000 description 2
- OYTNZCBFDXGQGE-XQXXSGGOSA-N Thr-Gln-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O OYTNZCBFDXGQGE-XQXXSGGOSA-N 0.000 description 2
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 2
- FKIGTIXHSRNKJU-IXOXFDKPSA-N Thr-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CN=CN1 FKIGTIXHSRNKJU-IXOXFDKPSA-N 0.000 description 2
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 2
- JLNMFGCJODTXDH-WEDXCCLWSA-N Thr-Lys-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O JLNMFGCJODTXDH-WEDXCCLWSA-N 0.000 description 2
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 2
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 2
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 2
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 2
- VUXIQSUQQYNLJP-XAVMHZPKSA-N Thr-Ser-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N)O VUXIQSUQQYNLJP-XAVMHZPKSA-N 0.000 description 2
- SOUPNXUJAJENFU-SWRJLBSHSA-N Thr-Trp-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O SOUPNXUJAJENFU-SWRJLBSHSA-N 0.000 description 2
- CJEHCEOXPLASCK-MEYUZBJRSA-N Thr-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=C(O)C=C1 CJEHCEOXPLASCK-MEYUZBJRSA-N 0.000 description 2
- AXEJRUGTOJPZKG-XGEHTFHBSA-N Thr-Val-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O AXEJRUGTOJPZKG-XGEHTFHBSA-N 0.000 description 2
- DQDXHYIEITXNJY-BPUTZDHNSA-N Trp-Gln-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N DQDXHYIEITXNJY-BPUTZDHNSA-N 0.000 description 2
- NJNCVQYFNKZMAH-JYBASQMISA-N Trp-Thr-Cys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CS)C(O)=O)=CNC2=C1 NJNCVQYFNKZMAH-JYBASQMISA-N 0.000 description 2
- UPUNWAXSLPBMRK-XTWBLICNSA-N Trp-Thr-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UPUNWAXSLPBMRK-XTWBLICNSA-N 0.000 description 2
- SSSDKJMQMZTMJP-BVSLBCMMSA-N Trp-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSSDKJMQMZTMJP-BVSLBCMMSA-N 0.000 description 2
- SWSUXOKZKQRADK-FDARSICLSA-N Trp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N SWSUXOKZKQRADK-FDARSICLSA-N 0.000 description 2
- MICSYKFECRFCTJ-IHRRRGAJSA-N Tyr-Arg-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O MICSYKFECRFCTJ-IHRRRGAJSA-N 0.000 description 2
- WDIJBEWLXLQQKD-ULQDDVLXSA-N Tyr-Arg-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O WDIJBEWLXLQQKD-ULQDDVLXSA-N 0.000 description 2
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 2
- IXTQGBGHWQEEDE-AVGNSLFASA-N Tyr-Asp-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 IXTQGBGHWQEEDE-AVGNSLFASA-N 0.000 description 2
- DZKFGCNKEVMXFA-JUKXBJQTSA-N Tyr-Ile-His Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O DZKFGCNKEVMXFA-JUKXBJQTSA-N 0.000 description 2
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 2
- PMHLLBKTDHQMCY-ULQDDVLXSA-N Tyr-Lys-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMHLLBKTDHQMCY-ULQDDVLXSA-N 0.000 description 2
- YYLHVUCSTXXKBS-IHRRRGAJSA-N Tyr-Pro-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YYLHVUCSTXXKBS-IHRRRGAJSA-N 0.000 description 2
- QRCBQDPRKMYTMB-IHPCNDPISA-N Tyr-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N QRCBQDPRKMYTMB-IHPCNDPISA-N 0.000 description 2
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 2
- XQVRMLRMTAGSFJ-QXEWZRGKSA-N Val-Asp-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XQVRMLRMTAGSFJ-QXEWZRGKSA-N 0.000 description 2
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 2
- DLYOEFGPYTZVSP-AEJSXWLSSA-N Val-Cys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N DLYOEFGPYTZVSP-AEJSXWLSSA-N 0.000 description 2
- VFOHXOLPLACADK-GVXVVHGQSA-N Val-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N VFOHXOLPLACADK-GVXVVHGQSA-N 0.000 description 2
- VCAWFLIWYNMHQP-UKJIMTQDSA-N Val-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N VCAWFLIWYNMHQP-UKJIMTQDSA-N 0.000 description 2
- WDIGUPHXPBMODF-UMNHJUIQSA-N Val-Glu-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N WDIGUPHXPBMODF-UMNHJUIQSA-N 0.000 description 2
- RKIGNDAHUOOIMJ-BQFCYCMXSA-N Val-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 RKIGNDAHUOOIMJ-BQFCYCMXSA-N 0.000 description 2
- PMDOQZFYGWZSTK-LSJOCFKGSA-N Val-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C PMDOQZFYGWZSTK-LSJOCFKGSA-N 0.000 description 2
- MJXNDRCLGDSBBE-FHWLQOOXSA-N Val-His-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N MJXNDRCLGDSBBE-FHWLQOOXSA-N 0.000 description 2
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 2
- SBJCTAZFSZXWSR-AVGNSLFASA-N Val-Met-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N SBJCTAZFSZXWSR-AVGNSLFASA-N 0.000 description 2
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 2
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 108010057412 arginyl-glycyl-aspartyl-phenylalanine Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229940098166 bactrim Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000019628 coolness Nutrition 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 2
- 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 2
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 2
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 108010085325 histidylproline Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950000844 mizoribine Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108010025826 prolyl-leucyl-arginine Proteins 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 108010078580 tyrosylleucine Proteins 0.000 description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101100091691 Chlorobium chlorochromatii (strain CaD3) rpoA gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101001001496 Homo sapiens Interferon gamma receptor 2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 1
- 101710174028 Interferon gamma receptor 1 Proteins 0.000 description 1
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical class CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108010086662 phytohemagglutinin-M Proteins 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
- A47J37/00—Baking; Roasting; Grilling; Frying
- A47J37/04—Roasting apparatus with movably-mounted food supports or with movable heating implements; Spits
- A47J37/049—Details of the food supports not specially adapted to one of the preceding types of food supports
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A22—BUTCHERING; MEAT TREATMENT; PROCESSING POULTRY OR FISH
- A22C—PROCESSING MEAT, POULTRY, OR FISH
- A22C17/00—Other devices for processing meat or bones
- A22C17/006—Putting meat on skewers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
Abstract
本文披露了一种通过抑制T淋巴细胞的活化来治疗免疫性疾病的药物组合物,包括选自由以下物质组成的组中的两种或多种物质作为活性成分:能够阻断MHC(主要组织相容性复合体)II类分子与其受体结合的物质,能够阻断协同刺激分子与其受体结合的物质,能够阻断粘附分子与其受体结合的物质,以及能够阻断细胞因子与其受体结合的物质。
Description
技术领域
本发明涉及一种通过抑制T淋巴细胞的活化来治疗免疫性疾病的药物组合物,其包括选自由以下物质组成的组中的两种或多种物质作为活性成分:能够阻断MHC(主要组织相容性复合体)II类分子与其受体结合的物质,能够阻断协同刺激分子与其受体结合的物质,能够阻断粘附分子与其受体结合的物质,以及能够阻断细胞因子与其受体结合的物质。
背景技术
免疫反应是保护自身免受异己例如多种杂质、细菌或病毒攻击的过程。免疫系统被精细调控使得不会攻击自身。然而,在某些情况下,免疫反应会攻击自身并损害机体,移植器官或组织的免疫排斥以及自身免疫性疾病是其代表性例子。
治疗由器官或组织移植引起的疾病时,最重要的问题涉及到受体严重的移植排斥反应,发生在从供体移植组织或器官后。免疫排斥指的是受体内试图清除来自与受体遗传背景不同的供体移植物的免疫反应,这是由于受体将移植物识别为外源物质。移植排斥是源于复杂的通过T淋巴细胞介导的细胞免疫和通过抗体介导的体液免疫的联合作用而发生,但主要是源于通过T淋巴细胞介导的细胞免疫。
治疗移植排斥的一种方法是采用化合物抑制T淋巴细胞的活性。这样的免疫抑制剂包括咪唑立宾(MZ)、环胞菌素(CsA)、他克莫司(FK-506)、硫唑嘌呤(AZ)、莱氟米特(LEF)、肾上腺皮质类固醇例如泼尼松龙(predonisolone)或甲基泼尼松龙(methylpredonisolone)、deoxypergualin(DGS)和西罗莫司。
PCT公开出版物第WO 1999/65908号披露了一种利用吡咯[2,3-d]嘧啶化合物作为免疫抑制剂治疗自身免疫性疾病的方法。PCT公开出版物第WO 2000/21979号披露了一种利用环四肽化合物治疗移植排斥或自身免疫性疾病的方法。另一方面,在某些情况下,免疫细胞不能区分自身和异己(外源)物质并攻击自身,这种现象称为“自身免疫”。自身免疫反应可以在全身各个部位引起疾病。自身免疫性疾病的例子包括风湿性关节炎、多发性硬化症、重症肌无力、格雷夫斯病(Grave’sdisease)、慢性淋巴细胞性甲状腺炎、阿狄森病(Addison’sdisease)、白癜风、硬皮病、肺出血肾炎综合症、Becet’s病、节段性回肠炎(Crohne’s病)、强直性脊柱炎、葡萄膜炎、血小板减少性紫癜、寻常型天疱疮、儿童糖尿病、自身免疫性贫血、冷球蛋白血症、肾上腺脑白质营养不良(ALD)以及系统性红斑狼疮(SLE)。
PCT公开出版物第WO1996/40246号阐述了一种治疗和预防T细胞介导的自身免疫性疾病如多发性硬化的方法。该方法包括给予受治疗者治疗性或预防性有效量的T细胞表面受体拮抗剂,该受体介导接触依赖性的辅助效应器功能。该拮抗剂是抗体或其片段,能够特异性结合T细胞受体gp39。
PCT公开出版物第WO2002/22212号披露了一种治疗自身免疫性疾病(尤其B细胞介导的自身免疫性疾病)的方法,利用至少一种免疫调节性抗体以及至少一种B细胞消耗性抗体的组合,例如针对CD19、CD20、CD22、CD23或CD37的抗体。
然而,上述化合物用于治疗免疫性疾病时引起显著的不良反应,从而限制了其应用。正如PCT公开出版物第WO1996/40246号中所描述的,当抗体单独施加时,难以达到预期的疗效。而且,由于自身免疫性疾病或移植排斥起因于T淋巴细胞的活化,如PCT公开出版物第WO2002/22212号中所述阻断B细胞功能不能够有效的抑制免疫反应。
发明内容
通过对更有效的免疫抑制剂的开发进行深入而彻底的研究,本发明的发明人得到一个结论即当选自参与活化T淋巴细胞的几组蛋白的至少两组蛋白被同时阻断时,与已知的方法相比,T淋巴细胞的活性被有效地抑制,因此促成了本发明。
一方面,本发明提供了一种通过抑制T淋巴细胞的活化来治疗免疫性疾病的药物组合物,其包括选自由以下物质组成的组中的两种或多种物质作为活性成分:能够阻断MHCII类分子与其受体结合的物质,能够阻断协同刺激分子与其受体结合的物质,能够阻断粘附分子与其受体结合的物质,以及能够阻断细胞因子与其受体结合的物质。
附图说明
从以下结合附图的详细说明,可以更清楚地理解本发明的上述以及其他目的、特征和其他优点,在附图中:
图1是根据本发明的重组表达质粒pCD22Ig的遗传学图,表达连接融合单体蛋白CD2-CD2/Fc。
图2是根据本发明的重组表达质粒pCT44Ig的遗传学图,表达连接融合单体蛋白CTLA4-CTLA4/Fc。
图3是根据本发明的重组表达质粒pLAG33Ig的遗传学图,表达连接融合单体蛋白LAG3-LAG3/Fc。
图4是根据本发明的重组表达质粒pTR21Ig-Top’的遗传学图,表达连接融合单体蛋白TNFR2-TNFR1/Fc。
图5a示出了根据本发明对简单融合二聚体蛋白([CD2/Fc]2、[CTLA4/Fc]2和[LAG3/Fc]2)以及连接融合二聚体蛋白([CD2-CD2/Fc]2、[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2)进行SDS-PAGE分析的结果。
图5b示出了根据本发明对简单融合二聚体蛋白(1:[TNFR1/Fc]2、2:[TNFR2/Fc]2)以及连接融合二聚体蛋白(3:[TNFR2-TNFR1/Fc]2、4:[TNFR2-TNFR2/Fc]2)进行SDS-PAGE分析的结果。
图6a示出了根据本发明的简单融合二聚体蛋白([TNFR2/Fc]2、[CD2/Fc]2、[CTLA4/Fc]2和[LAG3/Fc]2)对T淋巴细胞增殖的抑制效应的曲线图。
图6b示出了根据本发明的简单融合二聚体蛋白的组合[CTLA4/Fc]2+[TNFR2/Fc]2、[CTLA4/Fc]2+[CD2/Fc]2和[CTLA4/Fc]2+[LAG3/Fc]2以及单独的[CTLA4/Fc]2对T淋巴细胞增殖的抑制效应的曲线图。
图6c示出了根据本发明的连接融合二聚体蛋白([TNFR2-TNFR2/Fc]2、[CD2-CD2/Fc]2、[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2)对T淋巴细胞增殖的抑制效应的曲线图。
图6d示出了根据本发明的连接融合二聚体蛋白的组合[CTLA4-CTLA4/Fc]2+[TNFR2-TNFR2/Fc]2、[CTLA4-CTLA4/Fc]2+[CD2-CD2/Fc]2和[CTLA4-CTLA4/Fc]2+[LAG3-LAG3/Fc]2以及单独的[CTLA4+CTLA4/Fc]2对T淋巴细胞增殖的抑制效应的曲线图。
图7a示出了根据本发明的简单融合二聚体蛋白([TNFR2/Fc]2、[CD2/Fc]2、[CTLA4/Fc]2和[LAG3/Fc]2)对小鼠胶原诱导的关节炎(collagen-induced arthritis,CIA)的严重程度的减弱效应曲线图。
图7b示出了根据本发明的简单融合二聚体蛋白的组合[CTLA4/Fc]2+[TNFR2/Fc]2、[CTLA4/Fc]2+[CD2/Fc]2和[CTLA4/Fc]2+[LAG3/Fc]2以及单独的[CTLA4/Fc]2对小鼠CIA严重程度的减弱效应曲线图。
图7c示出了根据本发明的连接融合二聚体蛋白([TNFR2-TNFR2/Fc]2、[CD2-CD2/Fc]2、[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2)对小鼠CIA严重程度的减弱效应曲线图。
图7d示出了根据本发明的连接融合二聚体蛋白的组合[CTLA4-CTLA4/Fc]2+[TNFR2-TNFR2/Fc]2、[CTLA4-CTLA4/Fc]2+[CD2-CD2/Fc]2和[CTLA4-CTLA4/Fc]2+[LAG3-LAG3/Fc]2以及单独的[CTLA4-CTLA4/Fc]2对小鼠CIA严重程度的减弱效应曲线图。
图8a示出了根据本发明的简单融合二聚体蛋白([CD2/Fc]2、[CTLA4/Fc]2和[LAG3/Fc]2)对小鼠从移植物抗宿主病(GVHD)存活的改善效应曲线图。
图8b示出了根据本发明的简单融合二聚体蛋白的组合[CTLA4/Fc]2+[LAG3/Fc]2和[CD2/Fc]2+[CTLA4/Fc]2对小鼠从移植物抗宿主病(GVHD)存活的改善效应曲线图。
图8c示出了根据本发明的简单融合二聚体蛋白[CTLA4/Fc]2和连接融合二聚体蛋白[CTLA4-CTLA4/Fc]2对小鼠移植物抗宿主病(GVHD)存活的改善效应曲线图。
图8d示出了根据本发明的简单融合二聚体蛋白[TNFR2/Fc]2和连接融合二聚体蛋白[TNFR2-TNFR2/Fc]2对小鼠移植物抗宿主病(GVHD)存活的改善效应曲线图。
图8e示出了根据本发明的简单融合二聚体蛋白[TNFR2/Fc]2和连接融合二聚体蛋白[TNFR2-TNFR1/Fc]2和[TNFR2-TNFR2/Fc]2对小鼠移植物抗宿主病(GVHD)存活的改善效应曲线图;以及
图8f示出了根据本发明的连接融合二聚体蛋白[CD2-CD2/Fc]2、[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2及其组合:[CD2-CD2/Fc]2+CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2+[CTLA4-CTLA4/Fc]2对小鼠移植物抗宿主病(GVHD)存活的改善效应曲线图。
具体实施方式
本文涉及一种通过抑制T淋巴细胞的活化来治疗免疫性疾病的药物组合物,其包括选自由以下物质组成的组中的两种或多种物质作为活性成分:能够阻断MHCII类分子与其受体结合的物质,能够阻断协同刺激分子与其受体结合的物质,能够阻断粘附分子与其受体结合的物质,以及能够阻断细胞因子与其受体结合的物质。
本领域中众所周知,T淋巴细胞仅识别抗原呈递细胞表面上与MHC(主要组织相容性复合体)II类分子相连的抗原,然后被活化并引起针对该抗原的免疫反应。除了MHC II类分子,抗原呈递细胞上还存在其他将活化信号传递至T淋巴细胞的分子,这些分子被称为“协同刺激分子”。另外,所谓的“粘附分子”通过传递信号的功能来增强抗原呈递细胞和T淋巴细胞之间的细胞间粘附。还有多种“细胞因子”参与包括T细胞活化的免疫反应。
“MHC II类分子”启动T淋巴细胞的活化,其受体包括CD4和LAG3。MHC II类分子结合抗原,随后被T淋巴细胞表面上的它们的受体(CD4)识别,从而导致T淋巴细胞的活化。因此,MHCII类分子的这种功能可以通过阻断MHC II类分子与其受体之间的结合而抑制。能够表现出这种抑制活性的物质包括但不限于MHC II类分子的抗体以及游离形式的MHC II类分子受体。这里所述的MHC II类分子的游离受体包括所有能够特异性结合MHC II类分子的受体,优选为Ig融合蛋白,其中的MHC II类分子受体或者其可溶性的细胞外结构域连接到整个免疫球蛋白或其Fc段上。Ig融合蛋白还可以是另外的糖基化形式。
“协同刺激分子”包括B7(B7.1和B7.2)、CD154、CD70、0X40L、ICOSL、4-1BBL、HVEM、FASL和PDL(PDL-1和PDL-2)以及它们的受体分别包括:分别为CD28、CTLA-4、CD40、CD27、0X40、ICOS、4-1BB(CD137)、LIGHT、FAS(CD95)和PD-1。协同刺激分子在抗原呈递细胞的表面表达,结合到其在T淋巴细胞表面表达的受体上,从而引起T淋巴细胞的活化。因此,协同刺激分子引起的T细胞活化可以通过阻断协同刺激分子与其受体之间的结合而抑制。能够表现出这种抑制活性的物质包括但不限于协同刺激分子的抗体以及游离形式的协同刺激分子的受体。这里所述的协同刺激分子的游离受体包括所有能够特异性结合协同刺激分子的受体,优选为Ig融合蛋白,其中协同刺激分子的受体或者其可溶性的细胞外结构域连接到免疫球蛋白或其Fc段上。此外,Ig融合蛋白还可以是糖基化形式。
“粘附分子”包括LFA-3、ICAM-1和VCAM-1以及它们的受体分别为CD2、LFA-1和VLA-4。粘附分子在抗原呈递细胞的表面表达,并结合到其在T淋巴细胞表面表达的受体上,从而引起T淋巴细胞的活化。因此,粘附分子引起的T细胞活化可以通过阻断粘附分子与其受体之间的结合而抑制。能够表现出这种抑制活性的物质包括但不限于粘附分子的抗体以及游离形式的粘附分子的受体。这里所述的粘附分子的游离受体包括所有能够特异性结合粘附分子的受体,优选为Ig融合蛋白,其中粘附分子的受体或者其可溶性的细胞外结构域连接到免疫球蛋白或其Fc段上。此外,Ig融合蛋白还可以是糖基化形式。
“细胞因子”包括IL-1、IL-2、IL-3、IL-4、IL-5、IL-6、IL-7、TNF、TGF、IFN、GM-CSF、G-CSF、EPO、TPO、M-CSF以及它们的受体分别包括:分别为IL-1R、IL-2R、IL-3R、IL-4R、IL-5R、IL-6R、IL-7R、TNFR、TGFR、IFNR(例如,IFN-γRα链、IFN-γRβ链)、IFN-αR、-βR和-γR、GM-CSFR、G-CSFR、EPOR、cMpl以及gp130。细胞因子结合其在B淋巴细胞或T淋巴细胞上的受体,诱发免疫反应。因此,由细胞因子诱发的免疫反应可以通过阻断细胞因子与其受体之间的结合而抑制。能够表现出这种抑制活性的物质包括但不限于细胞因子的抗体以及游离形式的细胞因子的受体。这里所述的细胞因子的游离受体包括所有能够特异性结合细胞因子的受体,优选为Ig融合蛋白,其中细胞因子的受体或者其可溶性的细胞外结构域连接到免疫球蛋白或其Fc段上。此外,Ig融合蛋白还可以是糖基化形式。
I.抗体
能够阻断MHC II类分子与其受体结合的物质可包括MHC II类分子的抗体。能够阻断协同刺激分子与其受体结合的物质可包括协同刺激分子的抗体。能够阻断粘附分子与其受体结合的物质可包括粘附分子的抗体。能够阻断细胞因子与其受体结合的物质可包括细胞因子的抗体。
抗体可以为多克隆或者单克隆。多克隆和单克隆抗体可以商购获得,或者可按照本领域所熟知的方法进行生产。多克隆抗体通常通过用合适量的抗原一次或多次免疫哺乳动物来生产,当抗体滴度达到预期水平时从被免疫的哺乳动物收集抗血清。如果需要,抗血清可以用已知的过程进行纯化,储存在冷冻缓冲液中直至使用。另一方面,单克隆抗体可以这样制备:给哺乳动物注射抗原、分离产生的B淋巴细胞、将B淋巴细胞与骨髓瘤细胞融合并培养由此得到的杂交瘤细胞。这些过程的细节在本领域是熟知的。
II.Ig融合蛋白
能够阻断MHC II类分子与其受体结合的物质可包括带有MHCII类分子受体的Ig融合蛋白。能够阻断协同刺激分子与其受体结合的物质可包括带有协同刺激分子受体的Ig融合蛋白。能够阻断粘附分子与其受体结合的物质可包括带有粘附分子受体的Ig融合蛋白。能够阻断细胞因子与其受体结合的物质可包括带有细胞因子受体的Ig融合蛋白。下文中,MHC II类分子受体、协同刺激分子受体、粘附分子受体以及细胞因子受体统称为“受体”。
如在本文中所使用的,术语“Ig融合蛋白”指的是一种含有可以连接到免疫球蛋白或其Fc段上的受体蛋白或者可溶性的细胞外结构域的融合蛋白。详细地,Ig融合蛋白包括简单融合单体形式、简单融合二聚体形式、连接融合(concatameric fusion)单体形式、连接融合二聚体形式以及其糖基化形式。
如在本文中所使用的,术语“可溶性的细胞外结构域”指的是含有磷脂的跨越细胞膜的完整膜蛋白的暴露在细胞外区域的部分,其中完整的膜蛋白含有一个或者多个主要由疏水氨基酸组成的跨膜结构域。这样的细胞外结构域主要含有亲水氨基酸,亲水氨基酸通常定位于蛋白质折叠结构的表面,因此在水相环境中可溶。对于大多数细胞表面受体蛋白,细胞外结构域用来结合特异的配体,而细胞内结构域则在信号转导中发挥重要作用。
如在本文中所使用的,术语“免疫球蛋白”指的是B细胞中产生的蛋白质分子,用作特异性识别多种抗原的抗原受体。这些分子具有Y型结构,含有两个相同的轻链(L链)以及两个相同的重链(H链),其中这四条链由包括铰链区的H链之间的二硫桥在内的多个二硫键保持在一起。L链和H链均含有可变区和恒定区。L链可变区与H链可变区相连,从而产生了两个相同的抗原结合区。根据H链恒定区的特征,免疫球蛋白(Ig)可以分为五个亚型:A(IgA)、D(IgD)、E(IgE)、G(IgG)和M(IgM)。免疫球蛋白分子的生物学功能例如补体活化、Fc受体介导的噬菌作用以及抗原依赖的细胞毒性,是由H链Fc区的结构决定子(互补决定区)介导的。这样的H链的Fc区用来构建根据本发明的二聚体蛋白,可以从上述免疫球蛋白的所有亚型中得到。
如在本文中所使用的,术语“免疫球蛋白分子的Fc段”指的是不具备抗原结合活性且易于结晶的片段(含有一个铰链区以及CH2和CH3结构域)以及用于将抗体结合到效应物质和效应细胞的部分。
如在本文中所使用的,术语“连接融合”指的是这样一种状态:受体蛋白的可溶性细胞外结构域的N末端连接到该受体蛋白的可溶性细胞外结构域的C末端,这样受体蛋白的两个可溶性细胞外结构域形成长的多肽。
如在本文中所使用的,术语“简单融合单体蛋白”指的是具有由单一多肽构成的单体结构的融合蛋白,该多肽由受体蛋白的可溶性细胞外结构域连接至免疫球蛋白分子Fc段铰链区而形成。在本发明中,为了方便起见,简单融合单体蛋白可以命名为“受体蛋白的名称/Fc”。例如,由LAG3蛋白的可溶性细胞外结构域连接到免疫球蛋白的Fc段而生成的简单融合单体蛋白命名为LAG3/Fc。如有需要,Fc段的来源也可以在命名中指出,例如,如果Fc段来自于IgG1,单体蛋白称为LAG3/IgG1Fc。
如在本文中所使用的,术语“简单融合二聚体蛋白”指的是具有二聚体结构的融合蛋白,其中两个简单融合单体蛋白通过在铰链区形成分子间二硫键而连接到一起。在本发明中,为了方便起见,这样的简单融合二聚体蛋白可以命名为“[受体蛋白名称/Fc]2”。例如,当通过在两个由LAG3蛋白的可溶性细胞外结构域与免疫球蛋白分子的Fc段连接生成的简单融合单体蛋白的铰链区形成分子间二硫键而融合时,得到的含有二聚体结构的融合蛋白命名为[LAG3/Fc]2。另外,如有需要,Fc段的来源也可以在命名中指出,例如,如果Fc段来自于IgG1,二聚体蛋白命名为[LAG3/IgG1Fc]2。
如在本文中所使用的,术语“连接融合单体蛋白”指的是具有由单一多肽组成的单体结构的融合蛋白,其中受体蛋白可溶性细胞外结构域的N末端连接到该受体蛋白可溶性细胞外结构域的C末端,而前一个可溶性细胞外结构域的C末端连接到免疫球蛋白Fc段的铰链区。在本发明中,为了方便起见,连接融合单体蛋白可以命名为“受体蛋白名称-受体蛋白名称/Fc”。例如,由LAG3蛋白的可溶性细胞外结构域与免疫球蛋白Fc段连接产生的简单融合单体蛋白的LAG3的可溶性细胞外结构域连接到LAG3的可溶性细胞外结构域时,所得到的连接融合单体蛋白命名为LAG3-LAG3/Fc。如有需要,Fc段的来源也可以在命名中指出,例如,如果Fc段来自于IgG1,连接蛋白命名为LAG3-LAG3/IgG1Fc。
如在本文中所使用的,术语“连接融合二聚体蛋白”指的是具有二聚体结构的融合蛋白,其中两个连接融合单体蛋白通过在铰链区形成分子间二硫键融合。在本发明中,为了方便起见,连接融合二聚体蛋白可以命名为“[受体蛋白名称-受体蛋白名称/Fc]2”。例如,两个均由简单融合单体蛋白的LAG3的可溶性细胞外结构域连接到LAG3蛋白的可溶性细胞外结构域生成的连接融合单体蛋白,通过在铰链区形成分子间二硫键而融合,所得到的具有二聚体结构的融合蛋白命名为[LAG3-LAG3/Fc]2,其中该简单融合单体蛋白通过LAG3的可溶性细胞外结构域连接到免疫球蛋白分子的Fc段而形成。如有需要,Fc段的来源也可以在命名中指出,例如,如果Fc段来自于IgG1,融合蛋白命名为[LAG31-LAG3/IgG1Fc]2。
另一方面,简单融合单体蛋白或简单融合二聚体蛋白可以通过本领域所熟知的典型方法而制备。连接融合单体蛋白或者连接融合二聚体蛋白可以通过由本发明人提交的PCT公开出版物第WO2003/010202号中所描述的制备方法而获得。
根据本发明,连接融合二聚体蛋白通常按如下步骤制备:(a)利用编码免疫球蛋白分子Fc段的基因和编码受体蛋白可溶性细胞外结构域的基因制备编码简单融合单体蛋白的DNA构建体;(b)通过聚合酶链反应(PCR),在制备的编码简单融合单体蛋白的DNA构建体以及编码受体蛋白的可溶性细胞外结构域的基因中分别插入限制性酶的识别序列;(c)利用能够识别该识别序列的限制性酶,切割编码简单融合单体蛋白的DNA构建体以及编码受体蛋白可溶性细胞外结构域的基因中的识别序列;(d)利用连接酶连接经切割的DNA片段,以生成编码连接融合单体蛋白的DNA构建体;(e)将制备的编码连接融合单体蛋白的DNA构建体可操作地连接到载体上生成重组表达质粒;(f)用重组表达质粒转化或转染宿主细胞;以及(g)在适合编码连接融合单体蛋白的DNA构建体表达的条件下培养转化体或转染体,然后分离并纯化感兴趣的连接融合二聚体蛋白。
根据本发明,为了允许额外的O-连接或者N-连接糖基化,改变编码受体蛋白可溶性细胞外结构域的DNA序列中的一个或多个核苷酸,所得到的DNA在合适的动物宿主细胞中表达以利用宿主系统诱发糖基化。根据本发明的一个方面,根据本发明的糖基化的连接融合二聚体蛋白可以通过改变编码受体蛋白的可溶性细胞外结构域的DNA序列,通过加入Asn-X-Ser/Thr序列诱发或增强N-连接的糖基化而制备。
本发明将详细描述MHC II类分子以及B7分子(作为协同刺激分子的示例性实例)、LFA-3分子(作为粘附分子的示例性实例)和TNF(作为细胞因子的示例性实例)。
“MHC II类分子”被能够特异性结合MHC II类分子的CD4和LAG3受体所识别。因此LAG3的Ig融合蛋白可以用来阻断MHCII类分子与CD4的结合。详细地,能够阻断MHC II类分子与CD4结合的物质包括(1)MHC II类分子的抗体;(2)简单融合单体蛋白,通过LAG3的可溶性细胞外结构域连接到免疫球蛋白分子Fc段铰链区形成;(3)简单融合二聚体蛋白,由两分子的简单融合单体蛋白通过在铰链区的分子间二硫键而连接得到;(4)连接融合单体蛋白,通过连接在简单融合单体蛋白铰链区的LAG3可溶性细胞外结构域的N-末端连接到另一个LAG3分子可溶性细胞外结构域的C-末端而得到;(5)连接融合二聚体蛋白,其中两分子连接融合单体蛋白通过在铰链区形成的分子间二硫键而连接;以及(6)从(2)到(5)中蛋白的糖基化形式。
“B7分子”被能够特异性结合到B7分子的CD28和CTLA4所识别。特别的是,B7分子结合到T淋巴细胞表面表达的CD28上,活化T淋巴细胞。与之形成对比的是,当B7分子结合到另一个受体CTLA4(在T淋巴细胞活化后表达)上时则抑制T淋巴细胞的活化。因此,CTLA4的Ig融合蛋白被优选用来阻断B7分子与CD28的结合。详细地,能够用于阻断B7分子与CD4结合的物质包括(1)B7分子的抗体;(2)简单融合单体蛋白,通过CTLA4的可溶性细胞外结构域连接到免疫球蛋白分子Fc段铰链区而形成;(3)简单融合二聚体蛋白,其中两分子简单融合单体蛋白通过在铰链区形成分子间二硫键而连接;(4)连接融合单体蛋白,通过连接在简单融合单体蛋白铰链区的CTLA4可溶性细胞外结构域的N-末端连接到另一个CTLA4分子可溶性细胞外结构域的C-末端而得到;(5)连接融合二聚体蛋白,其中两分子连接融合单体蛋白通过在铰链区形成的分子间二硫键而连接;以及(6)根据(2)到(5)中蛋白的糖基化形式。
通过阻断LFA3与T淋巴细胞表面CD2的结合,可以抑制“LFA3分子”的T淋巴细胞活化功能。这种免疫抑制物质包括(1)LFA3分子的抗体;(2)简单融合单体蛋白,通过CD2的可溶性细胞外结构域连接到免疫球蛋白分子Fc段铰链区形成;(3)简单融合二聚体蛋白,由两分子简单融合单体蛋白通过在铰链区的分子间二硫键而连接得到;(4)连接融合单体蛋白,通过连接在简单融合单体蛋白铰链区的CD2可溶性细胞外结构域的N-末端连接到另一个CD2分子可溶性细胞外结构域的C-末端而形成;(5)连接融合二聚体蛋白,其中两分子连接融合单体蛋白通过在铰链区的分子间二硫键而连接;以及(6)根据(2)到(5)中蛋白的糖基化形式。
“TNF”的免疫反应激活功能可以通过阻断TNF与T淋巴细胞表面的TNFR之间的结合而抑制。这种免疫抑制物质包括(1)TNF的抗体;(2)简单融合单体蛋白,通过TNFR的可溶性细胞外结构域连接到免疫球蛋白分子Fc段的铰链区而形成;(3)简单融合二聚体蛋白,其中两分子简单融合单体蛋白通过在铰链区的分子间二硫键而连接;(4)连接融合单体蛋白,通过连接在简单融合单体蛋白铰链区的TNFR可溶性细胞外结构域的N-末端连接到另一个TNFR分子可溶性细胞外结构域的C-末端而形成;(5)连接融合二聚体蛋白,其中两分子连接融合单体蛋白通过在铰链区的分子间二硫键而连接;以及(6)根据(2)到(5)中蛋白的糖基化形式。
III.免疫性疾病
根据本发明的活性成分因为能够抑制T淋巴细胞的活化,因此可以用来治疗多种由不需要的T淋巴细胞活化而引起的疾病。这样的疾病的代表性例子是移植排斥和自身免疫性疾病。
“移植排斥”指的是由于移植物(被移植的生命体的部分,细胞、组织或者器官)的供体与受体之间遗传背景的不同而引起的免疫反应,包括(1)一种被称为“移植物抗宿主病(GVHD)”的疾病,当来自供体移植物的免疫细胞将受体识别为外源性物质并攻击受体时而引起,以及(2)一种被称为“移植排斥”的疾病,当受体将供体的移植物识别为外源性物质并攻击移植物时而引起。
另一方面,当免疫细胞不区分自身与异己(外源)物质并攻击自身时发生的疾病统称为“自身免疫性疾病”。详细地,自身免疫性疾病包括风湿性关节炎、多发性硬化症、重症肌无力、格雷夫斯病(Grave’s病)、慢性淋巴细胞性甲状腺炎、阿狄森病(Addison’s病)、白癜风、硬皮病、肾炎-肺出血综合症(Goodpasture综合征)、Becet’s病、节段性回肠炎(Crohne’s病)、强直性脊柱炎、葡萄膜炎、血小板减少性紫癜、寻常型天疱疮、儿童糖尿病、自身免疫性贫血、冷球蛋白血症、肾上腺脑白质营养不良(ALD)以及系统性红斑狼疮(SLE)。
IV.药物组合物
本发明的药物组合物可能优选这样一种形式使得有效治疗量的两种或多种活性成分加载在药学上可接受的载体上,该活性成分选自由以下物质组成的组:能够阻断MHCII类分子与其受体结合的物质,能够阻断协同刺激分子与其受体结合的物质,能够阻断粘附分子与其受体结合的物质,以及能够阻断细胞因子与其受体结合的物质。
本发明的药物组合物中所用的载体包括药学领域中通常所用的载体、佐剂与赋形剂,总称为“药学上可接受的载体”。本发明的药物组合物中所用的非限制性药学上可接受的载体包括离子交换剂、氧化铝、硬脂酸铝、卵磷脂、血清蛋白质(例如:人血清白蛋白)、缓冲试剂(例如:磷酸钠、甘氨酸、山梨酸、山梨酸钾、植物饱和脂肪酸的偏甘油酯混合物),水,盐或电解质(例如,硫酸钾、磷酸氢二钠、磷酸氢钾、氯化钠以及锌盐)、硅胶、三硅酸镁、聚乙烯吡咯烷酮、基于纤维素的基质、聚乙二醇、羧甲基纤维素钠、聚丙烯酸酯(聚芳基化物)(polyarylate)、蜡、聚乙烯-聚氧丙烯-嵌段共聚物、聚乙二醇以及羊毛脂。
本发明的药物组合物可以通过任何一种能够到达预期组织的常用途径给药。因此本发明的药物组合物可以局部给药、口服、肠胃外给药、眼内用药、透皮给药、直肠内以及管腔内给药,可以配制成溶液、悬浮液、片剂、丸剂、胶囊以及缓释剂。如在本文中所使用的,“肠胃外(用药)”包括皮下、鼻内、静脉内、腹膜内、肌肉内、关节内、滑膜内、胸骨内、贲门内、鞘内、病灶内以及颅内注射或者灌注技术。
一方面,本发明的药物组合物可以配制成水相溶液用于肠胃外给药。合适的缓冲液,比如Hank’s液、林格溶液(Ringer’s液)或者生理缓冲盐水可以优选采用。水相注射悬浮液可以补充一些能够增加其粘度的物质,例如羧甲基纤维素钠、山梨糖醇和右旋糖酐。另外,活性成分的悬浮液例如油性注射悬浮液含有亲脂溶剂或者载体,例如脂油如芝麻油以及合成脂肪酸酯如油酸乙酯、甘油三酯或脂质体。多聚阳离子非脂质氨基聚合物也可以用作赋形剂。可选择地,悬浮液可以包含合适的稳定剂或者药物以增强蛋白变异体的溶解度,获得高浓度的蛋白变异体。
本发明的药物组合物优选为无菌注射制剂的形式,例如无菌注射水相或油相悬浮液。根据本领域所熟知的方法,利用合适的分散剂或湿润剂(如Tween 80)以及悬浮剂,即可配制该悬浮液。无菌注射制剂还可以是在无毒肠胃外可接受的稀释剂或溶剂里的无菌注射溶液或者悬浮液,比如1,3-丁二醇溶液。可接受的赋形剂和溶剂包括甘露醇、水、林格溶液、等渗氯化钠溶液。此外,无菌不挥发性油也方便用作溶剂或者悬浮介质。任何温和的不挥发性油均可用于此目的,包括合成的单甘油酯或甘油二酯。另外脂肪酸例如油酸及其甘油酯衍生物也可用于注射性制剂的制备,例如药学上可接受的天然油(如:橄榄油或蓖麻油),特别是,其聚氧乙烯(乙烷)化衍生物。
上述水相组合物的灭菌主要是通过用滤器过滤除去细菌、混入消毒剂或者与放射线联合使用。无菌组合物可以通过如冻干等方法硬化而获得硬化产品,在实际应用中,硬化产品可溶于无菌水或无菌稀释液中。
根据本发明,为了增加室温稳定性、降低低温储存所需的高费用以及延长存放期,含有根据本发明的活性成分的药物组合物可以冻干。冻干的过程包括以下步骤:冷冻、第一次干燥和第二次干燥。冷冻后,组成物在高压下加热以蒸发水蒸气。在第二次干燥步骤中可以将残余水分从干燥产品除去。
如在本发明中与本发明的药物组合物联合使用的,术语“有效治疗量”意指这样的量,将其中本发明的药物组合物应用于免疫性疾病时,活性成分显示出对免疫性疾病的改善或者治疗的效果。本发明药物组合物的有效治疗量可能随着患者的年龄和性别、应用部位、给药频率、给药持续时间、制剂类型以及佐剂类型而变化。通常,本发明的药物组合物以如0.01-1000微克/千克/天、更优选0.1-500微克/千克/天、最优选1-100微克/千克/天的量给药。
参照以下实施例并结合附图来更加详细的解释本发明。然而,下面的实施例仅是为了说明本发明而本发明不局限于此。
以下实施例1涉及LAG3。关于LAG3/Fc和LAG3-LAG3/Fc融合蛋白的氨基酸序列、编码该融合蛋白的DNA序列以及用来制备该融合蛋白的引物的信息总结在下面的表1中。
表1关于LAG3/Fc和LAG3-LAG3/Fc的DNA和氨基酸序列以
及用来制备融合蛋白的引物的信息
序列ID号 | 备注 | |
Oligo-LAG3-F-EcoRI | 1 | 引物,含有LAG3可溶性细胞外结构域的5’末端以及EcoRI位点 |
Oligo-LAG3-R-5P | 2 | 引物,含有LAG3可溶性细胞外结构域的3’末端 |
Oligo-LAG3-F-5P | 3 | 引物,含有LAG3可溶性细胞外结构域的5’末端 |
Oligo-LAG3-R-SpeI | 4 | 引物,含有LAG3可溶性细胞外结构域的3’末端以及SpeI位点 |
hIgG-F-SpeI | 5 | 引物,含有IgG铰链区的5’末端以及SpeI位点 |
hIgG-R-XbaI | 6 | 引物,含有IgG的3’末端以及XbaI位点 |
编码LAG3/Fc的DNA序列 | 7 | - |
LAG3/Fc的氨基酸序列 | 8 | - |
编码LAG3-LAG3/Fc的DNA序列 | 9 | - |
LAG3-LAG3/Fc的氨基酸序列 | 10 | - |
实施例1:根据本发明的编码Ig融合蛋白的DNA构建体的制备
A.制备编码简单融合单体蛋白LAG3/Fc的DNA构建体
a.编码LAG3可溶性细胞外结构域的DNA片段
编码LAG3可溶性细胞外结构域的DNA片段可以通过PCR构建,利用具有EcoRI限制性位点以及编码引导序列(序列ID号为8的1-22氨基酸序列)的序列(序列ID号为7的核苷酸序列)的引物(序列ID号为1的核苷酸序列);以及具有SpeI限制性位点以及编码所述LAG3的可溶性细胞外结构域3’末端的部分的序列(序列ID号为7的核苷酸序列)的反义引物(序列ID号为4的核苷酸序列)。该反应的模板cDNA通过从健康成人单核细胞(T淋巴细胞)提取的mRNA的逆转录PCR(RT-PCR)来构建。
抽取健康成人的血液后,用RPMI-1640(Gibco BRL,USA)稀释成1∶1,用Ficoll-hypaque(Amersham,USA)通过密度梯度离心法可以得到上层部分形成的T淋巴细胞层。该细胞用RPMI-1640洗涤三次,加入含有10%胎牛血清(FBS,Gbico BRL,USA)的RPMI-1640培养基使细胞浓度达到5×105个细胞/毫升,然后在加入植物血球凝集素-M(Calbiochem,Germany)至2微克/毫升之后进行刺激。
mRNA用Tri-Reagent(MRC,USA)mRNA纯化试剂盒进行纯化。首先,将2×107的人类T淋巴细胞用磷酸盐缓冲盐水(PBS,pH7.2)洗涤三次,然后混入1毫升Tri-Reagent几次以溶解RNA。试管中加入0.2毫升氯仿并彻底混匀后,在室温(RT)孵育该试管15分钟,然后15,000rpm 4℃离心15分钟。将溶液的上面部分转移至1.5毫升管中,加入0.5毫升异丙醇,然后在4℃以15,000rpm离心15分钟。弃上清后,沉淀用1毫升经75%乙醇-25%DEPC(Sigma,USA)处理过的3°蒸馏水重新悬浮,然后15,000rpm 4℃离心15分钟。在彻底去除上清液并在空气中干燥以去除残留乙醇后,将RNA用50微升DEPC处理过的3°蒸馏水重新悬浮。
初始cDNA的合成如下:在1.5毫升管中混合2微克纯化的mRNA以及1微升oligo-dT(dT30,Promega,USA)引物至10μM,70℃加热2分钟,冰上冷却2分钟。随后,在混合物中加入200U的M-MLV逆转录酶(Promega,USA)、10微升5×反应缓冲液(250mM Tris-HCl、pH8.3、375mM KCl、15mM MgCl2以及50mMDTT)、1微升dNTP(每种10mM,Takara,Japan)以及DEPC处理过的3°蒸馏水至50微升,于42℃反应1小时。
b.编码免疫球蛋白G1的Fc段的DNA片段
编码免疫球蛋白G1的Fc段的DNA片段可以利用引物通过PCR构建,该引物(序列ID号为5的核苷酸序列)具有SpeI限制性位点以及编码免疫球蛋白G1(IgG1)铰链区5’末端的部分的序列;反义引物(序列ID号为6的核苷酸序列)具有XbaI限制性位点以及编码IgG1Fc段3’末端的序列。该反应的模板cDNA通过从不明原因发热的康复期患者的外周血细胞(B淋巴细胞)提取的mRNA的RT-PCR构建。
c.编码简单融合单体蛋白LAG3/Fc的DNA构建体
如上所述生成的编码LAG可溶性细胞外结构域的DNA片段和编码免疫球蛋白Fc段的DNA片段均采用SpeI限制性切割(restricted),然后用T4连接酶(USB,USA)进行连接,从而生成简单融合单体蛋白LAG/Fc。
d.编码简单融合单体蛋白LAG/Fc的DNA构建体的克隆
如上所述的编码简单融合单体蛋白LAG/Fc的DNA构建体用EcoRI和XbaI限制性切割,通过在EcoRI/XbaI位点插入到市售的克隆载体pBluescript KS II(+)(Stratagene,USA)而进行克隆。整个编码区的序列通过DNA测序确定(序列ID号:7)。作为简单融合单体蛋白,生成的融合蛋白命名为LAG3/Fc,推测的简单融合单体蛋白LAG3/Fc氨基酸序列与序列ID号8一致。
B.制备编码连接融合单体蛋白LAG3-LAG3/Fc的DNA构建体
为了生成编码连接融合单体蛋白LAG3-LAG3/Fc的DNA构建体,编码LAG3的可溶性细胞外结构域的DNA片段可以利用引物通过PCR构建,引物(序列ID号为1的核苷酸序列)具有EcoRI限制性位点以及编码引导序列(序列ID号为8的1-22氨基酸序列)的序列(序列ID号为7的核苷酸序列);反义引物(序列ID号为4的核苷酸序列)具有编码所述的LAG3的可溶性细胞外结构域的3’末端的部分的序列(序列ID号为7的核苷酸序列)。同样,编码简单融合单体蛋白LAG3/Fc的DNA片段可以利用引物通过PCR构建,引物(序列ID号为3的核苷酸序列)编码LAG3的可溶性细胞外结构域的引导序列的末端部分(序列ID号为7的核酸序列),以及反义引物(序列ID号为6的核苷酸序列)具有XbaI限制性位点以及编码IgG1Fc段3’末端的序列。对于这些PCR,编码简单融合单体蛋白LAG3/Fc(序列ID号为7的核苷酸序列)的DNA片段被用作模板。
PCR通过加入1微升初始cDNA、2U的Pfu DNA聚合酶(Stratagene,USA)、10微升10×反应缓冲液[200mM Tris-HCl,pH8.75、100mM(NH4)2SO4、100mM KCl、20mM MgCl2]、1%TritonTMX-100、1毫克/毫升BSA、3微升引物1(10μM)、3微升引物2(10μM)、2微升dNTP(每种10mM),以及3°蒸馏水至100微升而进行。反应条件如下:94℃,5分钟;95℃,1分钟;58℃,1分30秒;72℃,1分钟31个循环;72℃,15分钟,以使PCR产物具有完整的平端。
在0.8%的琼脂糖凝胶上电泳后,PCR产物用QiaexII凝胶提取试剂盒(Qiagen,USA)进行纯化。纯化的PCR产物用BamHI限制性切割,并用酚-氯仿抽提的方法进行提取。接下来,用BamHI限制性切割的两种DNA片段用连接酶进行连接。
C.编码连接融合单体蛋白LAG3-LAG3/Fc的DNA构建体的克隆
如上所述的编码连接融合单体蛋白LAG3-LAG3/Fc的DNA构建体用EcoRI和XbaI限制性切割,通过在EcoRI/XbaI位点插入市售的克隆载体pBluescript KS II(+)(Stratagene,USA)而克隆。整个编码区的序列通过DNA测序确定(序列ID号:9)。作为连接融合单体蛋白,生成的融合蛋白命名为LAG3-LAG3/Fc,其推测的氨基酸序列与序列ID号10一致。
10微克用作载体的pBluescript KS II(+)(Stratagene,USA)与15U EcoRI、15UXbaI、5微升10×反应缓冲液(100mM Tris-HCl,pH7.5、100mM MgCl2、10mM DTT、500nM NaCl)、5微升0.1%BSA(Takara,Japan)以及3°蒸馏水混合至50微升,通过在37℃孵育2小时DNA被限制性切割。在0.8%的琼脂糖凝胶上电泳后,PCR产物用Qiaex II凝胶提取试剂盒(Qiagen,USA)进行纯化。
100ng被EcoRI和XbaI限制性切割的pBluescript KS II(+)(Stratagene,USA)与20ng被限制性酶切割的PCR产物混合之后,加入0.5U T4DNA连接酶(Amersham,USA)、1微升10×反应缓冲液(300mM Tris-HCl,pH7.8、100mM MgCl2、100mM DTT、10mMATP)和3°蒸馏水至10微升,混合物在16℃水浴孵育16小时。
通过氯化铷(RbCl,Sigma,USA)的方法将E.coli Top10(Novex,USA)制成感应细胞(competent cell),用上面所述的质粒进行转化,然后涂在含有50微克/毫升氨苄青霉素(Sigma,USA)的固体LB培养基上,37℃孵育16小时。形成的菌落接种在4毫升含有50微克/毫升氨苄青霉素的液体LB培养基中,37℃孵育16小时。根据Sambrook et al.(Molecular Cloning,Cold Spring Harbor Laboratorypress,p1.25-1.31,p1.63-1.69,p7.26-7.29,1989)的碱裂解法,从1.5毫升上述孵育液中纯化质粒,克隆的存在用EcoRI和XbaI限制性切割进行确认。
整个编码区的序列通过如下的双脱氧链末端终止法(dideoxychain termination method)(Sanger et al.,Proc.Natl.Acad.Sci.,74:5483,1977)的DNA测序方法来确定。根据操作指南,利用通过如上所述的碱裂解法纯化所得的质粒和测序酶(SequenaseTM)ver2.0(Amersham,USA)进行DNA测序反应。如上所述的反应混合物加样到6%聚丙烯酰胺凝胶上,50℃恒定电压1,800~2,000V电泳(electrophorized)2小时,待凝胶干燥后通过曝光到X射线胶片(Kodak,USA)上,从而确认DNA序列。
实施例2:制备根据本发明的编码Ig融合蛋白的DNA构建体
其他蛋白TNFR1、TNFR2、CD2和CTLA4的简单融合二聚体蛋白以及连接融合二聚体蛋白,根据如实施例1中相同的步骤而制备。详细的步骤在PCT公开第WO2003/010202号中进行了描述,该PCT申请是由本发明人提交的。关于TNFR1、TNFR2、CD2和CTLA4的Ig融合蛋白的DNA和氨基酸序列的信息总结在下面的表2中。
表2根据本发明的Ig融合蛋白及其DNA和氨基酸序列
序列ID号 | |
编码TNFR2/Fc的DNA序列 | 11 |
TNFR2/Fc的氨基酸序列 | 12 |
编码TNFR2-TNFR2/Fc的DNA序列 | 13 |
TNFR2-TNFR2/Fc的氨基酸序列 | 14 |
编码CD2/Fc的DNA序列 | 15 |
CD2/Fc的氨基酸序列 | 16 |
编码CD2-CD2/Fc的DNA序列 | 17 |
CD2-CD2/Fc的氨基酸序列 | 18 |
编码CTLA4/Fc的DNA序列 | 19 |
CTLA4/Fc的氨基酸序列 | 20 |
编码CTLA4-CTLA4/Fc的DNA序列 | 21 |
CTLA4-CTLA4/Fc的氨基酸序列 | 22 |
编码TNFR1/Fc的DNA序列 | 23 |
TNFR1/Fc的氨基酸序列 | 24 |
编码TNFR2-TNFR1/Fc的DNA序列 | 25 |
TNFR2-TNFR1/Fc的氨基酸序列 | 26 |
实施例3:简单/连接融合二聚体蛋白LAG3/Fc的表达和纯化
为了在CHO-K1细胞(ATCC CCL-61,卵巢,中国仓鼠,Cricetulus griseus)中表达融合蛋白,含有LAG3-LAG3/Fc融合基因的pBluescript KS II(+)质粒DNA从转化的E.coli中纯化后,用EcoRI和XbaI限制性切割产生的LAG3-LAG3/Fc片段在动物表达载体pCRTM3(Invitrogen,USA)质粒的EcoRI/XbaI位点插入,从而构建动物细胞表达载体。这些命名为质粒pLAG3-TOP10′,以登记号KCCM-10556于2004年1月13日保藏在韩国微生物培养中心(KCCM,361-221,Yurim B/D,Hongje-1-dong,Seodaemun-gu,SEOUL 120-091,韩国)。
将含有如上所述LAG3-LAG3/Fc融合基因的质粒pLAG33IgDNA与LipofectaminTM(Gibco BRL,USA)试剂混合后进行转染。CHO-K1细胞以1~3×105个细胞/孔的浓度接种在6孔组织培养板(Nunc,USA)中,在含10%FBS-DMEM培养基中孵育至50~80%。然后将DNA-脂质体复合物(该复合物与1~2微克含有如上所述LAG3-LAG3/Fc融合基因的质粒pLAG33Ig DNA和2~25微升LipofectaminTM(Gibco BRL,USA)反应了15~45分钟)加入细胞培养板的无血清DMEM培养基中。孵育5小时后,加入含有20%血清的DMEM培养基,进一步孵育细胞18~24小时。初次转染后,细胞在具有1.5毫克/毫升Geneticin(G418,Gibco BRL,USA)的10%FBS-DMEM培养基中孵育3周,筛选形成的菌落用于扩大培养。利用过氧化物酶标记的羊抗人IgG(KPL,USA)通过ELISA分析融合蛋白的表达。
ELISA如下实施:首先,将1毫克/毫升过氧化物酶标记的羊抗人IgG(KPL,USA)用0.1M重碳酸钠稀释到1∶2000,将100微升该抗体稀释液等分装进弹性96孔板(Falcon,USA)中并用塑料覆盖物密封,4℃孵育16小时以上,以将其覆盖在板的表面。此后,用洗涤缓冲液(含有0.1%Tween-20的1×PBS)洗3次,然后稀释缓冲液(48.5毫升1×PBS、1.5毫升FBS、50微升Tween-20)被等分装成180微升。在第一个孔内滴加20微升培养上清(液),然后用微量加液器进行连续(serially)稀释,作为阳性对照的0.01微克/微升人免疫球蛋白G(Sigma,USA)以及作为阴性对照的未转染的CHO-K1细胞的培养基进行相等的稀释。稀释后,96孔ELISA板(Falcon,USA)用铝箔包裹,在37℃孵育1小时30分钟,用洗涤缓冲液洗3次。连接羊抗人IgG(KPL,USA)的过氧化物酶用稀释缓冲液1∶5000稀释,等分为100微升,用铝箔包裹,在37℃反应1小时。反应后,将该板洗3次,用TMB微孔过氧化物酶底物系统(KPL,USA)显色,用微板读数仪(Bio-Rad,Model 550,Japan)测量655纳米波长处的吸光度而确定表达的存在。
使如上所述的转染体适应一种无血清培养基CHO-S-SFM II(Gibco BRL,USA)以纯化由该转染体产生的蛋白,方法如下:将大约3×105个细胞接种到6孔板后,细胞在5%CO2于37℃培养16个小时以上以附着(贴壁),显微镜下检查细胞在该板的约30~50%的面积贴壁,然后细胞在含有比例为8∶2的10%FBS DMEM与CHO-S-SFM II的培养基中进行培养。在这个比例连续传代培养3次后,以6∶4的比例培养三次;以4∶6的比例培养三次;以3∶7的比例培养三次;以2∶8的比例培养三次;以1∶9的比例培养三次;最后在100%CHO-S-SFM II培养基中培养。表达水平通过ELISA进行测量。
当这些转染细胞在CHO-S-SFM II中大规模培养后,含有每种融合蛋白的上清液以200×g离心12分钟去除细胞碎片,蛋白通过利用如下的HiTrap protein A柱(Amersham,USA)的方法进行纯化。在20mM磷酸钠(pH7.0,Sigma,USA)以1毫升/分钟的速率通过柱子2分钟之后,使10毫升上清液以同样的速率通过以使融合蛋白结合到蛋白A上。使20mM磷酸钠(pH7.0)以同样的速率通过2分钟以进行洗涤后,随着使0.1M柠檬酸(pH3.0,Sigma,USA)以同样速率通过柱子3分钟,500微升提取物连续分装到1.5毫升管中。其采用1M Tris(pH 11.0,USB,USA)调整为pH7.0,管中融合蛋白的存在通过如上描述的ELISA来确定。纯化的蛋白用Centricon30(Amicon,USA)以2000×g 4℃离心30分钟而浓缩。
实施例4:CD2、CTLA4和TNFR简单/连接融合二聚体蛋白的表达和纯化
对于CD2、CTLA4和TNFR的简单/连接融合二聚体蛋白根据与实施例3中相同的方法而制备。该方法在PCT公开出版物第WO2003/010202号中进行了详细的描述,该PCT申请由本发明人提交。这样所得到的重组表达质粒分别命名为pCD22Ig(图1)、pCT44Ig(图2)以及pTR2Ig-Top’(图4)。
另外,进行SDS-PAGE以确定实施例3和实施例4中纯化的蛋白是否是预期的简单融合二聚体蛋白[CD2/Fc]2、[LAG3/Fc]2和[CTLA4/Fc]2以及是否是预期的连接融合二聚体蛋白[CD2-CD2/Fc]2、[LAG3-LAG3/Fc]2和[CTLA4-CTLA4/Fc]2(图5a)。对[TNFR1/Fc]2、[TNFR2/Fc]2、[TNFR2-TNFR1/Fc]2和[TNFR2-TNFR2/Fc]2也进行了SDS-PAGE(图5b)。
实施例5:评估简单融合二聚体蛋白或者连接融合二聚体蛋白单独使用或联合使用时对T淋巴细胞增殖的抑制效应
A.简单融合二聚体蛋白单独使用时对T淋巴细胞增殖的抑制效应
B淋巴细胞的细胞系WT100B1S,通过转染来自感染了EB病毒的发热患者的B淋巴细胞而制备,在含有10%胎牛血清(FBS)的RPMI 1640中培养,以用作T淋巴细胞的抗原呈递细胞。然后将细胞以2000rpm离心2分钟,细胞沉淀用含有10%FBS的RPMI1640悬浮,密度为5.0×105个细胞/毫升,并用γ射线照射(3,000rad)。
利用Ficoll-Hypaque(Amersham,USA)从收集的健康人血液样品中分离T淋巴细胞,并在含有10%FBS的RPMI 1640中培养,以获得2.0×106个细胞/毫升的细胞悬浮液。
初级混合淋巴细胞反应(MLR)实施如下。将15毫升WT100B1S细胞悬浮液与15毫升T淋巴细胞悬浮液在150毫米培养皿中混合。该细胞培养3天,继续在15ml含有10%FBS的RPMI 1640中培养3天。培养6天后,存活的T淋巴细胞利用Ficoll-Hypaque(Amersham,USA)分离。这样分离所得的T淋巴细胞在含有45%FBS、45%RPMI1640和10%DMSO的培养基中冷冻并保存在液氮中。
来自初级MLR的T淋巴细胞再进行(rechallenged)二级MLR。首先,将冷冻的T淋巴细胞解冻、用RPMI 1640洗涤两次,重悬在含有10%FBS的RPMI 1640中,密度为3.0×105个细胞/毫升。
将用作抗原呈递细胞的WT100B 1S按照上述方法重新培养。该细胞用γ射线(3,000rad)照射,悬浮在含有10%FBS的RPMI 1640中,密度为7.5×104个细胞/毫升。100微升WT100B 1S细胞悬浮液平铺到96孔平底板的每个孔上,简单融合二聚体蛋白[TNFR2/Fc]2、[CD2/Fc]2、[CTLA4/Fc]2和[LAG3/Fc]2加入每个孔内,终浓度为10、1、10-1、10-2、10-3和10-4微克/毫升。然后,100微升来自初级MLR的T淋巴细胞加入每个孔内。该板在5%CO2孵箱于37℃孵育2天,每个孔内加入100微升含有10%FBS的RPMI 1640,然后再孵育2天。在4天培养期的最后6小时,细胞用1.2μCi/mL 3H-胸腺嘧啶核苷(Amersham)进行处理。
随后,96孔板在110×g 4℃离心10分钟以沉淀T淋巴细胞。弃上清后,细胞沉淀用200微升1×缓冲磷酸盐水(PBS)洗涤。96孔板在同样条件下离心以去除PBS。为了消除残存的3H-胸苷(Amersham),每孔加入200微升预冷的10%三氯酸(trichloridicacid)(TCA,Merck),将该板涡旋2分钟后,4℃反应5分钟。
该板在同样条件下离心。弃上清后,每孔加入200微升预冷的70%乙醇,该板4℃保持5分钟以固定T淋巴细胞。将该板离心弃上清后,细胞用10%TCA处理,根据如上所述的相同方法,将残存的3H-胸腺嘧啶核苷(Amersham)彻底去除。
每孔内加入100微升2%SDS(pH8.0)/0.5N NaOH,该板在37℃孵育30分钟以裂解T淋巴细胞。96孔板在110×g 25℃离心10分钟以沉淀细胞碎片,50微升每种上清液转移至96孔样品板(Wallac)中。每孔内加入1.5倍体积(1.5volumes)OptiPhase SuperMix(Wallac),将该板涡旋5分钟。通过用液体闪烁计数器(1450MicroBeta TriLux微板液体闪烁和发光计数器,Wallac)测量放射性(记录为计数/分钟,cpm)来估计整合的3H-胸苷,从而确定T淋巴细胞的增殖(图6a)。
如图6a所示,简单融合二聚体蛋白[TNFR2/Fc]2、[CD2/Fc]2、[CTLA4/Fc]2和[LAG3/Fc]2均抑制T淋巴细胞的增殖。具体地,[CTLA4/Fc]2和[LAG3/Fc]2对T淋巴细胞的增殖显示出比[TNFR2/Fc]2和[CD2/Fc]2更强的抑制效应。
B.简单融合二聚体蛋白联合使用时对T淋巴细胞增殖的抑制效应
T淋巴细胞的增殖按照与实施例5A中相同的方法进行评估,只是简单融合二聚体蛋白不是单独使用而是联合使用:[CTLA4/Fc]2+[TNFR2/Fc]2、[CTLA4/Fc]2+[CD2/Fc]2和[CTLA4/Fc]2+[LAG3/Fc]2;单独使用[CTLA4/Fc]2作为对照(图6b)。
如图6b所示,组合[CTLA4/Fc]2+[TNFR2/Fc]2、[CTLA4/Fc]2+[CD2/Fc]2和[CTLA4/Fc]2+[LAG3/Fc]2以及单独的[CTLA4/Fc]2均抑制T淋巴细胞的增殖。而且发现简单融合二聚体蛋白二者联合使用比单独使用时在抑制T淋巴细胞增殖方面更加有效。
C.连接融合二聚体蛋白单独使用时对T淋巴细胞增殖的抑制效应
T淋巴细胞的增殖按照实施例5A中相同的方法进行评估,只是单独使用的不是简单融合二聚体蛋白,而是连接融合二聚体蛋白,包括:[TNFR2-TNFR2/Fc]2、[CD2-CD2/Fc]2[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2(图6c)。
如图6c所示,连接融合二聚体蛋白[TNFR2-TNFR2/Fc]2、[CD2-CD2/Fc]2、[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2均抑制T淋巴细胞的增殖。而且发现单独使用的连接融合二聚体蛋白比单独使用的简单融合二聚体蛋白对T淋巴细胞的增殖有更强的抑制效应。
D.连接融合二聚体蛋白联合使用时对T淋巴细胞增殖的抑制效应
T淋巴细胞的增殖按照与实施例5A中相同的方法进行评估,只是替代简单融合二聚体蛋白的连接融合二聚体蛋白不是单独使用而是联合使用:[CTLA4-CTLA4/Fc]2+[TNFR2-TNFR2/Fc]2、[CTLA4-CTLA4/Fc]2+[CD2-CD2/Fc]2和[CTLA4-CTLA4/Fc]2+[LAG3-LAG3/Fc]2;单独使用[CTLA4-CTLA4/Fc]2作为对照(图6d)。
如图6d所示,组合[CTLA4-CTLA4/Fc]2+[TNFR2-TNFR2/Fc]2、[CTLA4-CTLA4/Fc]2+[CD2-CD2/Fc]2和[CTLA4-CTLA4/Fc]2+[LAG3-LAG3/Fc]2以及单独使用的[CTLA4-CTLA4/Fc]2均抑制T淋巴细胞的增殖。而且发现连接融合二聚体蛋白二者联合使用比单独使用时在抑制T淋巴细胞增殖方面更加有效。特别的是,[CTLA4-CTLA4/Fc]2+[LAG3-LAG3/Fc]2对T淋巴细胞的增殖表现出最强的抑制效应。
实施例6:评估简单融合二聚体蛋白或者连接融合二聚体蛋白单独使用或联合使用时对胶原诱导的关节炎的减弱效应
A.简单融合二聚体蛋白单独使用时对胶原诱导的关节炎的减弱效应
一种纯化的II型胶原,Arthrogen-CIA佐剂(Chondrex,USA),以2毫克/毫升的浓度溶于0.05M醋酸中,以每只小鼠100微克的量注射入DBA/1小鼠的尾静脉,以诱发胶原诱导关节炎(CIA)。三周后,用不完全Freund’s佐剂(Difco,USA)进行加强。
DBA/1小鼠用100微克II型胶原免疫三到四周后,开始出现关节炎。关节炎开始三到五天后,小鼠足部肿胀,炎症性关节炎持续超过三到四周。尽管炎症消退了,但关节却永久僵直了。基于评估关节炎严重性的视觉评分系统(列于下面的表3),每周两或三次对于关节的红斑和肿胀的发作,检查关节炎的严重性(计算每个实验组5只小鼠严重性评分的平均值)。
表3
评估关节炎严重性的视觉评分系统
严重性评分 | 大体病理 |
0 | 没有红斑和肿胀的迹象 |
1 | 红斑和轻微肿胀,局限于踝或足中央关节(跗骨) |
2 | 红斑和轻微肿胀,从踝延伸到足中央 |
3 | 红斑和中度肿胀,从踝延伸到跖骨关节 |
4 | 红斑和严重肿胀,包括踝、腿和足趾 |
简单融合二聚体蛋白[TNFR2/Fc]2、[CD2/Fc]2、[CTLA4/Fc]2和[LAG3/Fc]2以200微克/0.5毫升的浓度分别溶解到PBS中,经腹膜内注射入患(developing)CIA的小鼠。从第19天至第45天,每隔一天将CD2/Fc、TNFR2/Fc、CTLA4/Fc和LAG3/Fc的二聚体形式以10微克的剂量注射入每个实验组的5只小鼠,并评估关节炎的严重性(图7a)。
如图7a所示,当简单融合二聚体蛋白单独给予患CIA的小鼠时,与注射PBS的对照组相比,第45天时基于严重性测量的关节炎严重性减弱了26-38%。
B.简单融合二聚体蛋白联合使用时对CIA的减弱效应
CIA小鼠关节炎的严重性按照与实施例6A中相同的方法进行评估,只是简单融合二聚体蛋白不是单独使用而是与[CTLA4/Fc]2联合使用:[CTLA4/Fc]2+[TNFR2/Fc]2、[CTLA4/Fc]2+[CD2/Fc]2和[CTLA4/Fc]2+[LAG3/Fc]2;单独使用[CTLA4/Fc]2作为对照(图7b)。
如图7b所示,以下组合[CTLA4/Fc]2+[TNFR2/Fc]2、[CTLA4/Fc]2+[CD2/Fc]2和[CTLA4/Fc]2+[LAG3/Fc]2以及单独使用[CTLA4/Fc]2均减弱小鼠关节炎严重性。而且发现简单融合二聚体蛋白二者联合使用比单独使用时在减弱小鼠关节炎严重性方面更加有效。
C.连接融合二聚体蛋白单独使用时对CIA的减弱效应
CIA小鼠关节炎严重性按照与实施例6A中相同的方法进行评估,只是不再用简单融合二聚体蛋白,而是单独使用连接融合二聚体蛋白:[TNFR2-TNFR2/Fc]2、[CD2-CD2/Fc]2、[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2(图7c)。
如图7c所示,连接融合二聚体蛋白[TNFR2-TNFR2/Fc]2、[CD2-CD2/Fc]2、[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2均减弱CIA小鼠关节炎严重性。发现单独使用的连接融合二聚体蛋白比单独使用的简单融合二聚体蛋白在减弱小鼠关节炎严重性方面更加有效,而且表现出的关节炎减弱效应类似于简单融合二聚体蛋白联合使用时的效应。
D.连接融合二聚体蛋白联合使用时对CIA的减弱效应
CIA小鼠关节炎严重性按照与实施例6A中相同的方法进行评估,只是不再用简单融合二聚体蛋白,而是使用连接融合二聚体蛋白,不是单独使用,而是联合使用:[CTLA4-CTLA4/Fc]2+[TNFR2-TNFR2/Fc]2、[CTLA4-CTLA4/Fc]2+[CD2-CD2/Fc]2和[CTLA4-CTLA4/Fc]2+[LAG3-LAG3/Fc]2;单独使用[CTLA4/Fc]2作为对照(图7d)。
如图7d所示,以下组合[CTLA4-CTLA4/Fc]2+[TNFR2-TNFR2/Fc]2、[CTLA4-CTLA4/Fc]2+[CD2-CD2/Fc]2和[CTLA4-CTLA4/Fc]2+[LAG3-LAG3/Fc]2以及单独使用的[CTLA4/Fc]2均能减弱CIA小鼠关节炎的严重性。而且发现连接融合二聚体蛋白二者联合使用比单独使用时在减弱小鼠关节炎严重性方面更加有效。
实施例7:评估简单融合二聚体蛋白或者连接融合二聚体蛋白单独使用或联合使用时对移植物抗宿主病(GVHD)的疗效
A.简单融合二聚体蛋白对GVHD的疗效
年龄8到12周、重20到25克的雌性C57BL/6和BDF1[(C57BL/6×DBA/2)F1]小鼠,用于本试验,在无菌滤器盖微小隔离盒(sterile filter-top microisolator)中生长。在用来自供体小鼠脾细胞进行移植的前一天,受体小鼠接受复方新诺明(bactrim)。获自韩国延世大学(Yonsei University)微生物实验室的BDF1(H-2Kb/d)受体小鼠,用700cGyγ射线照射。来自C57BL/6供体小鼠的脾细胞用含10%RPMI和1%青霉素/链霉素的培养基制备,然后通过400g离心10分钟收集细胞。
为了诱发移植物抗宿主病(GVHD),使25×106来自异源C57BL/6供体小鼠(H-2Kb)的活的脾细胞通过反向注射法移植进用γ射线照射过的BDF1受体小鼠。
然后,将简单融合二聚体蛋白[CD2/Fc]2、[LAG3/Fc]2和[CTLA4/Fc]2以200微克/0.5毫升的浓度分别溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠。对照受体小鼠给予PBS。通过每两天称量小鼠来监测受体小鼠的存活情况(图8a)。
如图8a所示,对照受体小鼠由于患GVHD体重迅速减轻,而且由于来自供体小鼠活化T淋巴细胞的增殖,还表现出脾细胞数量的减少。将脾细胞移植到受体小鼠后约两周,本试验中所用的所有对照小鼠均表现出体重严重减轻,最后死亡。与之形成对比的是,当给予小鼠每一种简单融合二聚体蛋白[CD2/Fc]2、[LAG3/Fc]2和[CTLA4/Fc]2,与对照组相比其全部小鼠的GVHD死亡率有所降低。当将简单融合二聚体蛋白单独给予GVHD小鼠时,[LAG3/Fc]2表现出最长的存活期,约4周,因此其具有最强的免疫抑制效应,其次是[CTLA4/Fc]2,最后是[CD2/Fc]2,这些二聚体单独使用时也能改善GVHD小鼠的存活。
B.简单融合二聚体蛋白单独使用或联合使用时对GVHD的疗效
简单融合二聚体蛋白[CD2/Fc]2、[LAG3/Fc]2和[CTLA4/Fc]2以200微克/0.5毫升的浓度分别溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠。同样地,将简单融合二聚体蛋白的组合[CD2/Fc]2+[CTLA4/Fc]2以及[LAG3/Fc]2+[CTLA4/Fc]2以200微克/0.5毫升的浓度分别溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠(图8b)。
如图8b所示,简单融合二聚体蛋白的联合施药,与实施例7A(其中简单融合二聚体蛋白单独施药)的结果相比,得到更高的GVHD小鼠存活率。特别的是,当用组合[LAG3/Fc]2+[CTLA4/Fc]2施加给GVHD小鼠时,所有个体存活均超过40天,并且发现这种组合最能降低GVHD死亡率。这些结果通过测量来自每组的10只小鼠的存活期并计算测得存活期的平均值而得到(图4)。结果表明简单融合二聚体蛋白当两种或多种联合给予治疗GVHD时比单独给予更加有效。
表4
简单融合二聚体蛋白单独使用或联合使用对GVHD的疗效比较
免疫抑制剂(毫克/千克/天) | 供体小鼠 | 受体小鼠 | 小鼠数目 | 存活期(天) | 平均存活期(平均值±标准差) |
PBS | C57BL/6 | BDF1 | 10 | 11~15 | 13.7±1.06 |
[CD2/Fc]2 | C57BL/6 | BDF1 | 10 | 14~22 | 15.7±3.37 |
[LAG3/Fc]2 | C57BL/6 | BDF1 | 10 | 13~26 | 18±5.12 |
[CTLA4/Fc]2 | C57BL/6 | BDF1 | 10 | 19~28 | 23.2±3.49 |
[CD2/Fc]2+[CTLA4/Fc]2 | C57BL/6 | BDF1 | 10 | 16~29 | 23.2±5.71 |
[LAG3/Fc]2+[CTLA4/Fc]2 | C57BL/6 | BDF1 | 10 | 21~40 | 28±7.71 |
C.简单融合二聚体蛋白和连接融合二聚体蛋白对GVHD的疗效比较
(1)CTLA-4
将简单融合二聚体蛋白[CTLA4/Fc]2以200微克/0.5毫升的浓度溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠。同样地,将连接融合二聚体蛋白[CTLA4-CTLA4/Fc]2以200微克/0.5毫升的浓度溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠(图8c)。
如图8c所示,当GVHD受体小鼠单独给予[CTLA4/Fc]2时,小鼠最多存活约26天。与之形成对比的是,当单独给予GVHD受体小鼠[CTLA4-CTLA4/Fc]2时,小鼠最多存活约38天。这些结果通过测量每组10只小鼠的存活期并计算测得存活期的平均值而得到(表5)。结果表明连接融合二聚体蛋白治疗GVHD比简单融合二聚体蛋白更加有效。
表5
简单融合二聚体蛋白和连接融合二聚体蛋白对GVHD的疗效比较
免疫抑制剂(毫克/千克/天) | 供体小鼠 | 受体小鼠 | 小鼠数目 | 存活期(天) | 平均存活期(平均值±标准差) |
PBS | C57BL/6 | BDF1 | 10 | 11~15 | 13.7±1.06 |
[CTLA4/Fc]2 | C57BL/6 | BDF1 | 10 | 14-26 | 18.4±4.70 |
[CTLA4-CTLA4/Fc]2 | C57BL/6 | BDF1 | 10 | 19-38 | 28.2±8.12 |
(2)TNFR2
将简单融合二聚体蛋白[TNFR2/Fc]2以200微克/0.5毫升的浓度溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠。同样地,将连接融合二聚体蛋白[TNFR2-TNFR2/Fc]2以200微克/0.5毫升的浓度溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠(图8d)。
如图8d所示,当GVHD受体小鼠单独给予[TNFR2/Fc]2时,小鼠最多存活约20天。与之形成对比的是,当GVHD受体小鼠单独给予[TNFR2-TNFR2/Fc]2时,小鼠最多存活约35天。这些结果表明连接融合二聚体蛋白治疗GVHD比简单融合二聚体蛋白更加有效。
D.[TNFR2/Fc]2、[TNFR2-TNFR2/Fc]2和[TNFR2-TNFR1/Fc]2对GVHD的疗效比较
将简单融合二聚体蛋白[TNFR2/Fc]2以200微克/0.5毫升的浓度溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠。同样地,将连接融合二聚体蛋白[TNFR2-TNFR2/Fc]2和[TNFR2-TNFR1/Fc]2以200微克/0.5毫升的浓度分别溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠(图8e)。
如图8e所示,当GVHD受体小鼠单独给予[TNFR2/Fc]2时,小鼠最多存活约20天。与之形成对比的是,当GVHD受体小鼠单独给予[TNFR2-TNFR1/Fc]2和单独给予[TNFR2-TNFR2/Fc]2时,小鼠最多存活分别为约30天和约35天。这些结果表明连接融合二聚体蛋白治疗GVHD比简单融合二聚体蛋白更加有效。而且与[TNFR2-TNFR1/Fc]2相比,[TNFR2-TNFR2/Fc]2显示出几乎相同的效应,但发现其具有较强的免疫抑制效应。
E.连接融合二聚体蛋白单独使用或联合使用对GVHD的疗效
将连接融合二聚体蛋白[CD2-CD2/Fc]2、[LAG3-LAG3/Fc]2、[CTLA4-CTLA4/Fc]2和[TNFR2-TNFR1/Fc]2以200微克/0.5毫升的浓度分别溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠。同样地,将连接融合二聚体蛋白的组合:[CD2-CD2/Fc]2+[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2+[CTLA4-CTLA4/Fc]2以200微克/0.5毫升的浓度分别溶解到PBS中,在移植后第0、2、4、6天经腹膜内注射入患GVHD的受体小鼠(图8f)。
如图8f所示,大约2周后对照组小鼠表现出100%的死亡率(表6),这些结果与上面的结果类似。与实施例7B(其中,给予简单融合二聚体蛋白)结果类似,连接融合二聚体蛋白联合给予时比单独使用时在改善GVHD小鼠存活方面更加有效。连接融合二聚体蛋白的联合使用,[CD2-CD2/Fc]2+[CTLA4-CTLA4/Fc]2和[LAG3-LAG3/Fc]2+[CTLA4-CTLA4/Fc]2,分别得到40%和50%的存活率,即使在注射脾细胞约10周后。这些结果表明,连接融合二聚体蛋白当两种或多种联合给予时治疗GVHD比单独给予更加有效。
表6
连接融合二聚体蛋白单独使用或联合使用对GVHD的疗效比较
免疫抑制剂(毫克/千克/天) | 供体小鼠 | 受体小鼠 | 小鼠数目 | 存活期(天) | 平均存活期(平均值±标准差) |
PBS | C57BL/6 | BDF1 | 10 | 11~15 | 13.7±4.3 |
[CD2-CD2/Fc]2 | C57BL/6 | BDF1 | 10 | 19~28 | 21.4±5.6 |
[TNFR2-TNFR2/Fc]2 | C57BL/6 | BDF1 | 10 | 20~34 | 26.2±6.1 |
[TNFR2-TNFR1/Fc]2 | C57BL/6 | BDF1 | 10 | 18~31 | 23.6±5.4 |
[CTLA4-CTLA4/Fc]2 | C57BL/6 | BDF1 | 10 | 19~38 | 28.2±8.2 |
[LAG3-LAG3/Fc]2 | C57BL/6 | BDF1 | 10 | 22~50 | 34.6±10.6 |
[CD2-CD2/Fc]2+[CTLA4-CTLA4/Fc]2 | C57BL/6 | BDF1 | 10 | >44 | >100 |
[LAG3-LAG3/Fc]2+[CTLA4-CTLA4/Fc]2 | C57BL/6 | BDF1 | 10 | >50 | >100 |
发现根据本发明的Ig融合蛋白均发现抑制T淋巴细胞的活化。尤其是,连接融合二聚体蛋白比简单融合二聚体蛋白具有更强的抑制效应。另外,发现简单融合以及连接融合二聚体蛋白当联合给予时均比单独给予时在抑制T淋巴细胞活化方面更加有效。
涉及微生物或其他生物材料保藏的证明
(PCT Rule 13bis)
A.以下证明涉及说明书第 27页,第 7-14行提及的微生物或其他生物材料的保藏 | |
B.保藏证明 更多保藏物见附页□ | |
保藏单位名称韩国微生物培养中心(KCCM) | |
保藏单位地址(包含邮政编码及国家)361-221,Yurim B/D,Hongje-1-dong,Seodaemum-gu,首尔120-091,韩国 | |
保藏日期2004年1月13日 | 保藏编号KCCM 10556 |
C.其它内容(如果没有则保留空白) 此信息接附页□ | |
D.指定的国家,为该指定国家提供证明(如果本证明不适用于所有指定的国家) | |
E.分别提交的证明(如果没有则保留空白) | |
下列证明将随后提交到国际局(详细说明该证明的一般内容,例如保藏编号) |
受理局专用 | 国际局专用 |
□此页与国际申请同时收到 | □此页由国际局在以下时间收到: |
代表人 | 代表人 |
PCT/RO/134表(1998年7月)
序列表
<110>魅德秀专公司
<120>治疗免疫性疾病的药物组合物
<130>P9351HYI
<140>PCT/KR2005/000457
<141>2005-2-18
<150>KR 10-2004-0010835
<151>2004-2-18
<160>26
<170>KopatentIn 1.71
<210>1
<211>31
<212>DNA
<213>Artificial Sequence
<220>
<223>primer,oligo-LAG3-F-EcoRI
<400>1
ggaattcatg tgggaggctc agttcctggg c 31
<210>2
<211>28
<212>DNA
<213>Artificial Sequence
<220>
<223>primer,oligo-LAG3-R-5P
<400>2
agtgaggt tatacatgatgg agacgttg 28
<210>3
<211>21
<212>DNA
<213>Artificial Sequence
<220>
<223>primer,oligo-LAG3-F-5P
<400>3
ctccagccag gggctgaggt c 21
<210>4
<211>30
<212>DNA
<213>Artificial Sequence
<220>
<223>primer,oligo-LAG3-R-SpeI
<400>4
gactagttgg gggctccaga cccagaacag 30
<210>5
<211>28
<212>DNA
<213>Artificial Sequence
<220>
<223>primer,hIgG-F-SpeI
<400>5
gagtagtgca gagcccaaat cttgtgac 28
<210>6
<211>34
<212>DNA
<213>Artificial Sequence
<220>
<223>primer,hIgG-R-XbaI
<400>6
gctctagagc tcatttaccc ggagacaggg agag 34
<210>7
<211>1503
<212>DNA
<213>Homo sapiens
<220>
<221>sig_peptide
<222>(1)..(66)
<220>
<221>CDS
<222>(1)..(1500)
<223>LAG3/Fc
<400>7
atg tgg gag gct cag ttc ctg ggc ttg ctg ttt ctg cag ccg ctt tgg 48
Met Trp Glu Ala Gln Phe Leu Gly Leu Leu Phe Leu Gln Pro Leu Trp
1 5 10 15
gtg gct cca gtg aag cct ctc cag cca ggg gct gag gtc ccg gtg gtg 96
Val Ala Pro Val Lys Pro Leu Gln Pro Gly Ala Glu Val Pro Val Val
20 25 30
tgg gcc cag gag ggg gct cct gcc cag ctc ccc tgc agc ccc aca atc 144
Trp Ala Gln Glu Gly Ala Pro Ala Gln Leu Pro Cys Ser Pro Thr Ile
35 40 45
ccc ctc cag gat ctc agc ctt ctg cga aga gca ggg gtc act tgg cag 192
Pro Leu Gln Asp Leu Ser Leu Leu Arg Arg Ala Gly Val Thr Trp Gln
50 55 60
cat cag cca gac agt ggc ccg ccc gct gcc gcc ccc ggc cat ccc ctg 240
His Gln Pro Asp Ser Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu
65 70 75 80
gcc ccc ggc cct cac ccg gcg gcg ccc tcc tcc tgg ggg ccc agg ccc 288
Ala Pro Gly Pro His Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro
85 90 95
cgc cgc tac acg gtg ctg agc gtg ggt ccc gga ggc ctg cgc agc ggg 336
Arg Arg Tyr Thr Val Leu Ser Val Gly Pro Gly Gly Leu Arg Ser Gly
100 105 110
agg ctg ccc ctg cag ccc cgc gtc cag ctg gat gag cgc ggc cgg cag 384
Arg Leu Pro Leu Gln Pro Arg Val Gln Leu Asp Glu Arg Gly Arg Gln
115 120 125
cgc ggg gac ttc tcg cta tgg ctg cgc cca gcc cgg cgc gcg gac gcc 432
Arg Gly Asp Phe Ser Leu Trp Leu Arg Pro Ala Arg Arg Ala Asp Ala
130 135 140
ggc gag tac cgc gcc gcg gtg cac ctc agg gac cgc gcc ctc tcc tgc 480
Gly Glu Tyr Arg Ala Ala Val His Leu Arg Asp Arg Ala Leu Ser Cys
145 150 155 160
cgc ctc cgt ctg cgc ctg ggc cag gcc tcg atg act gcc agc ccc cca 528
Arg Leu Arg Leu Arg Leu Gly Gln Ala Ser Met Thr Ala Ser Pro Pro
165 170 175
gga tct ctc aga gcc tcc gac tgg gtc att ttg aac tgc tcc ttc agc 576
Gly Ser Leu Arg Ala Ser Asp Trp Val Ile Leu Asn Cys Ser Phe Ser
180 185 190
cgc cct gac cgc cca gcc tct gtg cat tgg ttc cgg aac cgg ggc cag 624
Arg Pro Asp Arg Pro Ala Ser Val His Trp Phe Arg Asn Arg Gly Gln
195 200 205
ggc cga gtc cct gtc cgg gag tcc ccc cat cac cac tta gcg gaa agc 672
Gly Arg Val Pro Val Arg Glu Ser Pro His His His Leu Ala Glu Ser
210 215 220
ttc ctc ttc ctg ccc caa gtc agc ccc atg gac tct ggg ccc tgg ggc 720
Phe Leu Phe Leu Pro Gln Val Ser Pro Met Asp Ser Gly Pro Trp Gly
225 230 235 240
tgc atc ctc acc tac aga gat ggc ttc aac gtc tcc atc atg tat aac 768
Cys Ile Leu Thr Tyr Arg Asp Gly Phe Asn Val Ser Ile Met Tyr Asn
245 250 255
ctc act gtt ctg ggt ctg gag ccc cca act agt gca gag ccc aaa tct 816
Leu Thr Val Leu Gly Leu Glu Pro Pro Thr Ser Ala Glu Pro Lys Ser
260 265 270
tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg 864
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
275 280 285
ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc 912
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300
atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc 960
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
305 310 315 320
cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag 1008
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
325 330 335
gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg 1056
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
340 345 350
tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat 1104
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
355 360 365
ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc 1152
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
370 375 380
atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag 1200
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
385 390 395 400
gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag aac cag gtc 1248
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
405 410 415
agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg 1296
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
420 425 430
gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct 1344
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
435 440 445
ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc aag ctc acc 1392
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
450 455 460
gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg 1440
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
465 470 475 480
atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg 1488
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
485 490 495
tcc ccg ggt aaa tga 1503
Ser Pro Gly Lys
500
<210>8
<211>500
<212>PRT
<213>Homo sapiens
<400>8
Met Trp Glu Ala Gln Phe Leu Gly Leu Leu Phe Leu Gln Pro Leu Trp
1 5 10 15
Val Ala Pro Val Lys Pro Leu Gln Pro Gly Ala Glu Val Pro Val Val
20 25 30
Trp Ala Gln Glu Gly Ala Pro Ala Gln Leu Pro Cys Ser Pro Thr Ile
35 40 45
Pro Leu Gln Asp Leu Ser Leu Leu Arg Arg Ala Gly Val Thr Trp Gln
50 55 60
His Gln Pro Asp Ser Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu
65 70 75 80
Ala Pro Gly Pro His Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro
85 90 95
Arg Arg Tyr Thr Val Leu Ser Val Gly Pro Gly Gly Leu Arg Ser Gly
100 105 110
Arg Leu Pro Leu Gln Pro Arg Val Gln Leu Asp Glu Arg Gly Arg Gln
115 120 125
Arg Gly Asp Phe Ser Leu Trp Leu Arg Pro Ala Arg Arg Ala Asp Ala
130 135 140
Gly Glu Tyr Arg Ala Ala Val His Leu Arg Asp Arg Ala Leu Ser Cys
1451 50 155 160
Arg Leu Arg Leu Arg Leu Gly Gln Ala Ser Met Thr Ala Ser Pro Pro
165 170 175
Gly Ser Leu Arg Ala Ser Asp Trp Val Ile Leu Asn Cys Ser Phe Ser
180 185 190
Arg Pro Asp Arg Pro Ala Ser Val His Trp Phe Arg Asn Arg Gly Gln
195 200 205
Gly Arg Val Pro Val Arg Glu Ser Pro His His His Leu Ala Glu Ser
210 215 220
Phe Leu Phe Leu Pro Gln Val Ser Pro Met Asp Ser Gly Pro Trp Gly
225 230 235 240
Cys Ile Leu Thr Tyr Arg Asp Gly Phe Asn Val Ser Ile Met Tyr Asn
245 250 255
Leu Thr Val Leu Gly Leu Glu Pro Pro Thr Ser Ala Glu Pro Lys Ser
260 265 270
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu
275 280 285
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
305 310 315 320
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
325 330 335
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
340 345 350
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
355 360 365
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
370 375 380
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
385 390 395 400
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
405 410 415
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
420 425 430
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
435 440 445
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
450 455 460
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
465 470 475 480
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
485 490 495
Ser Pro Gly Lys
500
<210>9
<211>2211
<212>DNA
<213>Homo sapiens
<220>
<221>sig_peptide
<222>(1)..(66)
<220>
<221>CDS
<222>(1)..(2208)
<223>LAG3-LAG3/Fc
<400>9
atg tgg gag gct cag ttc ctg ggc ttg ctg ttt ctg cag ccg ctt tgg 48
Met Trp Glu Ala Gln Phe Leu Gly Leu Leu Phe Leu Gln Pro Leu Trp
1 5 10 15
gtg gct cca gtg aag cct ctc cag cca ggg gct gag gtc ccg gtg gtg 96
Val Ala Pro Val Lys Pro Leu Gln Pro Gly Ala Glu Val Pro Val Val
20 25 30
tgg gcc cag gag ggg gct cct gcc cag ctc ccc tgc agc ccc aca atc 144
Trp Ala Gln Glu Gly Ala Pro Ala Gln Leu Pro Cys Ser Pro Thr Ile
35 40 45
ccc ctc cag gat ctc agc ctt ctg cga aga gca ggg gtc act tgg cag 192
Pro Leu Gln Asp Leu Ser Leu Leu Arg Arg Ala Gly Val Thr Trp Gln
50 55 60
cat cag cca gac agt ggc ccg ccc gct gcc gcc ccc ggc cat ccc ctg 240
His Gln Pro Asp Ser Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu
65 70 75 80
gcc ccc ggc cct cac ccg gcg gcg ccc tcc tcc tgg ggg ccc agg ccc 288
Ala Pro Gly Pro His Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro
85 90 95
cgc cgc tac acg gtg ctg agc gtg ggt ccc gga ggc ctg cgc agc ggg 336
Arg Arg Tyr Thr Val Leu Ser Val Gly Pro Gly Gly Leu Arg Ser Gly
100 105 110
agg ctg ccc ctg cag ccc cgc gtc cag ctg gat gag cgc ggc cgg cag 384
Arg Leu Pro Leu Gln Pro Arg Val Gln Leu Asp Glu Arg Gly Arg Gln
115 120 125
cgc ggg gac ttc tcg cta tgg ctg cgc cca gcc cgg cgc gcg gac gcc 432
Arg Gly Asp Phe Ser Leu Trp Leu Arg Pro Ala Arg Arg Ala Asp Ala
130 135 140
ggc gag tac cgc gcc gcg gtg cac ctc agg gac cgc gcc ctc tcc tgc 480
Gly Glu Tyr Arg Ala Ala Val His Leu Arg Asp Arg Ala Leu Ser Cys
145 150 155 160
cgc ctc cgt ctg cgc ctg ggc cag gcc tcg atg act gcc agc ccc cca 528
Arg Leu Arg Leu Arg Leu Gly Gln Ala Ser Met Thr Ala Ser Pro Pro
165 170 175
gga tct ctc aga gcc tcc gac tgg gtc att ttg aac tgc tcc ttc agc 576
Gly Ser Leu Arg Ala Ser Asp Trp Val Ile Leu Asn Cys Ser Phe Ser
180 185 190
cgc cct gac cgc cca gcc tct gtg cat tgg ttc cgg aac cgg ggc cag 624
Arg Pro Asp Arg Pro Ala Ser Val His Trp Phe Arg Asn Arg Gly Gln
195 200 205
ggc cga gtc cct gtc cgg gag tcc ccc cat cac cac tta gcg gaa agc 672
Gly Arg Val Pro Val Arg Glu Ser Pro His His His Leu Ala Glu Ser
210 215 220
ttc ctc ttc ctg ccc caa gtc agc ccc atg gac tct ggg ccc tgg ggc 720
Phe Leu Phe Leu Pro Gln Val Ser Pro Met Asp Ser Gly Pro Trp Gly
225 230 235 240
tgc atc ctc acc tac aga gat ggc ttc aac gtc tcc atc atg tat aac 768
Cys Ile Leu Thr Tyr Arg Asp Gly Phe Asn Val Ser Ile Met Tyr Asn
245 250 255
ctc act ctc cag cca ggg gct gag gtc ccg gtg gtg tgg gcc cag gag 816
Leu Thr Leu Gln Pro Gly Ala Glu Val Pro Val Val Trp Ala Gln Glu
260 265 270
ggg gct cct gcc cag ctc ccc tgc agc ccc aca atc ccc ctc cag gat 864
Gly Ala Pro Ala Gln Leu Pro Cys Ser Pro Thr Ile Pro Leu Gln Asp
275 280 285
ctc agc ctt ctg cga aga gca ggg gtc act tgg cag cat cag cca gac 912
Leu Ser Leu Leu Arg Arg Ala Gly Val Thr Trp Gln His Gln Pro Asp
290 295 300
agt ggc ccg ccc gct gcc gcc ccc ggc cat ccc ctg gcc ccc ggc cct 960
Ser Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu Ala Pro Gly Pro
305 310 315 320
cac ccg gcg gcg ccc tcc tcc tgg ggg ccc agg ccc cgc cgc tac acg 1008
His Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro Arg Arg Tyr Thr
325 330 335
gtg ctg agc gtg ggt ccc gga ggc ctg cgc agc ggg agg ctg ccc ctg 1056
Val Leu Ser Val Gly Pro Gly Gly Leu Arg Ser Gly Arg Leu Pro Leu
340 345 350
cag ccc cgc gtc cag ctg gat gag cgc ggc cgg cag cgc ggg gac ttc 1104
Gln Pro Arg Val Gln Leu Asp Glu Arg Gly Arg Gln Arg Gly Asp Phe
355 360 365
tcg cta tgg ctg cgc cca gcc cgg cgc gcg gac gcc ggc gag tac cgc 1152
Ser Leu Trp Leu Arg Pro Ala Arg Arg Ala Asp Ala Gly Glu Tyr Arg
370 375 380
gcc gcg gtg cac ctc agg gac cgc gcc ctc tcc tgc cgc ctc cgt ctg 1200
Ala Ala Val His Leu Arg Asp Arg Ala Leu Ser Cys Arg Leu Arg Leu
385 390 395 400
cgc ctg ggc cag gcc tcg atg act gcc agc ccc cca gga tct ctc aga 1248
Arg Leu Gly Gln Ala Ser Met Thr Ala Ser Pro Pro Gly Ser Leu Arg
405 410 415
gcc tcc gac tgg gtc att ttg aac tgc tcc ttc agc cgc cct gac cgc 1296
Ala Ser Asp Trp Val Ile Leu Asn Cys Ser Phe Ser Arg Pro Asp Arg
420 425 430
cca gcc tct gtg cat tgg ttc cgg aac cgg ggc cag ggc cga gtc cct 1344
Pro Ala Ser Val His Trp Phe Arg Asn Arg Gly Gln Gly Arg Val Pro
435 440 445
gtc cgg gag tcc ccc cat cac cac tta gcg gaa agc ttc ctc ttc ctg 1392
Val Arg Glu Ser Pro His His His Leu Ala Glu Ser Phe Leu Phe Leu
450 455 460
ccc caa gtc agc ccc atg gac tct ggg ccc tgg ggc tgc atc ctc acc 1440
Pro Gln Val Ser Pro Met Asp Ser Gly Pro Trp Gly Cys Ile Leu Thr
465 470 475 480
tac aga gat ggc ttc aac gtc tcc atc atg tat aac ctc act gtt ctg 1488
Tyr Arg Asp Gly Phe Asn Val Ser Ile Met Tyr Asn Leu Thr Val Leu
485 490 495
ggt ctg gag ccc cca act agt gca gag ccc aaa tct tgt gac aaa act 1536
Gly Leu Glu Pro Pro Thr Ser Ala Glu Pro Lys Ser Cys Asp Lys Thr
500 505 510
cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca 1584
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
515 520 525
gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg 1632
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
530 535 540
acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct 1680
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
545 550 555 560
gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc 1728
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
565 570 575
aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc 1776
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
580 585 590
agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac 1824
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
595 600 605
aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc 1872
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
610 615 620
atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg 1920
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
625 630 635 640
ccc cca tcc cgg gag gag atg acc aag aac cag gtc agc ctg acc tgc 1968
Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
645 650 655
ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc 2016
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
660 665 670
aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac 2064
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
675 680 685
tcc gac ggc tcc ttc ttc ctc tat agc aag ctc acc gtg gac aag agc 2112
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
690 695 700
agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct 2160
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
705 710 715 720
ctg cac aac cac tac acg cag aag agc ctc tcc ctg tcc ccg ggt aaa 2208
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
725 730 735
tg a 2211
<210>10
<211>736
<212>PRT
<213>Homo sapiens
<400>10
Met Trp Glu Ala Gln Phe Leu Gly Leu Leu Phe Leu Gln Pro Leu Trp
1 5 10 15
Val Ala Pro Val Lys Pro Leu Gln Pro Gly Ala Glu Val Pro Val Val
20 25 30
Trp Ala Gln Glu Gly Ala Pro Ala Gln Leu Pro Cys Ser Pro Thr Ile
35 40 45
Pro Leu Gln Asp Leu Ser Leu Leu Arg Arg Ala Gly Val Thr Trp Gln
50 55 60
His Gln Pro Asp Ser Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu
65 70 75 80
Ala Pro Gly Pro His Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro
85 90 95
Arg Arg Tyr Thr Val Leu Ser Val Gly Pro Gly Gly Leu Arg Ser Gly
100 105 110
Arg Leu Pro Leu Gln Pro Arg Val Gln Leu Asp Glu Arg Gly Arg Gln
115 120 125
Arg Gly Asp Phe Ser Leu Trp Leu Arg Pro Ala Arg Arg Ala Asp Ala
130 135 140
Gly Glu Tyr Arg Ala Ala Val His Leu Arg Asp Arg Ala Leu Ser Cys
145 150 155 160
Arg Leu Arg Leu Arg Leu Gly Gln Ala Ser Met Thr Ala Ser Pro Pro
165 170 175
Gly Ser Leu Arg Ala Ser Asp Trp Val Ile Leu Asn Cys Ser Phe Ser
180 185 190
Arg Pro Asp Arg Pro Ala Ser Val His Trp Phe Arg Asn Arg Gly Gln
195 200 205
Gly Arg Val Pro Val Arg Glu Ser Pro His His His Leu Ala Glu Ser
210 215 220
Phe Leu Phe Leu Pro Gln Val Ser Pro Met Asp Ser Gly Pro Trp Gly
225 230 235 240
Cys Ile Leu Thr Tyr Arg Asp Gly Phe Asn Val Ser Ile Met Tyr Asn
245 250 255
Leu Thr Leu Gln Pro Gly Ala Glu Val Pro Val Val Trp Ala Gln Glu
260 265 270
Gly Ala Pro Ala Gln Leu Pro Cys Ser Pro Thr Ile Pro Leu Gln Asp
275 280 285
Leu Ser Leu Leu Arg Arg Ala Gly Val Thr Trp Gln His Gln Pro Asp
290 295 300
Ser Gly Pro Pro Ala Ala Ala Pro Gly His Pro Leu Ala Pro Gly Pro
305 310 315 320
His Pro Ala Ala Pro Ser Ser Trp Gly Pro Arg Pro Arg Arg Tyr Thr
325 330 335
Val Leu Ser Val Gly Pro Gly Gly Leu Arg Ser Gly Arg Leu Pro Leu
340 345 350
Gln Pro Arg Val Gln Leu Asp Glu Arg Gly Arg Gln Arg Gly Asp Phe
355 360 365
Ser Leu Trp Leu Arg Pro Ala Arg Arg Ala Asp Ala Gly Glu Tyr Arg
370 375 380
Ala Ala Val His Leu Arg Asp Arg Ala Leu Ser Cys Arg Leu Arg Leu
385 390 395 400
Arg Leu Gly Gln Ala Ser Met Thr Ala Ser Pro Pro Gly Ser Leu Arg
405 410 415
Ala Ser Asp Trp Val Ile Leu Asn Cys Ser Phe Ser Arg Pro Asp Arg
420 425 430
Pro Ala Ser Val His Trp Phe Arg Asn Arg Gly Gln Gly Arg Val Pro
435 440 445
Val Arg Glu Ser Pro His His His Leu Ala Glu Ser Phe Leu Phe Leu
450 455 460
Pro Gln Val Ser Pro Met Asp Ser Gly Pro Trp Gly Cys Ile Leu Thr
465 470 475 480
Tyr Arg Asp Gly Phe Asn Val Ser Ile Met Tyr Asn Leu Thr Val Leu
485 490 495
Gly Leu Glu Pro Pro Thr Ser Ala Glu Pro Lys Ser Cys Asp Lys Thr
500 505 510
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
515 520 525
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
530 535 540
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
545 550 555 560
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
565 570 575
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
580 585 590
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
595 600 605
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
610 615 620
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
625 630 635 640
Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
645 650 655
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
660 665 670
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
675 680 685
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
690 695 700
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
705 710 715 720
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
725 730 735
<210>11
<211>1473
<212>DNA
<213>Homo sapiens
<220>
<221>CDS
<222>(1)..(1470)
<223>TNFR2/Fc
<400>11
atg gcg ccc gtc gcc gtc tgg gcc gcg ctg gcc gtc gga ctg gag ctc 48
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
1 5 10 15
tgg gct gcg gcg cac gcc ttg ccc gcc cag gtg gca ttt aca ccc tac 96
Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
20 25 30
gcc ccg gag ccc ggg agc aca tgc cgg ctc aga gaa tac tat gac cag 144
Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
35 40 45
aca gct cag atg tgc tgc agc aaa tgc tcg ccg ggc caa cat gca aaa 192
Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
50 55 60
gtc ttc tgt acc aag acc tcg gac acc gtg tgt gac tcc tgt gag gac 240
Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
65 70 75 80
agc aca tac acc cag ctc tgg aac tgg gtt ccc gag tgc ttg agc tgt 288
Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
85 90 95
ggc tcc cgc tgt agc tct gac cag gtg gaa act caa gcc tgc act cgg 336
Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
100 105 110
gaa cag aac cgc atc tgc acc tgc agg ccc ggc tgg tac tgc gcg ctg 384
Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
115 120 125
agc aag cag gag ggg tgc cgg ctg tgc gcg ccg ctg cgc aag tgc cgc 432
Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg
130 135 140
ccg ggc ttc ggc gt g gcc aga cca gga act gaa aca tca gac gtg gtg 480
Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val
145 150 155 160
tgc aag ccc tgt gcc ccg ggg acg ttc tcc aac acg act tca tcc acg 528
Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
165 170 175
gat att tgc agg ccc cac cag atc tgt aac gtg gtg gcc atc cct ggg 576
Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
180 185 190
aat gca agc atg gat gca gtc tgc acg tcc acg tcc ccc acc cgg agt 624
Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser
195 200 205
atg gcc cca ggg gca gta cac tta ccc cag cca gtg tcc aca cga tcc 672
Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser
210 215 220
caa cac acg cag cca act cca gaa ccc agc act gct cca agc acc tcc 720
Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
225 230 235 240
ttc ctg ctc cca atg ggc ccc agc ccc cca gct gaa ggg agc act ggc 768
Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Thr Gly
245 250 255
gac gca gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc 816
Asp Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
260 265 270
cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca 864
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
275 280 285
aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc 912
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
290 295 300
gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg 960
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
305 310 315 320
tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag 1008
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
325 330 335
gag cag tac aac agc acg tac cgg gtg gtc agc gtc ctc acc gtc ctg 1056
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
340 345 350
cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac 1104
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
355 360 365
aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg 1152
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
370 375 380
cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag 1200
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
385 390 395 400
ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat 1248
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
405 410 415
ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac 1296
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
420 425 430
aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc tcc ttc 1344
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Ser Phe
435 440 445
ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac 1392
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
450 455 460
gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg 1440
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
465 470 475 480
cag aag agc ctc tcc ctg tct ccg ggt aaa tga 1473
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
485 490
<210>12
<211>490
<212>PRT
<213>Homo sapiens
<400>12
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
1 5 10 15
Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
20 25 30
Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
35 40 45
Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
50 55 60
Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
65 70 75 80
Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
85 90 95
Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
100 105 110
Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
115 120 125
Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg
130 135 140
Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val
145 150 155 160
Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
165 170 175
Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
180 185 190
Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser
195 200 205
Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser
210 215 220
Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
225 230 235 240
Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Thr Gly
245 250 255
Asp Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
260 265 270
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
275 280 285
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
290 295 300
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
305 310 315 320
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
325 330 335
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
340 345 350
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
355 360 365
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
370 375 380
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
385 390 395 400
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
405 410 415
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
420 425 430
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Ser Phe
435 440 445
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
450 455 460
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
465 470 475 480
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
485 490
<210>13
<211>2163
<212>DNA
<213>Homo sapiens
<220>
<221>CDS
<222>(1)..(2160)
<223>TNFR2-TNFR2/Fc
<400>13
atg gcg ccc gtc gcc gtc tgg gcc gcg ctg gcc gtc gga ctg gag ctc 48
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
1 5 10 15
tgg gct gcg gcg cac gcc ttg ccc gcc cag gtg gca ttt aca ccc tac 96
Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
20 25 30
gcc ccg gag ccc ggg agc aca tgc cgg ctc aga gaa tac tat gac cag 144
Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
35 40 45
aca gct cag atg tgc tgc agc aaa tgc tcg ccg ggc caa cat gca aaa 192
Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
50 55 60
gtc ttc tgt acc aag acc tcg gac acc gtg tgt gac tcc tgt gag gac 240
Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
65 70 75 80
agc aca tac acc cag ctc tgg aac tgg gtt ccc gag tgc ttg agc tgt 288
Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
85 90 95
ggc tcc cgc tgt agc tct gac cag gtg gaa act caa gcc tgc act cgg 336
Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
100 105 110
gaa cag aac cgc atc tgc acc tgc agg ccc ggc tgg tac tgc gcg ctg 384
Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
115 120 125
agc aag cag gag ggg tgc cgg ctg tgc gcg ccg ctg cgc aag tgc cgc 432
Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg
130 135 140
ccg ggc ttc ggc gtg gcc aga cca gga act gaa aca tca gac gtg gtg 480
Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val
145 150 155 160
tgc aag ccc tgt gcc ccg ggg acg ttc tcc aac acg act tca tcc acg 528
Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
165 170 175
gat att tgc agg ccc cac cag atc tgt aac gtg gtg gcc atc cct ggg 576
Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
180 185 190
aat gca agc atg gat gca gtc tgc acg tcc acg tcc ccc acc cgg agt 624
Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser
195 200 205
atg gcc cca ggg gca gta cac tta ccc cag cca gtg tcc aca cga tcc 672
Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser
210 215 220
caa cac acg cag cca act cca gaa ccc agc act gct cca agc acc tcc 720
Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
225 230 235 240
ttc ctg ctc cca atg ggc ccc agc ccc cca gct gaa ggg agc gga tcc 768
Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Gly Ser
245 250 255
aac gca act aca ccc tac gcc ccg gag ccc ggg agc aca tgc cgg ctc 816
Asn Ala Thr Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu
260 265 270
aga gaa tac tat gac cag aca gct cag atg tgc tgc agc aaa tgc tcg 864
Arg Glu Tyr Tyr Asp Gln Thr Ala Gln Met Cys Cys Ser Lys Cys Ser
275 280 285
ccg ggc caa cat gca aaa gtc ttc tgt acc aag acc tcg gac acc gtg 912
Pro Gly Gln His Ala Lys Val Phe Cys Thr Lys Thr Ser Asp Thr Val
290 295 300
tgt gac tcc tgt gag gac agc aca tac acc cag ctc tgg aac tgg gtt 960
Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val
305 310 315 320
ccc gag tgc ttg agc tgt ggc tcc cgc tgt agc tct gac cag gtg gaa 1008
Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln Val Glu
325 330 335
act caa gcc tgc act cgg gaa cag aac cgc atc tgc acc tgc agg ccc 1056
Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro
340 345 350
ggc tgg tac tgc gcg ctg agc aag cag gag ggg tgc cgg ctg tgc gcg 1104
Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala
355 360 365
ccg ctg cgc aag tgc cgc ccg ggc ttc ggc gtg gcc aga cca gga act 1152
Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala Arg Pro Gly Thr
370 375 380
gaa aca tca gac gtg gtg tgc aag ccc tgt gcc ccg ggg acg ttc tcc 1200
Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser
385 390 395 400
aac acg act tca tcc acg gat att tgc agg ccc cac cag atc tgt aac 1248
Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg Pro His Gln Ile Cys Asn
405 410 415
gtg gtg gcc atc cct ggg aat gca agc atg gat gca gtc tgc acg tcc 1296
Val Val Ala Ile Pro Gly Asn Ala Ser Met Asp Ala Val Cys Thr Ser
420 425 430
acg tcc ccc acc cgg agt atg gcc cca ggg gca gta cac tta ccc cag 1344
Thr Ser Pro Thr Arg Ser Met Ala Pro Gly Ala Val His Leu Pro Gln
435 440 445
cca gtg tcc aca cga tcc caa cac acg cag cca act cca gaa ccc agc 1392
Pro Val Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser
450 455 460
act gct cca agc acc tcc ttc ctg ctc cca atg ggc ccc agc ccc cca 1440
Thr Ala Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro
465 470 475 480
gct gaa ggg agc act ggc gac gca gag ccc aaa tct tgt gac aaa act 1488
Ala Glu Gly Ser Thr Gly Asp Ala Glu Pro Lys Ser Cys Asp Lys Thr
485 490 495
cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca 1536
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
500 505 510
gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg 1584
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
515 520 525
acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct 1632
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
530 535 540
gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc 1680
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
545 550 555 560
aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgg gtg gtc 1728
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
565 570 575
agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac 1776
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
580 585 590
aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc 1824
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
595 600 605
atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg 1872
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
610 615 620
ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc 1920
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
625 630 635 640
ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc 1968
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
645 650 655
aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac 2016
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
660 665 670
tcc gac ggc tcc tcc ttc ctc tac agc aag ctc acc gtg gac aag agc 2064
Ser Asp Gly Ser Ser Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
675 680 685
agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct 2112
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
690 695 700
ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa 2160
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
705 710 715 720
tga 2163
<210>14
<211>720
<212>PRT
<213>Homo sapiens
<400>14
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
1 5 10 15
Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
20 25 30
Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
35 40 45
Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
50 55 60
Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
65 70 75 80
Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
85 90 95
Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
100 105 110
Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
115 120 125
Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg
130 135 140
Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val
145 150 155 160
Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
165 170 175
Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
180 185 190
Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser
195 200 205
Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser
210 215 220
Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
225 230 235 240
Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Gly Ser
245 250 255
Asn Ala Thr Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu
260 265 270
Arg Glu Tyr Tyr Asp Gln Thr Ala Gln Met Cys Cys Ser Lys Cys Ser
275 280 285
Pro Gly Gln His Ala Lys Val Phe Cys Thr Lys Thr Ser Asp Thr Val
290 295 300
Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val
305 310 315 320
Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln Val Glu
325 330 335
Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro
340 345 350
Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala
355 360 365
Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala Arg Pro Gly Thr
370 375 380
Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser
385 390 395 400
Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg Pro His Gln Ile Cys Asn
405 410 415
Val Val Ala Ile Pro Gly Asn Ala Ser Met Asp Ala Val Cys Thr Ser
420 425 430
Thr Ser Pro Thr Arg Ser Met Ala Pro Gly Ala Val His Leu Pro Gln
435 440 445
Pro Val Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser
450 455 460
Thr Ala Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro
465 470 475 480
Ala Glu Gly Ser Thr Gly Asp Ala Glu Pro Lys Ser Cys Asp Lys Thr
485 490 495
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
500 505 510
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
515 520 525
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
530 535 540
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
545 550 555 560
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
565 570 575
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
580 585 590
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
595 600 605
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
610 615 620
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
625 630 635 640
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
645 650 655
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
660 665 670
Ser Asp Gly Ser Ser Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
675 680 685
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
690 695 700
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
705 710 715 720
<210>15
<211>1314
<212>DNA
<213>Homo sapiens
<220>
<221>CDS
<222>(1)..(1311)
<223>CD2/Fc
<400>15
atg agc ttt cca tgt aaa ttt gta gcc agc ttc ctt ctg att ttc aat 48
Met Ser Phe Pro Cys Lys Phe Val Ala Ser Phe Leu Leu Ile Phe Asn
1 5 10 15
gtt tct tcc aaa ggt gca gtc tcc aaa gag att acg aat gcc ttg gaa 96
Val Ser Ser Lys Gly Ala Val Ser Lys Glu Ile Thr Asn Ala Leu Glu
20 25 30
acc tgg ggt gcc ttg ggt cag gac atc aac ttg gac att cct agt ttt 144
Thr Trp Gly Ala Leu Gly Gln Asp Ile Asn Leu Asp Ile Pro Ser Phe
35 40 45
caa atg agt gat gat att gac gat ata aaa tgg gaa aaa act tca gac 192
Gln Met Ser Asp Asp Ile Asp Asp Ile Lys Trp Glu Lys Thr Ser Asp
50 55 60
aag aaa aag att gca caa ttc aga aaa gag aaa gag act ttc aag gaa 240
Lys Lys Lys Ile Ala Gln Phe Arg Lys Glu Lys Glu Thr Phe Lys Glu
65 70 75 80
aaa gat aca tat aag cta ttt aaa aat gga act ctg aaa att aag cat 288
Lys Asp Thr Tyr Lys Leu Phe Lys Asn Gly Thr Leu Lys Ile Lys His
85 90 95
ctg aag acc gat gat cag gat atc tac aag gta tca ata tat gat aca 336
Leu Lys Thr Asp Asp Gln Asp Ile Tyr Lys Val Ser Ile Tyr Asp Thr
100 105 110
aaa gga aaa aat gtg ttg gaa aaa ata ttt gat ttg aag att caa gag 384
Lys Gly Lys Asn Val Leu Glu Lys Ile Phe Asp Leu Lys Ile Gln Glu
115 120 125
agg gtc tca aaa cca aag atc tcc tgg act tgt atc aac aca acc ctg 432
Arg Val Ser Lys Pro Lys Ile Ser Trp Thr Cys Ile Asn Thr Thr Leu
130 135 140
acc tgt gag gta atg aat gga act gac ccc gaa tta aac ctg tat caa 480
Thr Cys Glu Val Met Asn Gly Thr Asp Pro Glu Leu Asn Leu Tyr Gln
145 150 155 160
gat ggg aaa cat cta aaa ctt tct cag agg gtc atc aca cac aag tgg 528
Asp Gly Lys His Leu Lys Leu Ser Gln Arg Val Ile Thr His Lys Trp
165 170 175
acc acc agc ctg agt gca aaa ttc aag tgc aca gca ggg aac aaa gtc 576
Thr Thr Ser Leu Ser Ala Lys Phe Lys Cys Thr Ala Gly Asn Lys Val
180 185 190
agc aag gaa tcc agt gtc gag cct gtc agc tgt cct gca gag ccc aaa 624
Ser Lys Glu Ser Ser Val Glu Pro Val Ser Cys Pro Ala Glu Pro Lys
195 200 205
tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc 672
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
210 215 220
ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 720
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
225 230 235 240
ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 768
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
245 250 255
agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 816
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
260 265 270
gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc 864
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
275 280 285
acg tac cgg gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg 912
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
290 295 300
aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc 960
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
305 310 315 320
ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca 1008
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
325 330 335
cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag 1056
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
340 345 350
gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc 1104
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
355 360 365
gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg 1152
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
370 375 380
cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc 1200
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
385 390 395 400
acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc 1248
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
405 410 415
gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc 1296
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
420 425 430
ctg tct ccg ggt aaa tga 1314
Leu Ser Pro Gly Lys
435
<210>16
<211>437
<212>PRT
<213>Homo sapiens
<400>16
Met Ser Phe Pro Cys Lys Phe Val Ala Ser Phe Leu Leu Ile Phe Asn
1 5 10 15
Val Ser Ser Lys Gly Ala Val Ser Lys Glu Ile Thr Asn Ala Leu Glu
20 25 30
Thr Trp Gly Ala Leu Gly Gln Asp Ile Asn Leu Asp Ile Pro Ser Phe
35 40 45
Gln Met Ser Asp Asp Ile Asp Asp Ile Lys Trp Glu Lys Thr Ser Asp
50 55 60
Lys Lys Lys Ile Ala Gln Phe Arg Lys Glu Lys Glu Thr Phe Lys Glu
65 70 75 80
Lys Asp Thr Tyr Lys Leu Phe Lys Asn Gly Thr Leu Lys Ile Lys His
85 90 95
Leu Lys Thr Asp Asp Gln Asp Ile Tyr Lys Val Ser Ile Tyr Asp Thr
100 105 110
Lys Gly Lys Asn Val Leu Glu Lys Ile Phe Asp Leu Lys Ile Gln Glu
115 120 125
Arg Val Ser Lys Pro Lys Ile Ser Trp Thr Cys Ile Asn Thr Thr Leu
130 135 140
Thr Cys Glu Val Met Asn Gly Thr Asp Pro Glu Leu Asn Leu Tyr Gln
145 150 155 160
Asp Gly Lys His Leu Lys Leu Ser Gln Arg Val Ile Thr His Lys Trp
165 170 175
Thr Thr Ser Leu Ser Ala Lys Phe Lys Cys Thr Ala Gly Asn Lys Val
180 185 190
Ser Lys Glu Ser Ser Val Glu Pro Val Ser Cys Pro Ala Glu Pro Lys
195 200 205
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
210 215 220
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
225 230 235 240
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
245 250 255
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
260 265 270
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
275 280 285
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
290 295 300
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
305 310 315 320
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
325 330 335
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
340 345 350
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
355 360 365
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
370 375 380
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
385 390 395 400
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
405 410 415
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
420 425 430
Leu Ser Pro Gly Lys
435
<210>17
<211>1854
<212>DNA
<213>Homo sapiens
<220>
<221>CDS
<222>(1)..(1851)
<223>CD2-CD2/Fc
<400>17
atg agc ttt cca tgt aaa ttt gta gcc agc ttc ctt ctg att ttc aat 48
Met Ser Phe Pro Cys Lys Phe Val Ala Ser Phe Leu Leu Ile Phe Asn
1 5 10 15
gtt tct tcc aaa ggt gca gtc tcc aaa gag att acg aat gcc ttg gaa 96
Val Ser Ser Lys Gly Ala Val Ser Lys Glu Ile Thr Asn Ala Leu Glu
20 25 30
acc tgg ggt gcc ttg ggt cag gac atc aac ttg gac att cct agt ttt 144
Thr Trp Gly Ala Leu Gly Gln Asp Ile Asn Leu Asp Ile Pro Ser Phe
35 40 45
caa atg agt gat gat att gac gat ata aaa tgg gaa aaa act tca gac 192
Gln Met Ser Asp Asp Ile Asp Asp Ile Lys Trp Glu Lys Thr Ser Asp
50 55 60
aag aaa aag att gca caa ttc aga aaa gag aaa gag act ttc aag gaa 240
Lys Lys Lys Ile Ala Gln Phe Arg Lys Glu Lys Glu Thr Phe Lys Glu
65 70 75 80
aaa gat aca tat aag cta ttt aaa aat gga act ctg aaa att aag cat 288
Lys Asp Thr Tyr Lys Leu Phe Lys Asn Gly Thr Leu Lys Ile Lys His
85 90 95
ctg aag acc gat gat cag gat atc tac aag gta tca ata tat gat aca 336
Leu Lys Thr Asp Asp Gln Asp Ile Tyr Lys Val Ser Ile Tyr Asp Thr
100 105 110
aaa gga aaa aat gtg ttg gaa aaa ata ttt gat ttg aag att caa gag 384
Lys Gly Lys Asn Val Leu Glu Lys Ile Phe Asp Leu Lys Ile Gln Glu
115 120 125
agg gtc tca aaa cca aag atc tcc tgg act tgt atc aac aca acc ctg 432
Arg Val Ser Lys Pro Lys Ile Ser Trp Thr Cys Ile Asn Thr Thr Leu
130 135 140
acc tgt gag gta atg aat gga act gac ccc gaa tta aac ctg tat caa 480
Thr Cys Glu Val Met Asn Gly Thr Asp Pro Glu Leu Asn Leu Tyr Gln
145 150 155 160
gat ggg aaa cat cta aaa ctt tct cag agg gtc atc aca cac aag tgg 528
Asp Gly Lys His Leu Lys Leu Ser Gln Arg Val Ile Thr His Lys Trp
165 170 175
acc acc agc ctg agt gca aaa ttc aag tgc aca gca ggg aac aaa gtc 576
Thr Thr Ser Leu Ser Ala Lys Phe Lys Cys Thr Ala Gly Asn Lys Val
180 185 190
agc aag gaa tcc agt gtc gag cct gtc agc tgt cct aaa gag att acg 624
Ser Lys Glu Ser Ser Val Glu Pro Val Ser Cys Pro Lys Glu Ile Thr
195 200 205
aat gcc ttg gaa acc tgg ggt gcc ttg ggt cag gac atc aac ttg gac 672
Asn Ala Leu Glu Thr Trp Gly Ala Leu Gly Gln Asp Ile Asn Leu Asp
210 215 220
att cct agt ttt caa atg agt gat gat att gac gat ata aaa tgg gaa 720
Ile Pro Ser Phe Gln Met Ser Asp Asp Ile Asp Asp Ile Lys Trp Glu
225 230 235 240
aaa act tca gac aag aaa aag att gca caa ttc aga aaa gag aaa gag 768
Lys Thr Ser Asp Lys Lys Lys Ile Ala Gln Phe Arg Lys Glu Lys Glu
245 250 255
act ttc aag gaa aaa gat aca tat aag cta ttt aaa aat gga act ctg 816
Thr Phe Lys Glu Lys Asp Thr Tyr Lys Leu Phe Lys Asn Gly Thr Leu
260 265 270
aaa att aag cat ctg aag acc gat gat cag gat atc tac aag gta tca 864
Lys Ile Lys His Leu Lys Thr Asp Asp Gln Asp Ile Tyr Lys Val Ser
275 280 285
ata tat gat aca aaa gga aaa aat gtg ttg gaa aaa ata ttt gat ttg 912
Ile Tyr Asp Thr Lys Gly Lys Asn Val Leu Glu Lys Ile Phe Asp Leu
290 295 300
aag att caa gag agg gtc tca aaa cca aag atc tcc tgg act tgt atc 960
Lys Ile Gln Glu Arg Val Ser Lys Pro Lys Ile Ser Trp Thr Cys Ile
305 310 315 320
aac aca acc ctg acc tgt gag gta atg aat gga act gac ccc gaa tta 1008
Asn Thr Thr Leu Thr Cys Glu Val Met Asn Gly Thr Asp Pro Glu Leu
325 330 335
aac ctg tat caa gat ggg aaa cat cta aaa ctt tct cag agg gtc atc 1056
Asn Leu Tyr Gln Asp Gly Lys His Leu Lys Leu Ser Gln Arg Val Ile
340 345 350
aca cac aag tgg acc acc agc ctg agt gca aaa ttc aag tgc aca gca 1104
Thr His Lys Trp Thr Thr Ser Leu Ser Ala Lys Phe Lys Cys Thr Ala
355 360 365
ggg aac aaa gtc agc aag gaa tcc agt gtc gag cct gtc agc tgt cct 1152
Gly Asn Lys Val Ser Lys Glu Ser Ser Val Glu Pro Val Ser Cys Pro
370 375 380
gca gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca 1200
Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
385 390 395 400
gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa 1248
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
405 410 415
ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 1296
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
420 425 430
gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac 1344
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
435 440 445
gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag 1392
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
450 455 460
cag tac aac agc acg tac cgg gtg gtc agc gtc ctc acc gtc tgt cac 1440
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Cys His
465 470 475 480
cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa 1488
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
485 490 495
gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag 1536
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
500 505 510
ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg 1584
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
515 520 525
acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc 1632
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
530 535 540
agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac 1680
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
545 550 555 560
tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc 1728
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
565 570 575
tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc 1776
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
580 585 590
ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag 1824
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
595 600 605
aag agc ctc tcc ctg tct ccg ggt aaa tga 1854
Lys Ser Leu Ser Leu Ser Pro Gly Lys
610 615
<210>18
<211>617
<212>PRT
<213>Homo sapiens
<400>18
Met Ser Phe Pro Cys Lys Phe Val Ala Ser Phe Leu Leu Ile Phe Asn
1 5 10 15
Val Ser Ser Lys Gly Ala Val Ser Lys Glu Ile Thr Asn Ala Leu Glu
20 25 30
Thr Trp Gly Ala Leu Gly Gln Asp Ile Asn Leu Asp Ile Pro Ser Phe
35 40 45
Gln Met Ser Asp Asp Ile Asp Asp Ile Lys Trp Glu Lys Thr Ser Asp
50 55 60
Lys Lys Lys Ile Ala Gln Phe Arg Lys Glu Lys Glu Thr Phe Lys Glu
65 70 75 80
Lys Asp Thr Tyr Lys Leu Phe Lys Asn Gly Thr Leu Lys Ile Lys His
85 90 95
Leu Lys Thr Asp Asp Gln Asp Ile Tyr Lys Val Ser Ile Tyr Asp Thr
100 105 110
Lys Gly Lys Asn Val Leu Glu Lys Ile Phe Asp Leu Lys Ile Gln Glu
115 120 125
Arg Val Ser Lys Pro Lys Ile Ser Trp Thr Cys Ile Asn Thr Thr Leu
130 135 140
Thr Cys Glu Val Met Asn Gly Thr Asp Pro Glu Leu Asn Leu Tyr Gln
145 150 155 160
Asp Gly Lys His Leu Lys Leu Ser Gln Arg Val Ile Thr His Lys Trp
165 170 175
Thr Thr Ser Leu Ser Ala Lys Phe Lys Cys Thr Ala Gly Asn Lys Val
180 185 190
Ser Lys Glu Ser Ser Val Glu Pro Val Ser Cys Pro Lys Glu Ile Thr
195 200 205
Asn Ala Leu Glu Thr Trp Gly Ala Leu Gly Gln Asp Ile Asn Leu Asp
210 215 220
Ile Pro Ser Phe Gln Met Ser Asp Asp Ile Asp Asp Ile Lys Trp Glu
225 230 235 240
Lys Thr Ser Asp Lys Lys Lys Ile Ala Gln Phe Arg Lys Glu Lys Glu
245 250 255
Thr Phe Lys Glu Lys Asp Thr Tyr Lys Leu Phe Lys Asn Gly Thr Leu
260 265 270
Lys Ile Lys His Leu Lys Thr Asp Asp Gln Asp Ile Tyr Lys Val Ser
275 280 285
Ile Tyr Asp Thr Lys Gly Lys Asn Val Leu Glu Lys Ile Phe Asp Leu
290 295 300
Lys Ile Gln Glu Arg Val Ser Lys Pro Lys Ile Ser Trp Thr Cys Ile
305 310 315 320
Asn Thr Thr Leu Thr Cys Glu Val Met Asn Gly Thr Asp Pro Glu Leu
325 330 335
Asn Leu Tyr Gln Asp Gly Lys His Leu Lys Leu Ser Gln Arg Val Ile
340 345 350
Thr His Lys Trp Thr Thr Ser Leu Ser Ala Lys Phe Lys Cys Thr Ala
355 360 365
Gly Asn Lys Val Ser Lys Glu Ser Ser Val Glu Pro Val Ser Cys Pro
370 375 380
Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
385 390 395 400
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
405 410 415
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
420 425 430
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
435 440 445
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
450 455 460
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Cys His
465 470 475 480
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
485 490 495
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
500 505 510
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
515 520 525
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
530 535 540
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
545 550 555 560
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
565 570 575
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
580 585 590
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
595 600 605
Lys Ser Leu Ser Leu Ser Pro Gly Lys
610 615
<210>19
<211>1134
<212>DNA
<213>Homo sapiens
<220>
<221>CDS
<222>(1)..(1131)
<223>CTLA4/Fc
<400>19
atg agg acc tgg ccc tgc act ctc ctg ttt ttt ctt ctc ttc atc cct 48
Met Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro
1 5 10 15
gtc ttc tgc aaa gca atg cac gtg gcc cag cct gct gtg gta ctg gcc 96
Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala
20 25 30
agc agc cga ggc atc gcc agc ttt gtg tgt gag tat gca tct cca ggc 144
Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly
35 40 45
aaa gcc act gag gtc cgg gtg aca gtg ctt cgg cag gct gac agc cag 192
Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln
50 55 60
gtg act gaa gtc tgt gcg gca acc tac atg atg ggg aat gag ttg acc 240
Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr
65 70 75 80
ttc cta gat gat tcc atc tgc acg ggc acc tcc agt gga aat caa gtg 288
Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val
85 90 95
aac ctc act atc caa gga ctg agg gcc atg gac acg gga ctc tac atc 336
Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile
100 105 110
tgc aag gtg gag ctc atg tac cca ccg cca tac tac ctg ggc ata ggc 384
Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly
115 120 125
aac gga acc cag att tat gta att gat cca gaa ccg tgc cca gat tct 432
Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser
130 135 140
gca gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca 480
Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
145 150 155 160
gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa 528
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
165 170 175
ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg 576
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
180 185 190
gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac 624
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
195 200 205
gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag 672
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
210 215 220
cag tac aac agc acg tac cgg gtg gtc agc gtc ctc acc gtc ctg cac 720
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
225 230 235 240
cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa 768
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
245 250 255
gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag 816
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
260 265 270
ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg 864
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
275 280 285
acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc 912
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
290 295 300
agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac 960
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
305 310 315 320
tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc 1008
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
325 330 335
tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc 1056
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
340 345 350
ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag 1104
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
355 360 365
aag agc ctc tcc ctg tct ccg ggt aaa tga 1134
Lys Ser Leu Ser Leu Ser Pro Gly Lys
370 375
<210>20
<211>377
<212>PRT
<213>Homo sapiens
<400>20
Met Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro
1 5 10 15
Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala
20 25 30
Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly
35 40 45
Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln
50 55 60
Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr
65 70 75 80
Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val
85 90 95
Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile
100 105 110
Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly
115 120 125
Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser
130 135 140
Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
145 150 155 160
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
165 170 175
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
180 185 190
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
195 200 205
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
210 215 220
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
225 230 235 240
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
245 250 255
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
260 265 270
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
275 280 285
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
290 295 300
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
305 310 315 320
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
325 330 335
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
340 345 350
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
355 360 365
Lys Ser Leu Ser Leu Ser Pro Gly Lys
370 375
<210>21
<211>1509
<212>DNA
<213>Homo sapiens
<220>
<221>CDS
<222>(1)..(1506)
<223>CTLA4-CTLA4/Fc
<400>21
atg agg acc tgg ccc tgc act ctc ctg ttt ttt ctt ctc ttc atc cct 48
Met Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro
1 5 10 15
gtc ttc tgc aaa gca atg cac gtg gcc cag cct gct gtg gta ctg gcc 96
Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala
20 25 30
agc agc cga ggc atc gcc agc ttt gtg tgt gag tat gca tct cca ggc 144
Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly
35 40 45
aaa gcc act gag gtc cgg gtg aca gtg ctt cgg cag gct gac agc cag 192
Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln
50 55 60
gtg act gaa gtc tgt gcg gca acc tac atg atg ggg aat gag ttg acc 240
Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr
65 70 75 80
ttc cta gat gat tcc atc tgc acg ggc acc tcc agt gga aat caa gtg 288
Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val
85 90 95
aac ctc act atc caa gga ctg agg gcc atg gac acg gga ctc tac atc 336
Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile
100 105 110
tgc aag gtg gag ctc atg tac cca ccg cca tac tac ctg ggc ata ggc 384
Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly
115 120 125
aac gga acc cag att tat gta att gat cca gaa ccg tgc cca gat tcg 432
Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser
130 135 140
gat aac atg cac gtg gcc cag cct gct gtg gta ctg gcc agc agc cga 480
Asp Asn Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg
145 150 155 160
ggc atc gcc agc ttt gtg tgt gag tat gca tct cca ggc aaa gcc act 528
Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr
165 170 175
gag gtc cgg gtg aca gtg ctt cgg cag gct gac agc cag gtg act gaa 576
Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu
180 185 190
gtc tgt gcg gca acc tac atg atg ggg aat gag ttg acc ttc cta gat 624
Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp
195 200 205
gat tcc atc tgc acg ggc acc tcc agt gga aat caa gtg aac ctc act 672
Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr
210 215 220
atc caa gga ctg agg gcc atg gac acg gga ctc tac atc tgc aag gtg 720
Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val
225 230 235 240
gag ctc atg tac cca ccg cca tac tac ctg ggc ata ggc aac gga acc 768
Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr
245 250 255
cag att tat gta att gat cca gaa ccg tgc cca gat tct gca gag ccc 816
Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Ala Glu Pro
260 265 270
aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa 864
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
275 280 285
ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac 912
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
290 295 300
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac 960
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
305 310 315 320
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc 1008
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
325 330 335
gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac 1056
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
340 345 350
agc acg tac cgg gtg gtc agc gtc ctc acc gtc tgt cac cag gac tgg 1104
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Cys His Gln Asp Trp
355 360 365
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca 1152
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
370 375 380
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa 1200
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
385 390 395 400
cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac 1248
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
405 410 415
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc 1296
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
420 425 430
gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc 1344
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
435 440 445
acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag 1392
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
450 455 460
ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc 1440
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
465 470 475 480
tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc 1488
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
485 490 495
tcc ctg tct ccg ggt aaa tga 1509
Ser Leu Ser Pro Gly Lys
500
<210>22
<211>502
<212>PRT
<213>Homo sapiens
<400>22
Met Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro
1 5 10 15
Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala
20 25 30
Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly
35 40 45
Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln
50 55 60
Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr
65 70 75 80
Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val
85 90 95
Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile
100 105 110
Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly
115 120 125
Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser
130 135 140
Asp Asn Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg
145 150 155 160
Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr
165 170 175
Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu
180 185 190
Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr Phe Leu Asp
195 200 205
Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr
210 215 220
Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val
225 230 235 240
Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr
245 250 255
Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser Ala Glu Pro
260 265 270
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
275 280 285
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
290 295 300
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
305 310 315 320
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
325 330 335
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
340 345 350
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Cys His Gln Asp Trp
355 360 365
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
370 375 380
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
385 390 395 400
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
405 410 415
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
420 425 430
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
435 440 445
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
450 455 460
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
465 470 475 480
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
485 490 495
Ser Leu Ser Pro Gly Lys
500
<210>23
<211>1335
<212>DNA
<213>Homo sapiens
<220>
<221>CDS
<222>(1)..(1332)
<223>TNFR1/Fc
<400>23
atg ggc ctc tcc acc gtg cct gac ctg ctg ctg ccg ctg gtg ctc ctg 48
Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu Leu
1 5 10 15
gag ctg ttg gtg gga ata tac ccc tca ggg gtt att gga ctg gtc cct 96
Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly Leu Val Pro
20 25 30
cac cta ggg gac agg gag aag aga gat agt gtg tgt ccc caa gga aaa 144
His Leu Gly Asp Arg Glu Lys Arg Asp Ser Val Cys Pro Gln Gly Lys
35 40 45
tat atc cac cct caa aat aat tcg att tgc tgt acc aag tgc cac aaa 192
Tyr Ile His Pro Gln Asn Asn Ser Ile Cys Cys Thr Lys Cys His Lys
50 55 60
gga acc tac ttg tac aat gac tgt cca ggc ccg ggg cag gat acg gac 240
Gly Thr Tyr Leu Tyr Asn Asp Cys Pro Gly Pro Gly Gln Asp Thr Asp
65 70 75 80
tgc agg gag tgt gag agc ggc tcc ttc acc gct tca gaa aac cac ctc 288
Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr Ala Ser Glu Asn His Leu
85 90 95
aga cac tgc ctc agc tgc tcc aaa tgc cga aag gaa atg ggt cag gtg 336
Arg His Cys Leu Ser Cys Ser Lys Cys Arg Lys Glu Met Gly Gln Val
100 105 110
gag atc tct tct tgc aca gtg gac cgg gac acc gtg tgt ggc tgc agg 384
Glu Ile Ser Ser Cys Thr Val Asp Arg Asp Thr Val Cys Gly Cys Arg
115 120 125
aag aac cag tac cgg cat tat tgg agt gaa aac ctt ttc cag tgc ttc 432
Lys Asn Gln Tyr Arg His Tyr Trp Ser Glu Asn Leu Phe Gln Cys Phe
130 135 140
aat tgc agc ctc tgc ctc aat ggg acc gtg cac ctc tcc tgc cag gag 480
Asn Cys Ser Leu Cys Leu Asn Gly Thr Val His Leu Ser Cys Gln Glu
145 150 155 160
aaa cag aac acc gtg tgc acc tgc cat gca ggt ttc ttt cta aga gaa 528
Lys Gln Asn Thr Val Cys Thr Cys His Ala Gly Phe Phe Leu Arg Glu
165 170 175
aac gag tgt gtc tcc tgt agt aac tgt aag aaa agc ctg gag tgc acg 576
Asn Glu Cys Val Ser Cys Ser Asn Cys Lys Lys Ser Leu Glu Cys Thr
180 185 190
aag ttg tgc cta ccc cag att gag aat gtt aag ggc act gag gac tca 624
Lys Leu Cys Leu Pro Gln Ile Glu Asn Val Lys Gly Thr Glu Asp Ser
195 200 205
ggc acc aca gca gag ccc aaa tct tgt gac aaa act cac aca tgc cca 672
Gly Thr Thr Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
210 215 220
ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc 720
Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
225 230 235 240
ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc 768
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255
aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc 816
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
260 265 270
aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg 864
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285
cgg gag gag cag tac aac agc acg tac cgg gtg gtc agc gtc ctc acc 912
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300
gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc 960
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320
tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc 1008
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335
aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg 1056
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
340 345 350
gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc 1104
Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365
ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg 1152
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380
gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc 1200
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400
tcc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag 1248
Ser Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
405 410 415
ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac 1296
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430
tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tga 1335
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440
<210>24
<211>444
<212>PRT
<213>Homo sapiens
<400>24
Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu Leu
1 5 10 15
Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly Leu Val Pro
20 25 30
His Leu Gly Asp Arg Glu Lys Arg Asp Ser Val Cys Pro Gln Gly Lys
35 40 45
Tyr Ile His Pro Gln Asn Asn Ser Ile Cys Cys Thr Lys Cys His Lys
50 55 60
Gly Thr Tyr Leu Tyr Asn Asp Cys Pro Gly Pro Gly Gln Asp Thr Asp
65 70 75 80
Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr Ala Ser Glu Asn His Leu
85 90 95
Arg His Cys Leu Ser Cys Ser Lys Cys Arg Lys Glu Met Gly Gln Val
100 105 110
Glu Ile Ser Ser Cys Thr Val Asp Arg Asp Thr Val Cys Gly Cys Arg
115 120 125
Lys Asn Gln Tyr Arg His Tyr Trp Ser Glu Asn Leu Phe Gln Cys Phe
130 135 140
Asn Cys Ser Leu Cys Leu Asn Gly Thr Val His Leu Ser Cys Gln Glu
145 150 155 160
Lys Gln Asn Thr Val Cys Thr Cys His Ala Gly Phe Phe Leu Arg Glu
165 170 175
Asn Glu Cys Val Ser Cys Ser Asn Cys Lys Lys Ser Leu Glu Cys Thr
180 185 190
Lys Leu Cys Leu Pro Gln Ile Glu Asn Val Lys Gly Thr Glu Asp Ser
195 200 205
Gly Thr Thr Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
210 215 220
Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
225 230 235 240
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
260 265 270
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
340 345 350
Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400
Ser Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440
<210>25
<211>2028
<212>DNA
<213>Homo sapiens
<220>
<221>CDS
<222>(1)..(2025)
<223>TNFR2-TNFR1/Fc
<400>25
atg gcg ccc gtc gcc gtc tgg gcc gcg ctg gcc gtc gga ctg gag ctc 48
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
1 5 10 15
tgg gct gcg gcg cac gcc ttg ccc gcc cag gtg gca ttt aca ccc tac 96
Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
20 25 30
gcc ccg gag ccc ggg agc aca tgc cgg ctc aga gaa tac tat gac cag 144
Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
35 40 45
aca gct cag atg tgc tgc agc aaa tgc tcg ccg ggc caa cat gca aaa 192
Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
50 55 60
gtc ttc tgt acc aag acc tcg gac acc gtg tgt gac tcc tgt gag gac 240
Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
65 70 75 80
agc aca tac acc cag ctc tgg aac tgg gtt ccc gag tgc ttg agc tgt 288
Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
85 90 95
ggc tcc cgc tgt agc tct gac cag gtg gaa act caa gcc tgc act cgg 336
Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
100 105 110
gaa cag aac cgc atc tgc acc tgc agg ccc ggc tgg tac tgc gcg ctg 384
Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
115 120 125
agc aag cag gag ggg tgc cgg ctg tgc gcg ccg ctg cgc aag tgc cgc 432
Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg
130 135 140
ccg ggc ttc ggc gtg gcc aga cca gga act gaa aca tca gac gtg gtg 480
Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val
145 150 155 160
tgc aag ccc tgt gcc ccg ggg acg ttc tcc aac acg act tca tcc acg 528
Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
165 170 175
gat att tgc agg ccc cac cag atc tgt aac gtg gtg gcc atc cct ggg 576
Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
180 185 190
aat gca agc atg gat gca gtc tgc acg tcc acg tcc ccc acc cgg agt 624
Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser
195 200 205
atg gcc cca ggg gca gta cac tta ccc cag cca gtg tcc aca cga tcc 672
Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser
210 215 220
caa cac acg cag cca act cca gaa ccc agc act gct cca agc acc tcc 720
Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
225 230 235 240
ttc ctg ctc cca atg ggc ccc agc ccc cca gct gaa ggg agc gga tcc 768
Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Gly Ser
245 250 255
ggg aac att tca ctg gtc cct cac cta ggg gac agg gag aag aga gat 816
Gly Asn Ile Ser Leu Val Pro His Leu Gly Asp Arg Glu Lys Arg Asp
260 265 270
agt gtg tgt ccc caa gga aaa tat atc cac cct caa aat aat tcg att 864
Ser Val Cys Pro Gln Gly Lys Tyr Ile His Pro Gln Asn Asn Ser Ile
275 280 285
tgc tgt acc aag tgc cac aaa gga acc tac ttg tac aat gac tgt cca 912
Cys Cys Thr Lys Cys His Lys Gly Thr Tyr Leu Tyr Asn Asp Cys Pro
290 295 300
ggc ccg ggg cag gat acg gac tgc agg gag tgt gag agc ggc tcc ttc 960
Gly Pro Gly Gln Asp Thr Asp Cys Arg Glu Cys Glu Ser Gly Ser Phe
305 310 315 320
acc gct tca gaa aac cac ctc aga cac tgc ctc agc tgc tcc aaa tgc 1008
Thr Ala Ser Glu Asn His Leu Arg His Cys Leu Ser Cys Ser Lys Cys
325 330 335
cga aag gaa atg ggt cag gtg gag atc tct tct tgc aca gtg gac cgg 1056
Arg Lys Glu Met Gly Gln Val Glu Ile Ser Ser Cys Thr Val Asp Arg
340 345 350
gac acc gtg tgt ggc tgc agg aag aac cag tac cgg cat tat tgg agt 1104
Asp Thr Val Cys Gly Cys Arg Lys Asn Gln Tyr Arg His Tyr Trp Ser
355 360 365
gaa aac ctt ttc cag tgc ttc aat tgc agc ctc tgc ctc aat ggg acc 1152
Glu Asn Leu Phe Gln Cys Phe Asn Cys Ser Leu Cys Leu Asn Gly Thr
370 375 380
gtg cac ctc tcc tgc cag gag aaa cag aac acc gtg tgc acc tgc cat 1200
Val His Leu Ser Cys Gln Glu Lys Gln Asn Thr Val Cys Thr Cys His
385 390 395 400
gca ggt ttc ttt cta aga gaa aac gag tgt gtc tcc tgt agt aac tgt 1248
Ala Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys
405 410 415
aag aaa agc ctg gag tgc acg aag ttg tgc cta ccc cag att gag aat 1296
Lys Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn
420 425 430
gtt aag ggc act gag gac tca ggc acc aca gca gag ccc aaa tct tgt 1344
Val Lys Gly Thr Glu Asp Ser Gly Thr Thr Ala Glu Pro Lys Ser Cys
435 440 445
gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg 1392
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
450 455 460
gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg 1440
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
465 470 475 480
atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac 1488
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
485 490 495
gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg 1536
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
500 505 510
cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac 1584
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
515 520 525
cgg gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc 1632
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
530 535 540
aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc 1680
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
545 550 555 560
gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg 1728
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
565 570 575
tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc 1776
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
580 585 590
ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag 1824
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
595 600 605
tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc 1872
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
610 615 620
gtg ctg gac tcc gac ggc tcc tcc ttc ctc tac agc aag ctc acc gtg 1920
Val Leu Asp Ser Asp Gly Ser Ser Phe Leu Tyr Ser Lys Leu Thr Val
625 630 635 640
gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg 1968
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
645 650 655
cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct 2016
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
660 665 670
ccg ggt aaa tga 2028
Pro Gly Lys
675
<210>26
<211>675
<212>PRT
<213>Homo sapiens
<400>26
Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu
1 5 10 15
Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr
20 25 30
Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln
35 40 45
Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
50 55 60
Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp
65 70 75 80
Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys
85 90 95
Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg
100 105 110
Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu
115 120 125
Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg
130 135 140
Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val
145 150 155 160
Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
165 170 175
Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
180 185 190
Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser
195 200 205
Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser
210 215 220
Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser
225 230 235 240
Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Gly Ser
245 250 255
Gly Asn Ile Ser Leu Val Pro His Leu Gly Asp Arg Glu Lys Arg Asp
260 265 270
Ser Val Cys Pro Gln Gly Lys Tyr Ile His Pro Gln Asn Asn Ser Ile
275 280 285
Cys Cys Thr Lys Cys His Lys Gly Thr Tyr Leu Tyr Asn Asp Cys Pro
290 295 300
Gly Pro Gly Gln Asp Thr Asp Cys Arg Glu Cys Glu Ser Gly Ser Phe
305 310 315 320
Thr Ala Ser Glu Asn His Leu Arg His Cys Leu Ser Cys Ser Lys Cys
325 330 335
Arg Lys Glu Met Gly Gln Val Glu Ile Ser Ser Cys Thr Val Asp Arg
340 345 350
Asp Thr Val Cys Gly Cys Arg Lys Asn Gln Tyr Arg His Tyr Trp Ser
355 360 365
Glu Asn Leu Phe Gln Cys Phe Asn Cys Ser Leu Cys Leu Asn Gly Thr
370 375 380
Val His Leu Ser Cys Gln Glu Lys Gln Asn Thr Val Cys Thr Cys His
385 390 395 400
Ala Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys
405 410 415
Lys Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn
420 425 430
Val Lys Gly Thr Glu Asp Ser Gly Thr Thr Ala Glu Pro Lys Ser Cys
435 440 445
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
450 455 460
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
465 470 475 480
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
485 490 495
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
500 505 510
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
515 520 525
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
530 535 540
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
545 550 555 560
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
565 570 575
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
580 585 590
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
595 600 605
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
610 615 620
Val Leu Asp Ser Asp Gly Ser Ser Phe Leu Tyr Ser Lys Leu Thr Val
625 630 635 640
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
645 650 655
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
660 665 670
Pro Gly Lys
675
Claims (10)
1.一种通过抑制T淋巴细胞的活化来治疗免疫性疾病的药物组合物,包括选自由以下物质组成的组中的两种或多种作为活性成分:能够阻断MHC II类分子与其受体结合的物质,能够阻断协同刺激分子与其受体结合的物质,能够阻断粘附分子与其受体结合的物质,以及能够阻断细胞因子与其受体结合的物质。
2.根据权利要求1所述的用于治疗免疫性疾病的药物组合物,其中所述能够用于阻断MHC II类分子与CD4结合的物质选自由以下物质组成的组:(1)MHC II类分子的抗体;(2)简单融合单体蛋白,通过LAG3的可溶性细胞外结构域连接到免疫球蛋白分子的Fc段的铰链区而形成;(3)简单融合二聚体蛋白,其中两分子的所述简单融合单体蛋白通过在所述铰链区的分子间二硫键而连接;(4)连接融合单体蛋白,通过连接到所述简单融合单体蛋白的所述铰链区的LAG3的可溶性细胞外结构域的N-末端连接到另一个LAG3分子的可溶性细胞外结构域的C-末端而形成;(5)连接融合二聚体蛋白,其中两分子的所述连接融合单体蛋白通过在所述铰链区的分子间二硫键而连接;以及(6)根据(2)至(5)中所述蛋白的糖基化形式。
3.根据权利要求1所述的用于治疗免疫性疾病的药物组合物,其中所述协同刺激分子是B7、CD154、CD70、0X40L、ICOS-L、4-1BBL、HVEM、FASL或PDL,其受体是CD28和CTLA-4、CD40、CD27、0X40、ICOS、4-1BB、LIGHT、FAS或PD-1。
4.根据权利要求3所述的用于治疗免疫性疾病的药物组合物,其中能够阻断B7分子与CD28结合的物质选自由以下物质组成的组:(1)B7分子的抗体;(2)简单融合单体蛋白,通过CTLA4的可溶性细胞外结构域连接到免疫球蛋白分子的Fc段铰链区而形成;(3)简单融合二聚体蛋白,其中两分子的所述简单融合单体蛋白通过在所述铰链区的分子间二硫键而连接;(4)连接融合单体蛋白,通过连接到所述简单融合单体蛋白的所述铰链区的CTLA4的可溶性细胞外结构域的N-末端连接到另一个CTLA4分子的可溶性细胞外结构域的C-末端而形成;(5)连接融合二聚体蛋白,其中两分子的所述连接融合单体蛋白通过在所述铰链区的分子间二硫键而连接;以及(6)根据(2)至(5)中所述蛋白的糖基化形式。
5.根据权利要求1所述的用于治疗免疫性疾病的药物组合物,其中所述粘附分子是LFA-3、ICAM-1或VCAM-1,以及其受体为CD2、LFA-1或VLA-4。
6.根据权利要求5所述的用于治疗免疫性疾病的药物组合物,其中所述能够阻断LFA-3与CD2结合的物质选自由下列物质组成的组:(1)LFA-3的抗体;(2)简单融合单体蛋白,通过CD2的可溶性细胞外结构域连接到免疫球蛋白分子的Fc段的铰链区而形成;(3)简单融合二聚体蛋白,其中两分子的所述简单融合单体蛋白通过在所述铰链区的分子间二硫键而连接;(4)连接融合单体蛋白,通过连接到所述简单融合单体蛋白的铰链区的CD2的可溶性细胞外结构域的N-末端连接到另一个CD2分子的可溶性细胞外结构域的C-末端而形成;(5)连接融合二聚体蛋白,其中两分子的所述连接融合单体蛋白通过在所述铰链区的分子间二硫键而连接;以及(6)根据(2)至(5)中所述蛋白的糖基化形式。
7.根据权利要求1所述的用于治疗免疫性疾病的药物组合物,其中所述细胞因子是IL-1、IL-2、IL-3、IL-4、IL-5、IL-6、IL-7、TNF、TGF、IFN、GM-CSF、G-CSF、EPO、TPO或M-CSF,其受体是IL-1R、IL-2R、IL-3R、IL-4R、IL-5R、IL-6R、IL-7R、TNFR、TGFR、IFNR、IFN-αR、-βR和-γR、GM-CSFR、G-CSFR、EPOR、cMpl或gp130。
8.根据权利要求7所述的用于治疗免疫性疾病的药物组合物,其中所述能够阻断TNF与TNFR结合的物质选自由下列物质组成的组:(1)TNF的抗体;(2)简单融合单体蛋白,通过TNFR的可溶性细胞外结构域连接到免疫球蛋白分子的Fc段的铰链区而形成;(3)简单融合二聚体蛋白,其中两分子的所述简单融合单体蛋白通过在所述铰链区的分子间二硫键而连接;(4)连接融合单体蛋白,通过连接到所述简单融合单体蛋白的铰链区的TNFR的可溶性细胞外结构域的N-末端连接到另一个TNFR分子的可溶性细胞外结构域的C-末端而得到;(5)连接融合二聚体蛋白,其中两分子的所述连接融合单体蛋白通过在所述铰链区的分子间二硫键而连接;以及(6)根据(2)至(5)中所述蛋白的糖基化形式。
9.根据权利要求1到8中任一项所述的用于治疗免疫性疾病的药物组合物,其中所述免疫性疾病是自身免疫性疾病或者移植排斥。
10.根据权利要求9中所述的用于治疗免疫性疾病的药物组合物,其中所述自身免疫性疾病选自由下列疾病组成的组:风湿性关节炎、多发性硬化症、重症肌无力、格雷夫斯病、慢性淋巴细胞性甲状腺炎、阿狄森病、白癜风、硬皮病、肾炎-肺出血综合症、Becet’s病、节段性回肠炎、强直性脊柱炎、葡萄膜炎、血小板减少性紫癜、寻常型天疱疮、儿童糖尿病、自身免疫性贫血、冷球蛋白血症、肾上腺脑白质营养不良(ALD)以及系统性红斑狼疮(SLE)。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040010835A KR20050082389A (ko) | 2004-02-18 | 2004-02-18 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
KR1020040010835 | 2004-02-18 | ||
PCT/KR2005/000457 WO2005077415A1 (en) | 2004-02-18 | 2005-02-18 | Pharmaceutical composition for treatment of immunological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1942206A true CN1942206A (zh) | 2007-04-04 |
Family
ID=34858737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800082091A Pending CN1942206A (zh) | 2004-02-18 | 2005-02-18 | 治疗免疫性疾病的药物组合物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070110746A1 (zh) |
EP (1) | EP1615664A4 (zh) |
JP (1) | JP2007523158A (zh) |
KR (2) | KR20050082389A (zh) |
CN (1) | CN1942206A (zh) |
AU (1) | AU2005203104B2 (zh) |
BR (1) | BRPI0507216A (zh) |
CA (1) | CA2556739A1 (zh) |
RU (1) | RU2342950C2 (zh) |
WO (1) | WO2005077415A1 (zh) |
ZA (1) | ZA200606804B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103045646A (zh) * | 2012-12-27 | 2013-04-17 | 中国人民解放军军事医学科学院基础医学研究所 | 共表达两个独立的抗关节炎分子TNFR-Fc和CTLA4-FasL的重组腺相关病毒载体及其构建方法与应用 |
CN104231086A (zh) * | 2013-08-27 | 2014-12-24 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
WO2018152687A1 (en) * | 2017-02-22 | 2018-08-30 | I-Mab | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006033702A2 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
KR101301649B1 (ko) | 2006-11-10 | 2013-08-30 | 삼성전자주식회사 | 기록/재생 방법, 기록/재생 장치 및 정보 저장 매체 |
KR100963030B1 (ko) * | 2008-03-31 | 2010-06-10 | 한화케미칼 주식회사 | 이식 면역 반응을 억제할 수 있는 cd70 발현신경줄기세포 및 그의 이용 |
ES2588194T3 (es) * | 2008-04-11 | 2016-10-31 | Seattle Genetics, Inc. | Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres |
EP2193790A1 (en) | 2008-12-04 | 2010-06-09 | Klinikum der Universität Regensburg | IL-3 Inhibitors in use for treatment of rheumatoid arthritis in an early stage |
CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
BR112012013330A2 (pt) | 2009-12-02 | 2017-03-28 | Acceleron Pharma Inc | composições e métodos para aumentar meia vida do soro de proteínas de fusão fc |
EP2718328A4 (en) * | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM |
KR101640582B1 (ko) * | 2014-05-09 | 2016-07-18 | 고려대학교 산학협력단 | Lag-3의 세포질 도메인을 포함하는 면역세포 표면에의 단백질 발현용 조성물 및 그의 이용 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
FR3031112B1 (fr) * | 2014-12-24 | 2018-05-25 | Eyevensys | Construction d'adn pour le traitement de pathologies oculaires |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
IL297090A (en) | 2015-07-30 | 2022-12-01 | Macrogenics Inc | Molecules that bind pd-1 and methods of using them |
TWI758267B (zh) | 2015-12-14 | 2022-03-21 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
TR201807610T1 (tr) * | 2015-12-21 | 2018-06-21 | Brainon Inc | Hafizanin, öğrenme beceri̇si̇ni̇n ve bi̇li̇şsel beceri̇ni̇n geli̇şti̇ri̇lmesi̇ i̇çi̇n kompozi̇syon |
PT3565828T (pt) | 2017-01-05 | 2022-02-08 | Kahr Medical Ltd | Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização |
US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
CA3047707A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-41bbl fusion protein and methods of use thereof |
SG11201909154SA (en) | 2017-04-05 | 2019-10-30 | Hoffmann La Roche | Bispecific antibodies specifically binding to pd1 and lag3 |
US20210214417A1 (en) | 2018-07-11 | 2021-07-15 | Kahr Medical Ltd. | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4143214A1 (de) * | 1991-07-25 | 1993-01-28 | Boehringer Mannheim Gmbh | Synergistisch wirkende antikoerperzusammensetzung |
ATE210454T1 (de) * | 1991-10-07 | 2001-12-15 | Biogen Inc | Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins |
JPH09510952A (ja) * | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
AU2701895A (en) * | 1994-06-07 | 1996-01-05 | Regents Of The University Of Minnesota | Methods for inhibiting antigen specific t cell responses |
IL130168A (en) * | 1996-11-29 | 2006-09-05 | Serono Lab | Genetically engineered cells containing LAG-3-expressing DNA and their use |
EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
US6797263B2 (en) * | 2000-05-12 | 2004-09-28 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
EP1289554A4 (en) * | 2000-06-02 | 2004-05-26 | Univ Minnesota | IMMUNOTHERAPEUTIC PROCESS FOR PREVENTING REJECTION OF ISLAND CELLS |
KR100453877B1 (ko) * | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
-
2004
- 2004-02-18 KR KR1020040010835A patent/KR20050082389A/ko unknown
-
2005
- 2005-02-18 JP JP2006554029A patent/JP2007523158A/ja active Pending
- 2005-02-18 BR BRPI0507216-6A patent/BRPI0507216A/pt not_active Application Discontinuation
- 2005-02-18 WO PCT/KR2005/000457 patent/WO2005077415A1/en active IP Right Grant
- 2005-02-18 RU RU2006133911/13A patent/RU2342950C2/ru active IP Right Revival
- 2005-02-18 KR KR1020057011478A patent/KR100658050B1/ko not_active IP Right Cessation
- 2005-02-18 AU AU2005203104A patent/AU2005203104B2/en not_active Ceased
- 2005-02-18 CN CNA2005800082091A patent/CN1942206A/zh active Pending
- 2005-02-18 EP EP05721863A patent/EP1615664A4/en not_active Withdrawn
- 2005-02-18 US US10/539,946 patent/US20070110746A1/en not_active Abandoned
- 2005-02-18 CA CA002556739A patent/CA2556739A1/en not_active Abandoned
-
2006
- 2006-08-16 ZA ZA200606804A patent/ZA200606804B/xx unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103045646A (zh) * | 2012-12-27 | 2013-04-17 | 中国人民解放军军事医学科学院基础医学研究所 | 共表达两个独立的抗关节炎分子TNFR-Fc和CTLA4-FasL的重组腺相关病毒载体及其构建方法与应用 |
CN103045646B (zh) * | 2012-12-27 | 2015-02-25 | 中国人民解放军军事医学科学院基础医学研究所 | 共表达两个独立的抗关节炎分子TNFR-Fc和CTLA4-FasL的重组腺相关病毒载体及其构建方法与应用 |
CN104231086A (zh) * | 2013-08-27 | 2014-12-24 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
CN104231086B (zh) * | 2013-08-27 | 2019-12-13 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
WO2018152687A1 (en) * | 2017-02-22 | 2018-08-30 | I-Mab | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1615664A4 (en) | 2006-12-27 |
RU2006133911A (ru) | 2008-03-27 |
WO2005077415A1 (en) | 2005-08-25 |
ZA200606804B (en) | 2008-04-30 |
AU2005203104A9 (en) | 2005-09-01 |
AU2005203104B2 (en) | 2006-11-16 |
US20070110746A1 (en) | 2007-05-17 |
RU2342950C2 (ru) | 2009-01-10 |
JP2007523158A (ja) | 2007-08-16 |
AU2005203104A1 (en) | 2005-09-01 |
CA2556739A1 (en) | 2005-08-25 |
KR100658050B1 (ko) | 2006-12-15 |
EP1615664A1 (en) | 2006-01-18 |
KR20060002740A (ko) | 2006-01-09 |
KR20050082389A (ko) | 2005-08-23 |
BRPI0507216A (pt) | 2007-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1942206A (zh) | 治疗免疫性疾病的药物组合物 | |
CN1293098C (zh) | 多联免疫粘附 | |
CN1293190C (zh) | 介导细胞吸附和信号传递的细胞表面分子 | |
CN1217956C (zh) | 可溶性单链t细胞受体蛋白 | |
CN1241944C (zh) | 抗人白介素-5受体α链的抗体 | |
CN1195858C (zh) | Ob融合蛋白组合物及方法 | |
CN1271205C (zh) | 重新构建的人抗hm1.24抗体 | |
CN1181201C (zh) | Lag-3剪接变体 | |
CN1246335C (zh) | 用于治疗il-18介导疾病的重组il-18拮抗物 | |
CN1309735C (zh) | 可溶性ctla4突变体分子及其应用 | |
CN1263507C (zh) | April受体(bcma)及其用途 | |
CN1359302A (zh) | 治疗免疫性疾病的药用组合物 | |
CN1599867A (zh) | 具有调节的选择性的免疫细胞因子 | |
CN1522264A (zh) | 抗cd40单克隆抗体 | |
CN1509293A (zh) | 用于含杂合同种型抗体部分的蛋白质的表达技术 | |
CN1171118A (zh) | 纤连蛋白粘附抑制剂 | |
CN1200737A (zh) | 用于人治疗的重组抗cd4抗体 | |
CN1543476A (zh) | 用于将蛋白定向到胞外体的方法和化合物 | |
CN1671423A (zh) | 新型嵌合cd154 | |
CN1575303A (zh) | 人cdr-移植抗体及其抗体片段 | |
CN1898267A (zh) | 修饰的抗cd52抗体 | |
CN101037671A (zh) | 杂交瘤细胞株及其产生的抗人红细胞表面h抗原的单克隆抗体 | |
CN1809370A (zh) | B7-h3作为免疫调节剂的应用 | |
CN1656215A (zh) | 制备细胞毒性淋巴细胞的方法 | |
CN1543501A (zh) | 抗原特异性细胞毒性t细胞的扩大培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |